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I ntrod uction 
8 
Inlroduction 
a,-Adrenoceptor and vasopressin receptor subclassification 
Deve!opment and current state 
Historica! background of u·adrenoceptor 
c!assification 
Tt is weil established that noradrenaline, relcased 
in response to sympathetic stilTIulation, as weil as 
adrenaline, the honnone relcased from the adrenal 
medulla, interaet with spccific reccptors 
(adrenoceptors) that arc Iocated in the membrane 
ofthc vascular smooth muscle celis. Ahlquist [IJ 
proposed a division of adrenoceptors into a- and 
J3-adrcnoceptors, on the basis of different agonist 
potency orders in vascular smooth muscle 
preparations. The o:-adrcnoceptor rnediated 
vasoconstriction and the f3-adrenoceptor mcdiated 
vasodilation. This subdivisioll in a and n, was 
subsequently supported by the deveIopment of 
selectivc B- and a-adrenoceptor antagonists [2]. 
During the 1970's it bccame clcarthat there 
were subtypes ofthe a-adrenoceptor. At first the 
a-adrenoceptors were subclassified on an 
anatomical basis into prejunctional 
a 2-adrenoceptors and postjunetional 
a,-adrcnoceptors [3]. Bcrthelsen & Pettinger [4] 
noted that this anatomical c1assification was not 
completely satisfactory and sllggestcd to reclassify 
a-adrenoceptors on a fllnctional basis. According 
to this scheme aradrenoceptors mediated 
inhibitory responses (like inhibition ofthe release 
of neurotransmitter and renin etc.), whereas 
al-adrenoceptors mediate excitatory responses 
(Iike the vasoconstriction). However, shortly 
thereafter it becamc clear that in some vascular 
preparations not only a l- but also a1-adrenoccptors 
causcd vasoconstrietion [5-7]. Fram that time a 
classification scheme of a-adrenoccptors into al 
and a 2 evolved th at is neither anatomical nor 
fUllctional, but is based 011 the relative potency of 
selcetive agonists and antagonists [8]. Examplcs 
of selectivc al-adrenoceptor agonists are 
phcnylephrine, methoxamine and cirazoline, while 
UK 14,304, BHT 920 and elonidine bch ave as 
scleetive a 2-adrenoceptor agonists. In the case of 
antagonists, prazosin is regarded as a l-sc1ective aud 
rauwolscine and yohimbine as a 2-sclective. 
Noradrenaline and phentolamille are examples of 
a relatively nonsclective a-adrenoceptor agonist 
aud antagonist, respectively. 
Because ofthe differenccs in the receptors 
it has been suggested that a classification of 
adrenoceptors into three graups: al' a 2 and t3 is 
more apprapriate that the historical division into 
two (a and B) classes [8]. TIlC rationale behind 
this reasoning is threefold. First, differences in 
affinities of selectivc compounds for these three 
classes are large (3 to 4 orders of magnitude). 
Second, the amino acid scguences are more 
consistent with threc rather than two major types. 
Third, the tIuee classes couple to different secotld 
messenger systems. I3-Adrenoceptor subtypes, 
stimulatc adenylyl cyclase resulting in the 
generation of cAMP, a [-adrenoceptors arc believed 
to stimulate the phosphoinositide mctabolism and 
a 2-adrenoceptors inhibit adenylyl cyclase and 
deereasc eAMP levels [9]. 
The evo!ution of u,·adrenoceptor 
subc!assification since the ear!y 80's 
(see Fig/fre 1 for historical11lilestones) 
At present radioligand binding and molecular 
cloning studies identified four different 
a 2-adrenoceptor subtypes (a2M a m, a 2e and a w) 
(see [8, 10]). Howcver, it is ellrrently believed ,hat 
the a 2o-adrenoceptor represents a spccies variant 
ofthe human a2,', -adrelloceptor [8, I 1]. 
The subcIassificatioll of al-adrenoceptors by 
radioligalld binding <ind moleeular c10ning has 
occurrcd in a guite complementary fashion (sec 
Figure 1 for the historica] Illilestoncs). However, 
this has not yet resulted in a classification of 
al-adrenoceptors, with fUllctional identified 
subtypes studies being fully in congruellce with 
the outcomes from radioligand binding and 
moleelllar c10ning stlldies (sec [8]). 
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Radioligand binding and ma/ecu/ar 
clO/ling studies. In radioligand binding studies the 
fiTst suggestion for receptor hetcrogeneity camc 
from studies pcrfollncd by Battaglia et al. [12], who 
reported shal\ow competition curves of 
[JH]prazosin binding in rat cerebral c0!1ex for both 
phentolamine and W8-4101. Fmiher studies by 
MOlTowand co-workcrs [13, 14] confinncd and 
extended these fjndings and cOllcluded that 
[JH]prazosin label led two u[-adrcnoceptor 
subpopulations. Subscquently, these authors 
designated the binding site with high affinity for 
\VB-4101 and phentolamine as UIA and the binding 
site with lawer afflnity as Uw (Tabie I). Thc 
existence of two receptor subtypes was furthcr 
substantiated by the identification ofvarious other 
ligands, like 5-methyl-urapidil and (+)-niguldipine, 
which also discriminated between the two subtypes 
displaying higher affinity for the a[A-adrenoeeptor 
('[abie I; sec [8, 15, 16]). Interpretation of the 
results obtained with receptor alkylating 
compounds like chloroethylclonidine (CEC), 
phenoxybenzamine (PBZ) and benextramine also 
identified two al-adrenoceptor subtypes. Johnso11 
& Min11eman [17] demonstrated that CEC, only 
partially inaetivated the al-adrenoceptor 
population, whereas PBZ and benextramine 
e1iminated the complete population. Subsequcntly, 
Han et al. [18] examined the effects of CEC in 
various tissues and suggested the existence of 
CEC-sensitive and a CEC-insensitive 
a[-adrenoeeptor subtype, Fm1her experiments by 
i'vlinneman 's group demonstrated that the 
CEC-insensitive and the CEC-sensitive 
cOiTesponded with the subtypes designated a lA and 
a m, respcctively, by J'VlolTow and eo-workers [9, 
19]. 
Thc first cloned receptor subtype was 
isolated from a hamster vas deferencc eeilline [20). 
Using the classification tools that \Vere identified 
in radioligand binding studies, this receptor was 
designated as a m, because of its low affjnity for 
\\'B-41 Ol and phentolamine and its sensitivity for 
inactivation bl' CEC (Tabic I; [20, 21]). A second 
cON A clone co ding for a novel aj-adrenoceptor 
subtype was isolated from bovine brain [22, 23] 
was designated ale> sinee this novel subtype 
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displayed properties of both Ci. IA and 
aIB-adrenoceptors. This subtype was 
CEC-sensitive (a[s) yet displayed antagonist 
binding properties charaeteristic of a lA (high 
affinity for WB-41 0 land phentolamine). 
Initially, a third receptor, isolated from rat 
cerebral cortex by Lomasney et al, [21 J, was 
bclieved to cOlTespOJld to the phannacologically 
defined aIA-adrenoceptor, because of its high 
affinity for W8-4101 anel relative resistance to 
inactivation by CEC. Shortly after this finding was 
published, Perez and co-workers [24] reported the 
isolation of a nearly identical clone. However, 
upon pharmacological characterisatÎon these 
authors conc1uded that the receptor displayed a 
unique profile (CEC-sensitive) th at was not in 
agreement with that ofthe aIA-adrenoceptor. Perez 
et al. [24] argued that a sequencing elTor in the 
cloned al-adrenoceptor by Lomasney et al. [21] 
accounted for the small sequence dissimilarity 
between the studies, Furthennorc, the incongruity 
conceming CEC sensitivity eould be explained by 
a difference in concentration and time of exposure, 
Consequent!y, Perez and colleagues proposed the 
existenee of a fourth Ci.1-adrenoceptor subtype, 
which they designated UlO [24]. This 
alD-adrenoceptor subtype displayed high afflnity 
for WB-4 tOl, was inactivated by CEC and 
displayed low affinity for phentolamine, 
5-mcthl'lurapidil and (+)-niguldipine. 
Subsequently, Schwinn & Lomasncy [25] 
suggested that the clOlled ((IA- and am-receptor 
were identical and introduced the rathel' confusing 
designation ofalAlo-adrcnoceptor to distinguish it 
from the pharmacologically defincd aIA-adreno-
ceptor. They suggested the existence of four 
al-adrcnoceptors (alM ((m/a[b' alcla lco ((\ad) 
Figure 1. Histarical mi/estanes in the search far 
a classification of a, -adrenaceptar subtypes. 
Results from radialigand binding studies (right 
column), functianal studies (middle) and 
molecular c/aning studies (left column) are 
displayed in paraliel. 
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Table 1 Binding 
affinities of same antagonist human 
"important" tamsulosin 10.1 
antagonists for the 
c/oned prazosin 9.6 
al~adrenoceptor WB-4101 9.4 
subtypes. Data are 
means (n=1-11) of 5-Mu 8.7 
affinities reported 
BMY 7378 e/sewhere (21-24, 29. 30. 44, 
53-56, 84-91/, The Bold 
font indicates the 
Niguldipine 8.7 
subtype selectivity of RS-17053 9.0 
the antagonist. Ree 152739 9.1 
indoramin 8.4 
anticipating on the official nomcnc1ature of 
ui-adrcnoceptors [261 which refers to cloncd 
subtypes by lower-case letters, whereas the 
upper-casc letters refer to subtypes present in 
tissues. At about the same time, though in 
radioligand-binding studies, several groups 
produced evidcnce for a tissue correlate ofthc Uw 
D-adrenoceptor. Hiramatsu et al. [27] and 
Gcng-Sheng et al. [28) reported that within 
WB41 0 I-high affinity receptor poplliation, 
obtained after trcatment with CEC, 
5-mcthylurapidil could discriminate between two 
ar-adrenoccptor binding sites in rat hcart and lung. 
Both groups proposed the existence of a ncw 
CEC-insensitive a l-adrcl1oceptor subtype diftèrent 
from UIA with low affinity for 5-methylurapidil and 
high afftnity for WB-4101. 
Various groups [29-33J then sIlOwed that 
the pharmaeological profile of the cloned 
a,cadrenoceptor corresponds to that of the 
pharmacologically-defined alA-subtype, whieh 
could suggest th at al-adrenoceptors can be 
satisfactolily classified into thrce subtypes (alM a Hl 
and a lAio)' In the currcnt classification the 
confusing alAlD-adrenoceptor designation was 
rec1assified as a][)-adrenoceptor [26]. 
FUllcNollal studies. In sharp contrast to the 
radio\igand binding and molccu\ar cIoning studies 
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a" a lb a" 
bovine rat human hamster rat hamster rat 
10.3 9.1 8.9 9.9 9.7 
9.6 9.5 9.8 9.9 9.7 9.7 9.7 
9.6 9.0 8.3 8.3 7.7 9.0 9.2 
8.8 8.4 7.1 6.9 6.9 7.6 7.5 
6.5 7.1 8.6 
9.1 8.3 6.9 7.2 7.8 6.5 6.9 
9.5 7.3 7.1 7.8 
9.0 7.6 7.3 8.4 7.6 
8.2 7.7 6.9 7.0 7.3 
wh ere prazosin bccame established as a nOIl-
selective antagonist, early functional studies with 
antagonists have resulted in a c1assification th at is 
mainly based on the selectivity ofprazosin. Ho1ck 
et al. [34] rep0l1ed that within the same tissue, the 
rabbit main pulmonary artery. prazosin dispJayed 
a ten-fald higher affinity against clonidine 
(pA, ~ 9.4) than against methoxaminc (pA, ~ 8.4). 
In this tissue, a si mil ar difference was found for 
yohimbine. In the same year, Digges & Summers 
[35) showed that prazosin displayed a similar 
diITerence in inhibiting the l1oradrenaline-mediated 
response of rat a0l1a (pAl = 9.4) and th at of rat 
porta\ vein (pA2 = 8.4). Interestingly, in this case 
yohimbine did not display the same discdminatory 
potency. Up on a review of the available data, 
severa\ authors independently noted a wide 
variation in affinity for prazosin and yohimbine in 
functional studies on different tissues [36-39]. 
These observations led Flavahan & Vanhoutte [38] 
to propose the existence of two distinct 
aj-adrcnoceptors: an am-receptor which displays 
high affinity for prazosin and yohimbille and is 
preferentially stimu\ated by c1onidine, while the 
alL-receptor has low affinity for prazosin and 
yohimbillc and is preferelltially stimu\ated by 
methoxamine. More recently, rvluramatsLl et al. 




a'A U 1b1B U
'd.'D 
prazosin high high high 
WB-4101 high low 
HV723 medium/low low 
compefitive 5·mu bmy 7378 
antagonist 
functional studies in different vascular preparations 
with five ut-adrenoceptor antagonists. On thc basis 
ofthc pKa valucs for prazosin and yohimbinc, the 
u,-adrenoceptor poptIiation could be c1assified into 
thrce subtypes, a tll • all or ((IN' The 
u,l-adrcnoceptor popltlation defined by Flavahan 
& Vanhouttc [38] was subdivided on the basis of 
the obscrved affinities for yohimbinc and thc ncw 
u1-adrelloceptor antagonist, HV723. In summary, 
the ulH-adrcnoceptor displays a high affinity for 
prazosin, the ulL-adrenoccptar displays a law 
affinity far prazasin and yahimbine, whcreas the 
ulN-adrenoceptor also displays a law affinity for 
prazasÎn, a relative1y high affinity for yohimbine 
ancl, in addition, a high affinity for HV723. 
Subsequently, in an attempt ta harmanÎse these 
functionally recagnised subtypes with the 
classification propased fi'am radioligalld studies at 
that time, Muramatsu and ea-workers proposed a 
seheme (TabIe 2) which recognises fOllr 
uI~adrenoceptors based on the affinities for 
prazosin, \VB~4IOl and HV723, with a m fmiher 
divided inta UIA and alB [41,42]. More reeent!y, 
Ford and co~workers [43] suggested a similar 
sllbclassification, however, these authors did not 
inc!ude the uIN~adrenoceptor in their seherne 
(Tabic 2). 
Current classification 
In attempt to obtain consensus on the nomenc1ahlre 
of ul~adrenaceptors, Ford and eo-workers [43] 
proposed a subc1assification in receptors displaying 
high (pKp>9: Ulfl ) and low affinity for prazasin 
Inlroduction 
ul10fficial Table 2 
Overall scheme of IIle 
all a m proposed 
a,-adrenoceptor 
low low subtypes {26. 40-43J. 
. The a'N-sublype is 
low low prinled in ilaliGs 10 
ilJdiGale Ihal it is nol 
low high wide/y reGognised. 
HV723 
(pKD<9: UIL)' The UIA ~adrenaceptor was suggested 
to be equivalent ta the ulc-adrcilaceptor and the 
am-adrenoceptor replaces the confusing alM) 
dcsignation. The c10ned receptor subtypes (UIA' 
a w, UlO) were classified in the UlII class. Shortly 
afterwards, this classificatioll was largely adopted 
by IUPHAR subcommittee on nomenclature for 
adrenoceptors [26]. The uJA-(=u JC)' all~- and a W H 
(previously called a lAiD or UIA) adrellaceptors are 
now officially recognised as subtypes (Tabie 2). 
Becallsc moieclilar cloning and radioligatld binding 
data on ulL-adrenoceptors is lacking this 
adrenaceptor was not dcsignated as a separate 
subtype. 
Initially, Hieblc and colleagucs [26) 
identificd 5-methylllrapidil as a selective 
alA-adrenoceptor antagonist and BMY 7378 as a 
selective ulD-adrenoccptor antagonist. Later, 
RS-17053, RS-100329, Ro 70-004 and KMD-3213 
were also identificd as selective ulA-adrenoceptor 
antagonists [44-46). Thc binding affinities for 
variaus uJ-adrenoceptor subtypes of several widely 
IIsed aud impOliant antagonists are prcsented in 
Table 1. Interestingly, until now a truly sclective 
ulIl-adrenoceptor antagonist cauld not be 
identified. Although the prcferential susceptibility 
to irreversible inactivation by CEC has been llsed 
ta subclassify ulIl-adrenoceptors, the lack of a 
selective competitive antagonist has impeded a 
precise quantitative eharacterisation of 
alIl-adrcnoceptors. Initially, radioligmld binding 
experiments suggested that spipcrone [29, 47] and 
risperidone [43, 48] might be competitive, sclective 
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allJ-adrClloceptor antagonists. Howcver, functional 
studies in rat, guinea pig and mouse spleen 
(fuJlctional alB-adrenoccptor tissues) wcrc not ablc 
ta eanfirm this [49, 50]. In Chapter 4 we 
investigated the functional phannacolical profile 
of (+)-cyclazosin a compound that behaved as aH 
a 1u-aclrcl1occptor sclectivc antagonist in 
radiaJigand binding assays [5 I]. 
The O:'A-/O:,,- adrenoceptor controversy 
In accordancc with the cloncd receptors, binding 
affînitics at native CI. 1-adrcnoceptor subtypes 
yiclded high affinities torprazosin; pK i = 9.9-10.1 
for a 1A on rat submaxillary gland [44, 52, 53], pK j 
~ 10.1- I 0.2 far u,. at rat Iiver [44, 54] and pK; ~ 
9.8 at a 1D rat aorta [55]. Morcover, functional 
experimcnts in rat aOl1a and rat spleen, functional 
a iD- and am-tissues [26], consistently yielded high 
affinity estimates for prazosin: pAl values were 
9.4- I 0.0 and 9. I - 10.0 for rat aOl1a [35, 40,52,54, 
56,57] and rat spleen [49, 52, 57, 58] rcspeetivcly. 
Thc controversy over the existellce of an 
ul-adrenoeeptor subtype, which displays low 
aft1nity values for prazosin, now appears to focus 
on tissues that were initially characterised as 
fllllctional uIA-tissues like for example: rat 
mesenteric resistance vasculature [43], rat vas 
deferens [8,43], rat pOl1al vein [35, 59,60] and 
hliJllan lower urinary tra ct (see [6IJ). The 
Cf.l-adrenoceptor mediated fUllctional response of 
rat vas deferens is weil studied. There is, however, 
110 agreement on the antagonising potency of 
prazosin. Ohmura et al. [42] demonstrated high 
and low affinity binding sites for prazosin in the 
prostatic as weil as the epidydimal p0l1ion of the 
rat vas deferells. Low affinity values for prazosin 
(pK"~8.2-8.6) in bath pOliions dcmonstratcd that 
<Xll,-adrelloceptors dominate the fllllctional 
response [42, 54, 57]. However, ot her groups 
suggested that the contraction of rat vas deferens 
is mediated by <xIA-adrenoceptors displaying high 
affinity far prazosin (pA,~9.2-9.3; [6,49,58,62, 
63]. The pAl va lues of several antagonists 
correlated best with amnities on uIa clones, the 
response was not affected by CEe, and was 
antaganised by BMY 7378 with low affinity (pA, 
= 6.7), thereby exc1uding a lB aud um-adrenoceptor 
14 
involvement [49, 62]. lnterestingly, the more 
reeently developed selective alA-adrenoceptor 
antagonist, RS-17053, recognises the previollsly 
dcfined ulA-adrenoceptor (by the same group) in 
the prostatic and epididymal vas deferens with 
different affinities (pKil = 8.3 aud 9.5, respectively; 
[64, 65]). The law affinity estimate of 8.3 is in 
accordance with the affinity of RS-17053 that wc 
estimated in the rat small mesenteric artery (SMA, 
Chapter 2)[66], anotheru'A-/ulL-tissuc (see below). 
Similarly, in independent studies, <xl-adrenoceptors 
with law amnity (pA,~8.4/8.5; [35, 57]) as weil 
as high amnit)' (pA,~9.2; [59, 64]) lor prazasin 
were suggested to mediate the contract ion of rat 
portal vein. The u 1-adrenoceptor of rat pOI1al vein, 
however, displayed a 250 times lower potency for 
RS-17053 (pKB ~ 7.1;[59]) than rat vas deferens. 
Interestingly, this low affinity of RS-17053 is 
similar to the antagonising potency that was fotmd 
in human lowerurinary tract and prostate (pA2=7.3 
and 7.1 [44, 64]), which is another representative 
of a tissue where uIA-as well as alL -adrenoceptor 
have been implied to mediate the contraction (sec 
[67]). 
Rat mesenteric resistance vasculature: 
U1A or all 
Although thc rat isolated perfused meseutery was 
defined as a functional alA-adrenoceptor tissue 
displaying high amnity forprazosin (pA,~9.3; [43, 
68]), MePhcrsan et al. [69] alsa estimated a low 
affinity forprazosin (pA2=8.52) in this assay. Since 
small mesenteric m1elies (SrvlAs; intemal diameter 
1 00-300 ~lm) are believed to eantribute 
substantially to vascular resistanee in rat [70-72], 
isolated SMA assays have been used widcly as 
models of resistance vessels [70J. Högestatt & 
Andersson [73] and Nielsen & Mulvany [70] 
demonstratcd that prazosin antagoniscs 
noradrenaline-mediated contractions ofrat SMAs 
with high affinity (pA,~9.58-9.84 and 9.23, 
respeetively). Aeeordingly, it has been sllggested 
that <X[A -adrenoceptors predominantly mediate 
noradrcnaline-induced contraction ofrat SMA [74, 
75]. However, Schild analysis demonstrated 
complex antagollism by prazosin with its potency 
(pA,) ranging from 8.8 ta 9.6 and, therefore, 
additional involvcmcnt of alL -adrenoccptors was 
suggested [74]. Van der Graaf et al. [76] found 
th at dcspite significant cOlTciation of antagonist 
affinity values with pK j values at the cloned 
CJ.1a-adrcnoceptor, the pA, vaJuc ofprazosin in rat 
srvlA (8.5) was more consÎstent with thc profile of 
the phannacologically-defined all-subtype [38, 43, 
76, 77]. The affinity of RS-17053 in rat SMA 
(pKB~8.4; Chapter 2; [66]) was 35-fold lower than 
that reported by Ford et al. for antagonisillg pressor 
responses to noradrenaline in the perfused 
mesentery (pKB~9.9; [44]); the latter being in 
agreement with functiollal affinity cstimatcs for 
CJ. IA -adrcnoceptors in rat perfuscd kidncy (pA2=9.8; 
[44]) and rat vas defercns (pA,~9.5; [64]). 
Thereforc, it appears that CJ.1A-adrenoceptors 
mediate the pressor response in rat pcrfused 
mcsentery. whereas noradrcnaline-induced 
contractiol1 in rat isolated SlvIA is mediated by a 
different type of ul-adrenoceptor, possibly UIL' 
Emerging picture 
The different affinities in functionaI U 1'\-/ 
UIL -adrenoeeptor mediatcd responses indicate that 
RS-17053 can diseriminate at least three 
ulA-adrcnoceptor subtypes in the rat. A high 
affinity estimate was demonstratcd in epididymal 
rat vas dcferens (pK, ~ 9.5; [64]), rat perfused 
mesentery (pA, ~ 9.9; [44]) and rat perfused kidne)' 
(pA, ~ 9.9; [44]). Intcrestingly, this high affinity 
is similar to binding affinity ofthe ulc-clone (pK j 
~ 9.5; [44)) and might reprcsent thc "classical" 
a 1A-adrenoceptor. In addition two low affinity 
subtypes have been defined: an intermediate 
affinity subtype was demonstratcd in rat SMA and 
prostatie vas defcrcns (pK",pA,~8.3; [65, 66]), and 
a Iow affinity subtype in rat portal vein (pKB = 
7.1; [59]). This low affinit)' subtype was also 
demonstrated in lower minary tract tissues of 
humans and rabbits [44, 78, 79]. 
Intcrestingly, the classificatiol1 scheme of 
Muramatsu et al. previously suggested two low 
affinity u 1-adrenoceptor subtypes, alN and alL(see 
Table 2), which could be discriminated b)' a 
different order of afflnity for the antagonîsts HV723 
and prazosin [40]. Although it was suggestcd that 
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present in 11llman and rabbit prostate and rat 
epididymal vas deferens corresponded with 
lvIuramatsu's UIL -adrenoceptor [42, 79-81 J, the data 
with HV723 on the "intermediate" low affinity 
(pK, for RS-17053 ~8.3) subtype are to scarce to 
even suggest fu1l cOllgrllcnce wÎth Muramatsu's 
sehcme, with respect to the UIN subtype [40, 76]. 
It ShOllld be noted, however, that the assumption 
of three ul-adrenoceptor subtypes Jnight weil be 
an o"crsimplification of a range of affinities for 
RS-17053 that has becn observed in fUl1ctÎonal Uw 
l -adrenoceptor mediated responses (sec Figure 2). 
Possib!y more in line with the affinity range is the 
suggestiol1 th at the a1A-adrenoceptor cun present 
itsclf functionally in different affinity states [82]. 
Initia!ly, it was showll th at prazosill and RS-17053 
bind with subnanomolar affinity to cloned 
ula-adrenoceptors, whereas their potency to 
funetiona!ly inhibit inositol phosphate production 
by the same cells was one log unit Jower [82]. In 
Chapters 2 and 3 wc further c1aboratc on the nature 
ofthe u'L-adrenoceptor mediating the eontraction 
of the rat SMA. 
Vasopressin receptors 
Each species usually has two neurohypophysial 
h011110llCS: one belonging to the oxytocin family, 
illvoIved in reproduction, and one belollging to the 
vasopressin family, involved in cardiovascular 
regulation. Arginine-vasopressin (A VP) is 
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belicvcd to exelt îts action through binding to two 
major classes ofrcceptors (V[ and V2) [92]. Thc 
VI reccptors can be subdivided in Vla and 
Vlh rcceptors. Vla receptors, present on blood 
vessels and hepatocytes, mcdiate vasoconstrictÎon 
and glycogenolysis, respectively [93]. V
'b 
receptors, present in the anterior pituitary, mediate 
ACTH~release [93]. An indirect vasopressor effect 
is establishcd via V 2 rcccptors located in the fenal 
tublile and collecting duet and they mediate au 
antidiurctic effect [93]. Oxytocin receptors mediate 
utcrine contraction and milk-ejection in response 
to oxytocin [93]. In general, stimulation of OT 
and VI rcccptors results in illcreascd production of 
inositol 1 A,5-triphosphatc and 1,2-diacylglycerol 
and an increase in intracellular calcium 
cancentratian [92,94-96], while V1 receptors are 
associated with an increase in intracellular cAI\r!P 
[92, 97-99]. Cloning of ral and human V" [100-
102], V, receptor [97, 103, 104], V
'b [105, 106] 
and OT receptor [107, 108] have been reported. lt 
should be noted that although AVP and OT have 
their characteristic responses they can interact and 
activate each other's primary receptor [109, IJ 0]. 
A V IA receptor mediated vasoconstrictor 
action is well-established in different species. AVP 
induced V IA receptor mediated eontractions of 
isolated human coronary [111], uterine [109], 
gastric [I 12] intemal mammary [113], mesenteric 
[114], deferential [115] and cerebral arteries [114, 
116, 117J, rat smal! mesenteric arteries [I 18] and 
rabbit arteries [119], dog coronary resistance and 
femoral arteries [I20, 121]. In addition to this 
overwhelming support for the inductian of 
vasoconstriction by AVP, evidence far the 
(ca-)existence afa vasodilator response to AVP in 
several regions of the circulation was provided. 
A VP was reported to dilate the rat pulmonary 
circulation [122, 123], canine large coronary [120, 
121] and cerebral at1eries [121, 124, 125] human 
cercbral [126] and mesenleric arteries [114]. 
Different pathways Iike stimulation of VI [121, 
122], V, receptors [114, 126], in addition 10 all 
atypical pathway [114, 126] were reporled to 
establish this vasodilator response. The recent 
discovery of operative cardiovascular OT receptors 
on a hu man vascular smooth muscle cellline [95] 
and in rat cardiac tissue [127] might result in a 
complex action of AVP andlor OT on the 
vasculature. 
After charactcrisation of the vasopressin 
receptor(s) involved in the contraction of the rat 
small mcsenteric artery and aorta (Chapter 5) we 
studied the interaction between AVP and 
noradrenaline in rat SMA (Chapter 6). 
Aims and outline of the thesis 
In the classical receptor concept the binding 
afflnity is the only relevant parameter whieh 
accounts for an antagonist's capabiJity to recognise 
a receptor and fonn a complex with it. 13ecause 
this affinity is considered to be agonist and system 
independent, antagonist affinities for a given 
receptor are not expected to differ between 
functional and binding assays. Until recently the 
a1A1L-eontroversy was mainly based on the 
funetional affinity estimates for prazosin, which 
discriminated functional a iA- from 
alL-adrenoceptors by a one-log unit difference in 
affinity. This 'small ' diffcrence has not been taken 
serÎous by everyone. However, in 1996, Ford and 
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colleagues developed a selective a lA -adrenoceptor 
antagonist, RS-17053, which displayed more than 
IOO-fold discriminatory potency between 
functional a iA- and alL-adrenoceptors [44]. This 
fin ding flIrther substantiated the a 1/ 
IL-adrenoceptor controversy and provided a useflll 
tooi for fmther studies. Despite its recognised 
potential as a drug target in a cloning era, intensive 
cloning has th us far failed to identify a gene coding 
for the all.-adrenoceptor. This led several 
investigators to the bclicfthat the alL -adrenoceptor 
might not exist as a separate genomic entity, but 
Dlight be a conformational affinity state of the 
ala-gene product. However, traditional receptor 
theory does not account for affinÎty statcs. 
Thercfore, the alAIIL -adrcnoceptor controvcrsy 
l11ight pose a serious challengc for the classical 
concept of rmtagollist-rcceptor intcractiol1. 1110Ugh 
in the last decade this traditional theory has been 
questioned often by obscrvations in genetically 
cngineered systcllls such pressure is less C0111l11on 
from native tissue systems. Bccause ofthe possiblc 
impact of th is controvcrsy the primary objcctive 
ofthis thesis was ta filrther charactelÏsc and anal ysc 
the C,(IL-adrcnoceptor phannacology in rat StvlA. 
Thc Si'vIA cmbodies a reference model for studying 
the a lN1L -adrcnoceptor controversy. 
In Chapter 2 alld 3 wc aim to determinc the 
C(I-adrenoceptor subtype il1volved in the contractile 
response of rat SMA, and obtain further insight in 
its phannacological profile. ft has been suggested 
that the UIL -adrenoeeptor represents a 
pharmacological phcnotype of the 
alA-adrenoceptor gene product that is detenllined 
by environmental conditions. In Chaptel' 2, by 
using functional phannacological tools, we aim to 
identify factors that could or could not account for 
thc observed profile. Furthenllore, we investigate 
the possibility that U1A- as weil as 
ulL-adrenoceptors are co-existing subtypes in the 
Si'vlA, but the exhibition of either subtype Illight 
be favaured by experimcntal conditiolls. 
rvlcasurements of agonist affinity for 
a,-adrcnoeeptors in funetional studies displayed 
eonsiderable variability within a given tissue. 
Variabie receptor affinity rather than different 
subtypes, has been proposed to account for the 
variation in estimated agonist affinities [I 28J. 
COllsidering the variabIe receptor affinity for 
agonists, it is reasonable to assume that the affinity 
for other ligands, Iike antagonisls, mayalso vary. 
Thus, variabie receptor affinity cOlild passibly 
account for the observed alL-adrenaceptor 
phannaeology in rat SMA. In order to investigate 
this variabie affinity hypothesis in rat SMA we 
Introduction 
studied the agonism of noradrenaline by analysis 
of receptor inactivation expcriments (Chapter 3). 
Radioligand binding experiments initially proposcd 
spipcrone and risperidone as competitive, 
a lll-adrcnoceptor sclective antagonists. However, 
fUllctional studies were not able to confirm this. 
[29,43,47-50]. Thercfore, wc anticipatcd that also 
for the alB-adrenoceptor antagonist affinities 
measured in radioligand binding might diffcr from 
functionally measured estimates. In Chaptcl' 4 wc 
aim to investigatc this possibility by 
eharacterisation ofthe fUllctional phannacological 
protile of (+)-cyclazosin, a navel antagonist th at 
displayed selectivity for a1b-adrenoceptors in 
radioligatld binding experimcnts. 
In Chapters 2-4 we have focused on the 
phanllacological analysis of single receptor 
subtypes. However, the in vivo reality is that blood 
vessels are exposed to a variety of vasoactive 
substances, which stimulate different types of 
reccptors simultaneously. Therefore, functional 
responses in in vivo physiological and 
pathophysiological situations will be the resllit of 
interactions betwecll different receptor subtypes. 
Becallse of its impOliance, it was aur objecth'e to 
study and characterise the interactioll between thc 
alL-adrenoeeptors aud vasopressin receptors in rat 
SlvfA (Chapter 6). Vasopressin was choscn for 
three reasans: (I) vasopressin is an extreme!y 
patent vasoconstrictor agent and may thereforc be 
involved in interactions cven at low concentrations, 
(2) vasopressin has beell suggested ta be invalved 
in pathological eonditions and (3) the interaetion 
between alL-adrenoceptors and vasapressin 
rcceptors has Ilot been the subject of extensive 
study. In order to study the interaction thoroughly 
it was mandatory ta nrs! characterise thc 
vasopressin receptor(s) that mediates vasopressin 
responses in rat SMA. This was the subject ofstudy 
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Analysis of IXIL-adrenoceptor pharmacology in rat small mesenteric 
artery 
'\Viro B. Stam, 2Pieter H. Van der Graaf & *"Pramod R. Snxena 
IOeparlmenl ofPhaml<lCo!ogy, Faculty ofMedicine and Health ScÎenccs, Erasmus Universily Rotterdam, P.O. Box 1738,3000 OR 
Rotterdam, 'fhe Netherlunds and ~Leîden/Amsterdam Center for Drug Rescarth, Division ofPhamlucology, Sylvius Laboratories, 
P.O. Box 9503. 2300 RA Leiden, The Netherlands 
To i!luminate the controversy on O'IA~ or ~IL-adrenoceptor involvement in noradrenaline-
mediated contraclions of rat smal! mesenleric arlef)' (SMA), we have sludied the effecls of subtypc-
seleclh'c êI:.-adrenoceptor agonisis und antagonisis under different experimental conditions. 
2 The agonis! potenc}' order in rat SMA was: A61603 > > SKF89748+A > cirazolinc > 
noradrenalinc > ST-587 > ntethoxamine. Pmzosin antagonized all agonisls with a low potency 
(pA2: 8.29-8.80) indicating the involvement of ctw mlher than yü-adrenoceplors. 
3 The pulati\"e (lwadrenoceptor antagonist JTH-601, hut nol the (lm-adrenoceptor antagonist 
chloroethylc1onidine (10 IIM) antagonized noradrenalinc-induced contraclions of SMA. The potency 
of the sekctive ctlD-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 =6.16±O.I3) 
and of the selective (llA+adrenoceptor antagonist RS-17053 against noradrenaline (pK ll =8.35±0.IO) 
and against the selective ctlA-adrenoceplor agonisi A-61603 (pK n=8.40±O.09) were too low 10 
account for ctlD- and ctlA-adrenoceptor involvement. 
4 The potency of RS-17053 (pK II/plVS=7.72-8.46) was not afrected by lowering temperature, 
changing experimental protocol or inducing myogenic tone I'ia KCI or U46619. 
5 Selective proteclion of a putative ctJ,\-adrenoceplor population against Ihe irrewrsible aclion of 
phenoxyhenzamine also failed to increase the polency of RS-17053 (pA2 =8.25±O.06 againsi 
A61603). 
6 Combined concentration-ralio analysis demonslrated Ihal tamsulosin, which does nol 
discriminale belwecn ct]A- and ctjL-adrenoceptors, Ilnd RS-17053 compeled for binding al Ihe same 
site in Ihe S~"A. 
7 In summaf}', data obtained in our experimenls in rat SMA indicate that the !X]-adrenoceptor 
mediating noradrenaline-induced contraclion displays a distinct !XIL-adrenoceptor phamlacology. 
This study does nol provide evidence for Ihe hypolhesis Iha! (llL+adrenoceptors represen! an atllnity 
state of the ClIA-adrenoceptor in funclional assays. Furlhermore, there is no co-exisling !XIA-
adrenoceptor in the SMA. 
Kc}"\\"Ords: A61603; (l[-adrenoceplors; Bl\1Y 7378; chloroethyJclonidine: noradrenaline: resistance vessels: phenoxybenza-
mine: prazosin; RS-17053; small mesenteTÏc artery (rat) 
Abbrc\iations: 5-HT, 5-hydroxytryptamine creatine sulphale; A61603, N-[5-(4,5-dihydro-1 H-imidazol-2yl)-2-hydroxy-5,6,7,8-
telrahydronaphthalen-l-yl] melhanesulphonamide hydrobromide: BMY 7378, 8-[2-(4-{2-methoxyphenyl)-I-
piperazinyljethylj-8-azaspiro[4,5]decane-7 ,9-dione dihydrochloridc; E/(A], concentratÎon-effecl: JTH-601, N-(3-
h ydrox)' -6 -met hoxy- 2,4,5-lrimeth yJben zyl)- N-methyl- 2-( 4-hydroxy -2-isopropy I -5-mei hyl- phcnoxy) ethylamine 
hemifumarate; KHS, Krebs-Henselheit solulion; RS-17053, N-[2-(2-cyclopropylmelhox}'phenoxy)ethyl]-5-chloro-
ct, ct-dimethyl-IH-indole-3-ethamine hydrochloride: SCH-23390, R( + )-7-chloro-8-hydroxy-3-methyl-I-phenyl-
2,3,4,5-tetra h yd ro-I H -3-benzazepi ne hydrochloride; SK F89748-A, )-5-me! h yIthio-8-methoxy-2-ami notehali IJ 
hydrochloride: SMA, small mesenleric arlcf}': ST-587, 2-(2-chloro-5-triftuomlethyl-phenylimino)-imidazolin 
nilrale; U46619, 9, II-dideoxy-II!X,9:t-epoxy-methanoprostaglandin F~, 
Illtroduction 
Radioligand binding studies and molecular biology experi-
ments have demonstrated the exislence of at least thre.:: !X I -
adrenoceplor subtypes, now referred 10 as ctlA (previously 
known as !Xlc), !X lB and (lID (previously nlso known as !XIA or 
(ll,\.D) (sec Hiehle el af., 1995). These subtypes have heen 
c10ned and all display high, suhnanomolar, affinities for 
prazosin. However, functiona[ studies have pro\'ided evidence 
for the exislence of an additional ctj-adrenoceplor subtype 
(!XIL), displaying low affinity for prazosin (pK II <9) and some 
olher ctj-adrenoceptor antagonists, including RS-17053 (Fla-
\'ahan & Vanhoulle, 1986; Muramalsu el al., 1990; Ford el al., 
1994. 1996). The !XIL-ndrenoceptor has no molecular corre!ale, 
*AuthoT fOT corrt'spondence; E-mail: saxt.na(!.fUmlaJgg.t.ur.n! 
hut secms 10 mediate conslriclion of the human (Ford el al., 
1996) and rabbi! (Van der Graaf el al., 1997; Kava cl al., 1998) 
[ower urinary tract and rahbit and guinea-pig aorta (Mur-
amalsu et al., 1990). 
In rat isolated small mesenlcric arteries (SMAs: internal 
diameter 100-300 Jun), Högeslall & Andersson (1984) and 
Nie1sen & Mulvany (1990) demonstraled that prazosin 
antagonizes noradrenalinc-medialed conlractions with high 
nffinity (pA~=9.58-9.84 and 9.23, resiX'Ctively). Accordingly, 
it has been suggested Ihat ctl,\-adrenoceptors predominantly 
mediale nomdrenaline-induced contraction of ral SMA (Chen 
cl ol., )996: Ipsen ('I al., 1997). Howe\"er, Schild analysis 
demollstraled complex antagonism by prazosin wilh lts 
potency (pA~) mnging from 8.8 -9.6 and, Iherefore, additiollill 
in\"olvement of ctn.-adrenoceptors was sllggested (Chen et ol., 
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1996). Van der Graaf et al. (1996) fOlllld that dc-spite significant 
corre1ation of antagonist afflnity values with pK; values at the 
doned ''''l,~Hdrelloceplor.lhe pA~ value ofpra7.osin in ral SMA 
(8.5) was more consistent with the profile of Ihe pharmacolo-
gkally-defined ((IL-subtype (Havahan & VanhouHe. 1986: 
McGrath & Wilson, \988; Ford et al., 1994). Adding 10 (he 
confusion wus a recent report th at CllB~adrenoceptors mediated 
contraclion in rat SMA (Piascik el al., 1997). Thus, thc (11-
adrenoceptor subtypes În\'olved in noradrenaline-induced 
conlractions in ral SMA are still controversÎal. 
Using severaJ subtype-selecti\'e -:l[-adrenoeeptor agonists 
and antagonists in the present investigation, we providc further 
evidenee that the (li-adrenoeeplors mediating conlraction of 
ral SMA are of the (lIl sublype. Since Ford and co-wor kers 
(1997) ha\'e suggesled th<J.I the <tIl subtype may represent il 
parlicular confomlalional state (pharmacological phenotype) 
of the (lJ,\-adrenoceptor gene product. we havc atlempled to 
elahoralc on the nature of thc observed fJll-adrenoceplor 
phannacology under different experimenlal conditions. 
Methods 
Rat smal! mesellteric arter)' preparatioll 
Male \Vistar rats (250-350 g) were anaestlletized (sodium 
penlobarbitone, 60 mg kg-I, i.p.) and killed by cervieal 
dislocation and the mesentery was removed and plaeed in 
iee-cold modified Krehs-Henseleit solution (KHS) of tbc 
foHowing composilion (OlM): NaCI 119.0, NaHC03 25.0, KCI 
4.7, KH1PO~ 1.2, MgS04 1.2, glucose 5.5, CaCh 2.5 and 
EDTA 0.026. Arterial trees \Verc dissected and cleared from 
surrounding adipose tissue. As dcscribed previously (Mulvany 
& Halpern, 1977), from each arlerial tree a ring segment 
(~2 mOl in length) was mounted in a myograph (J.P. Trading, 
Aarhus, Dcnmark) wHh separaled 6 mi organ baths containing 
modified KHS al 37°C (or al 27'C for certain experilllcnts; see 
below). The KHS was conlinuously gassed with 95% O~ and 
5'-'10 CO2 and tissue responses were measured conlinuously as 
changes in isometrie forcc. 
Fol!owing H 30 min stahilization pcriod, Ihe internal 
dia meIer of each vessel was set 10 a tension equivalent 100.9 
times thc estimated diameter at 100 mmHgeffectivc transmural 
pressure (I[((,=200-300/lm) according 10 Ihe slandard 
procedure of Mulvany & Halpern (1977). The presence oflhe 
endolhe!ium was Ihen confirnled with JO JIM of melhacJlOJine 
after a pre-contraction with either 30 IIM 5-hydro;"ylryplamine 
(5-HT) or 10 JIM noradrenaline (sec be!ow). Tissues which 
responded with less Ihrm 60% relaxalion were rejecled. 
Tn all experiments, 60 min prior to conslruction of each 
agonist concentratÎon·efiècl (E/[A]) curve, cocaïne (30llM), 
timolol (6 JIM) and SCH-23390 (10 nM) werc added to Ihe 
KHS to block neuronal uptake, PdP2-adrenoceplors and DI 
receplors, rcspeclively (Van der Graaf et al., 1995). 
Experi/1tcl/lal desigl/s 
Single WH;' design After nonmlization and a furlher 30 min 
slabilizalion period, a calibration contraction (12.8±0.5 mN, 
1/=49) was ohlained \0 30llM 5-hydroxytryptaminc (5-HT). 
After confimling the presence of the endothelium, tissues were 
washed for 30 min and then incuhated ror 60 min with an-
tagonist or "ehicle. Subsequcntl}', a single agonist Ef[A] curve 
was obtained by cumulali\"e dosing at quarter~log unit con-
l..'enlration ineremenls. In the experimenls where thc antagon-
Îsm of chloroethylclonidine was investiguled, tissues were pre-
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incubated for 30 min with 10 111>1 afthe drug. followed by a 30~ 
min washout period (ten solulÎOIl changes). 
Paired cU(I"e dcsigll After standardizalion of thc inlernal 
diameter, the preparations were challenged five times wilh 
noradrenaline (10 jl1>l) with wushouts after each challenge. As 
described aboVl', Ihe inlegrity of the endothe!ium was assessed 
af ter the fiest challenge of noradrenaline. After a firsl agollisl 
EI[A] curve was obtained (se.: Results), eaeh tissue segment 
was washed (30 min) and equilibrated (60 min) with \"ehic\e or 
different concenlratiolls or antagonist. Subsequently. another 
agonist E/{A] curve was constructed in Ihe presence of vehicJe 
or unlugonist. 
DctcrmillatioJ/ of affillit)' of RS-17053 lmder durerenl 
c.\jJcrÏlllelllal conditiol/S 
The antagonist affinity of RS-17053 was detemlined under the 
fol!owing experimental condilions. 
Low bathjfuid temperature Single CUf\'e design was used al a 
lemperalure of 2TC. 
Protocol according lil ellen et aL (1996) The preparations 
were challenged Ollee wilh KC! (125 mM) and subsequently 
three times with a combination of KCI (125 OlM) and 
noradrenaline (10 JiM), and once more with KCI (125 nm) 
with washouts after each challenge. After a first agonist E/[A] 
curve, each lissue segment was waslled for 30 min and then 
equilibmted for 60 min with vehieJe Or different antagonist 
coneentralions as described ahove under Paired curve design. 
Subsequently, another noradrenaline ElIA] curve was obtained 
and thc responses were cxpressed as percentage of Ihe fifth 
noradrenaline challenge whieh sen'ed as calihration contrac-
Iion. 
Depo/ari::llliol/ Il"ith K· beji}f(' mul after illcuhatiol/ of RS-
17053 The single curve design was conducted except Ihal 
noradrenaline E/{A] curves were obtained after parlial 
dcpolarization by KCI (20 I11M). This depolarization by KCI 
was applied either after or before incubation orthe tissues with 
RS-17053 (0.1 IlM). 
Pre-cmllractiulI lI"illi U46619 (10- 25 11.I1) The single curvc 
design was condueted except thai after incubalion wilh RS-
17053 (0.\ IIM). noradrenaline Ef[A] cun'es were ohtained on 
top of a threshold conlraclion wilh the thromboxane A:,-
mimelie, U46619 (10-25 nM). 
Selecth'e protectioll (!{ fll.Cadrl'lloCeplOrs 
In a set of four experimenls, after fi\"e challenges with 
noradrenaline (as in Ihe paired curve design) the SMAs were 
incuhated with RS-17053 (2 n1>!) for 60 min 10 selcctively 
proleet C<IA-adrenoceplors. At Ihis concenlralion, RS-17053 is 
expeeled to oecupy ~95% of the C<1,\-adrenoceptor poplllalion 
(based on a pAl of 9.9 as observed in the perfused mesenlery: 
Ford et al., 1996), whcreas it would occupy only -30% ofthe 
(lll-adrenoceptor populalion (based on a pA2 or 8.35: see 
Results). In the presence or RS-17053, Ihe alkylating agent, 
phenm.ybezamine (I nM). was added ror 15 min rollo\ved by 
extensive washing (10 solution changes over 30 min). Af ter a 
first A61603 EliA] curve had heen oblained, vesse! segmenls 
were washed (30 min) and equilihrated (60 min) wilh vehicle 
or difièrent çoneentrations of RS-17053 (10. 30 and 100 n'-l). 
Suhsequently, a ~ecol1d A61603 EI[A] cun'e was obtained and 
a1L-Adrenoceplors in ral small mesenleric artery 
the responses werc e ... pressed as percentage of fifth nomdrena~ 
line challenge, which served as calibration contmction. 
Individual agonist curve data were fitted 10 the Hili equation 
using an iterative, least-squares method: 
. a * [A]"/l 
f. -- [AjiU + [A]"/l 
10 provide estimates oflllidpoint slope (nu), Illidpointlocation 
({Ah estimated as logarithm) and upper asylllptote C~). The 
eITect of drug tn;atmenl on these parameters was assessed by 
one-wa)' analysis of variancc (ANOV A) or Stlldent's Hest. as 
appropriate. Vallles of P<0.05 were considered to he 
significant. 
Whcn the minimum criteria for competitiw antagonism 
\\we satisfied, that is the antagonist produced parallel 
rightward shifl of the agonist EftA] curves with no change in 
upper asymplote, antagonist allinity eSlÎmates \Vere oblained 
by fitting Ihe individual midpoint location values obtained in 
Ihe absence (log[AJ..,o) and presence (log[Ah-'B) of antagonist 
(B) 10 the following derivation of the Schild equation (Black ct 
al.. [985): 
10g[Ahoa = Iog[A]s!J + 10g(1 + [Bt /1O'",(K8 ). 
When the Schild plot slope parameter (b) was not significantly 
dinerent from unit}', Ihen the data were re-filled with b 
constrained to unit)' so that the antagonist dissociation 
equilibrium constant. KR' could bc estilllated as log Kn±s.e. 
(Jenkinson et al .. (995). When less than thre.! dinercnt 
concentralions of anlagonist were lesled or the criteria of 
competitive antagonism were not complete1y satisfied, an 
empirical pA2 value was estimated using the ahove equation, 
with h constrained to unity. 
Combinet! eOlleelllralÎOIl-ratio mwlysis 
In order to test whether RS-17053 and tamsulosin acted althe 
same site (syntopically), a combined concentration-ratio 
analysis was perfomled according to the procedure deve1oJX"d 
by Shankley ,md co-workers (1988). Briefty, when two 
antagonisls act syntopically, then their combined concentra-
(jon-ratio is given by; 
rBtC ='" rB + rc - 1 
where ril and r(" are the concentration-ratios oblained 
independently in the presence of the antagonists Band C. 
respectively. This relationship can he re-wrillen in temlS of 
log[A:;,] va lues of the agonist Ef[A] curves in the presence and 
absence of untagonisis Band C using Ihe following equation: 
SA = 10g[A.~O)B+(· -log({A.<nlB + [A.<oJc - [A5'J]), 
where S" is Ihe lest statistic for the addilive model. Thm, iflhe 
experimenlal data comply with the addilive model, SA should 
have a value of zero. In contrast, when two anlagonists act at 
different sites, that is allotopical!y, Iheir combined concentra-
tion-ratios lIlultiply; 
and expressed in lemlS of log [A~)J values; 
S.II = 10g[A.<fI)B+C -log{A.<oJB - 10g[A.ln]c + 10g[A.<o], 
whcre SM is the lest stalistic for Ihe lIlultiplicative model. Ifthe 
antagonists hehave al!otopicall)', SM should have a value of 
zero. 
Bec.:luse the distrihutions of SA and lts standard estimator 
are unknown, Ihere is no fonnal statistical method a\'<lilable 10 
decide in which cases the additive model should he accepted or 
rejected. In the present study. the nul! hypotheses (Hl,) was 
fonnulaled as '8+ C act synlopically' and it was assumed Ihal 
SA and SM and their associated standard error estimalors are 
approximate1y nOffiwlly distributed. Dc\'iations of SA and S.\I 
from zero were tested for significance using 1\\'0- and one-sided 
I-tesIs. respectiwly, alld Hro was accepted in cases whcn S,,=O 
<lnd SM <0. In al! other C,lses Ho was rejected. 
COl1lpOIllU/S 
Compouilds weT<~ oblained from the following sources; 
A61603 (N -[5-(4,5 - dihydro - lH -imidazol- 2yl) - 2-hydroxy-
5,6,7 ,8-letrahydronaphthalen-! -ylJ met!Janesulp!Jonamide hy-
drobromide); Abbotl labomlories, Norlh Chicago, IL. 
U.S.A.: cocaine hydrochloride. 5-HT, melhacholine bromide, 
I-noradrenaline hydrochloride, methoxamine hydrochloride. 
phenoxybenzamine hydrochloride and timolol maleale, 
U46619 (9,1 I -dideoxy- Ila.9~-epoxy- methanoproslaglandin 
F~»: all from Sigma, Zwijndrecht, The Netherlands: BMl' 
7378 (8 - [2 -14 -(2-methoxypheny!)-I-piperazinyl]ethyl]-8-azas-
piro[4,5]decane-7,9-dione dihydrochloride), ch[oroelhylcloni-
dine dihydrochloride, cirazoline hydrochloride and SCH-
23390 (R{ +)- 7 -chloro -8-hydroxy-3-methyl~l-phenyl-2.3A,5-
tetrahydro-! H-3-benzazepine hydrochloridc); all from Re-
search Biochemicals Incorporated, Nalick, !\fA. U.S.A.: 
JTII-601 (N-(3-hydroxy-6-melhoxy-2A.5-lrilllethylbenzyl)-N-
methyl-2-(4~hydroxy-2-isopropyl-5-methyl-phenoxy) ethyl a-
mine hemifumarate); Japan Tobacco Company, Tokyo, Japan: 
RS-17053 (N - [2 - (2 -cyclopropylmethoxyphenoxy)ethyl] - 5-
chloro-~, a-dimethyl- I H-indoJc-3-ethamine hydrochloride): 
Roche Bioscience, Palo Alto, CA, USA.: tamsulosin: 
l'amanouchi Plwrmaceutica! Co. LId .. Ibaraki. Tsukuba, 
Jaran; SKF89748-A (1-5-methylthio~8-methoxy-2-aminoteha­
!in hydrochloride): Smith Kline lleecham Phamlaceutica!s, 
King of Prussia. PA, U.S.A.: ST 587 (2-(2-chloro-5-
Irifluormethyl-phenylimino)·imidazolin ni tra te): Boehringer 
Ingelheim LId., Dracknell, 8erkshire, U.K. Noradrenaline was 
dissolwd in stoichiometric ascorbic acid solu\ion. Methacho~ 
linc was dissolved in ethanol. JTH-601 was dissolved in 
dimcthyl sulphoxide as a 10 pM stock solution and further 
diluted in dislil!ed waler. Phenoxyhenzamine was dissol\'ed in 
absolutc ethanol. RS-17053 was dissolved in a mixture of 10% 
dimethylsulphoxide, 20% propylene glycol and 70% distilled 
water as a 10 I!~I stock so!ution and further diluted in disti!!ed 
water. SKF89748-A was dissolved in a mixturc of 50% 
distil!ed water and 50% ethanol as a 20 mM stock solution 
and further di!uted in dislilled water. U46619 was dissolved 
initially În 20% ethanol to give a 1 mM stock solu!Îon and 
sllbsequent1y diluted in dislilled water. All other drugs were 
dis$olved in distilled water. 
ResIllts 
PotelIC)' ral/k order of arm/rel/oeep/or agollislS al/t! 
e./Jèct oflhe I/on-seleelil'c f'J.rat!renoceptor amogonÎSI 
prazosin 
The antagonism of prazosin (30 nM) against several agonists 
was studied in a paired curve design. All Cll-adrenoceptor 
agonists used in this in\'estigation contracted ral SMA, 
displaying either full (noradrenaline, cirazoline, melhoxamine, 
A61603) or partial (SKF89748-A, ST-587) agonism (see Table 
29 
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I). The potenc)' order (pEC'.<,,) of the agonisls in rilt St\lA was: 
1\61603 > > SKF89748-A=cirazoline > noradrenaline> 
ST-587 > methoxaminc. Half of the ST-587 EJ(AJ curves 
obtaincd were fitted wilh a fixed Hili slope (nI! = 5), sillce these 
individual cum:~s were extremel}' sleep. Prazosin (30 nM) 
antagonized the responses 10 al! six agonists and the atllnil}' 
estimates of prazosin (pA2: 8.29-8.80), which were consis-
tentl}' lower than those reported at êll-\-' 'lUI- or -'lID-
actrenoceptor subtypes (Burt el al., 1995: Ford e/ a/" 1996. 
1997), did not difTer belween agonisls (Tabk I). 
f:Ytèct of adrelloceptor olltagoJlisrs, clllaroefhy/clonidille 
(':1.18) Olld BM}' 7378 (7./1)) 
Noradrenaline produced concc::ntnltion-dependent contrac-
IÎons of SM As <lnd the individual E/[A] curves were fitted 10 
Ihe Hî1l equation to provide estimates of Ihe midpoinllocalion 
(pEC~,= 5.92±O.l!), Hî1l slope (nll=3.1±0.5) and upper 
asymplote (ct = 162± 16% of Ihe 5-HT ealibralion contrac-
Iion). Pretreatment of the lissues with 10 JI~I chloroethylclo-
nidine, a ligand known to irreversibl}' inactivate C1:w 
adrenoceptors (sC(! !Hebie ('/ a/., 1995), had no significant 
e!Tects 01\ the Hili parameters of the noradrenaline EJ[A] curve 
(pEC~.,,=5,71 ±0.09. nll=2.5±OA, ':1.= 162± 13% ofthe 5-HT 
calibration contraction (Figure I, lef! panel). 
In a concentration (100 nM) that is sdectiv.: for C1:H)" 
adrenoceptors (see Goetz el af., 1995), BMY 7378 did not shift 
Ihe Ef[A] cur\'t's 10 noradrenaline (data noL shown). However, 
Tabl.. I Hili p,Jfdmelers of JitTerenl ll,\-,ldreno<:eplor 
agonisls i.md llllinily e,tiu];!I'" for prdzosin in roll SMA 
(1/=4-6) 
l (% oflOJN 
IIlIrt/dr('/llIfine 
Agvnhl ('OIl1radÎolI) pl'.(',<1! 111/ pA! f'ra~tJ.IÎII 
Noradren~lîn~ 10218 6.3l±O.11 l.,H0.3 lUO±O,1' 
Cirazoline IOl±3 6.SHO.OS 3.6±O.8 8.44±0.O6 
l\lelho:\amine 9H4 5.0,H0.15 4.6±0.7 i01±O.I1 
SKF89N8·A 90±4 7.IHO.15 3.9± 1.1 S.5S±0.15 
A61603 109±4 8.15±0.05 l.J±O.3 8.80±O.OS 
ST-5S7 47± J\ 5.56±O.20 4.,HO.4 8.19±O.J3 
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higher concenlratiolls (I and 10 IIM) of llr.,tY 7378 produced a 
significant rightward shift orthe noradrenaline curve (Figure L 
right panel). and a pA2 value of 6. 16±O.13 was estimatcd. This 
pA! "alue is Illuch lower than thaI r\'ported for the C1:nr 
adrenoceplor in rat aorta (pA2 = 8.9; Goelz et al.. 1995). 
t..lIect 4 se!cctÎve 'X/,j-adrelloceplOl' {/1I{agolli~'{ RS-/7053 
againsl noradrenaline alld A61603 as agollisls 
Thc selèCth'e .:ll.\-adrenoceptor antagonist RS-17053 (10-
300 mI; Ford et al.. 1996) also produced concentration-
dependent, parallel. rightward shifts of the noradrenaline EI 
[A] curves. The Schild plot sJopt.' parameter (1.14 ±O. [I) was 
nol significantly difrerent from unit)' aod a pKB of 8.35±0.1O 
was eslimaled (Figure 2, upp!.'r panels). 
The selectivc "I,\-adrenoceptor agonist A61603 (Kneppa N 
al .. (995) behaved as a full agonist with respect to noradrena-
line aod [he Hili parameters were: pEC",=7.S2±0.12. 
llu=2.60±0.21. C1:= 149±6% of the 5-HT calihration con-
traclion (Figure 2, lower panels). RS-17053 (10-300 111>1) also 
competitiw:ly antagonized the A61603-induced contraclions 
(b= J.!4±O.09) nnd a pKB=8AO±O.09 was eslimated. 
E.Oèc/ (!f puta/he 'l./L-ad/'elloceptor muagoltÎsl JTH-60f 
agaillsf J/oradr{'1/alille as agollÎsl 
Previously. JTH-601 W,IS demonstrated to have a -10 times 
higher affinity than prazosin for the C1:ll-adrenoceptor. wher~'as 
ho th compounds displayed equal hinding affinities for Ihe ~IA 
receptor subtype (Muramatsu et 0/., 1996). In the SMA. JTH-
601 (3-IOO n~t) produced rightward shifts of the nomdrena-
line EJ[A] Curves (Figure 3). However, the shift did not occur in 
a concentralion·dependent manner. sinee the concentration-
ratios oblained with JO and 30 nM JTH-601 were practica!!}' 
identical (Figure 3). Fromthe shifts oblained with 3 and 10 mi 
11 pA2 "alue of 8.34±O.16 was estimated for the high aOlnity 
component. 
EJJèct of cxperÎmellfa{ conditiolls 011 tlIe C!t/illitJ' ('stimall' 
DJ RS-/7053 
It was reçentJy suggested thai the -:tIL -adrenoceplor, instead of 
being a distinct molecular enlil}', might represent a conforma-
" '" '" I ~ 












o (e); 1 (0); 10 (11) ,M DMY 7378 
Figure I Concentration-effect curws to noradrenaline in mt sma]] mesenteric af ter}' in the absence or presence of 
chlorÜl!lhyklonidine ([eft p~nd; 1/=3) and RMY 7378 (right p;mel; 1/=4). The lines shown sup<>rimposed on the me.an data 
points were simulated u~ing tbe Hili equalion. 
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o (e), om (0), 0.03 (B), 0.1 (0), 0.3 (A)"M RS-17053 
Figu(e 2 Lef! pJneJs. Concenlralion·effe~l curves 10 nO[;ldren~li[]e (upper panel: 11=5) nnd A61603 ([o\\,<;,r p.mel: 1/=5-6) obt,lined 
on rut SMA in the absence or presence of RS-17053. The-Iincs sll~rimpo;;ed on th", me.in data points \\'"re simul,Hed ming the Hili 
equation. Right p,l!lels. Schild plots for the intewction of RS-17053 \\'ilh noradunaHlle (Up~f pand) (Ind A6160J (lower p.lnel). 
Thc soJid Jines supenmpo<;ed on meao dat'l points wae simulated ming the p,lfameters ob\uincd from the con<;trained model fits. 
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o (e), 3 (0); 10 (B), 30 (0); 100 (A) oM JTH·601 
Figure 3 Left paneL Concentration-effc.:t curves 10 noradrenaline obtained on rat SMA in the absence or presence of JTH-601 
(11""5). The lines superimposed on the mean data points were simulated using the Hili equation. Right panel. Schild plot for the 
interaction of JTH-60l wilh noradrenaline. 
tional atllnily stale of the CiIA-adrenoceptor nnd thai it is 
possible 10 switch Ihe phammcological oïlL-adrenoceptor 
profile into an ((IA-profile hy changing experimcntal conditions 
(Williams et al., 1996). Therefore, we studied the antagonizing 
polency of RS-17053 under different experimental conditions 
(see Table 2). 
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Lml' hath fluit! Wil/flern/ufe When temperature was lowered 
10 27-'C, noradrenaline still produced concçnlralion~dependenl 
conlractions of the Sl\1As. RS-17053 (10- 100 01>1) behaved as 
a competilive antagonist (h=O.98±O.16) with an estimaled 
afllllÎly (pK B=8.421 thaI was similar 10 thai oblained under 
standard çonditions (Tab!c 2). 
Protow/ according 10 Cllell et al. (1996) In a recent study, 
ehen cl al. (1996). conc1uded thai noradrenaline-induced 
conlraction or thc SMA involves predominanti)' iil,\-adreno-
ceptors. In experiments carried out according 10 their 
experimental protocol (sec Methods fOT details), RS-17053 
(10-100 n:-l) again caused a parallel rightward shift 
(b=O.95±O.23) and dispJayed a similar affinit}' as under 
slandard conditions (pK11 =8.46: Table 2). 
Depolari:atiull wir" K- he/iJre (IIuf af ter illC/lhalioll of RS-
17053 Partial depolarization by KCl (20 m~l) after pre-
incubation with RS-17053 induced a threshold contractioll of 
4.7±0.7% of the 5-HT calibration contractioll. Under these 
conditions RS-17053 (0.1 JI~1) behave-d as a competitiye 
antagonist. The pA~ \'aIlIe (7.72±0.26: Table 2) was slighlly 
lower compared la standard condilions. but due 10 a large 
between-lissue variahility (95% confidence interval: ±0.63) 
this dilTerence was not slatÎslÎcally significant. Thc notabie 
large varÎllflce could indicate perturbation of the equilibrium 
~tween antagonisl and re-ceptor by 20 m~1 KCI. Therefore. a 
threshold contraction (6.1 ± 1.1 % of 5-HT calibration con-
traction) by partial depolarization with KCI (20 m~1) WHS 
induced before the 60 min pre-incubatioll wilh RS-17053 
(0.1 JlMl. Co-equilibmtion of RS-1705J and KCl (20IllM) 
decreased the variance (95% confidence interval:±O.33). but 
did nol significantly atTe-ct the affinÎly estimate of RS-17053 
(pA~=8.31 ±0.16: Table 2). 
Pre-collf{(1ctioll Jrith U466/9 (10-25 n\!) In the presence of 
a Ihreshold contraction induce-d by 10-25 nM U46619 
(l4.7±0.8% of Ihe 5-HT calibralion contraction). RS-17053 
(0.1 JIM) unexpectedly caused a significant flattening of Ihe 
noradrenaline EJ[A] curve (nJ[=0.9±O.l and 1.4±0.1. 
n::spe-cli\'ely, with or without RS-17053: 1'<0.05). Howe\'er, 
the eslÎmated pA! \'alue (7.87±0.33, Table 2) was not 
significantly ditTerent from the affinity of RS-17053 estimated 
under slandard conditions (95% confidence interval: ±0.80). 
SeleClil'e protectioll of Cl.J.radrclIoceptors 
If the CtlA- and CtIL-adrenoceptor are distinct subtypes, both 
might co-exist in rat SMA, but different experimental set-ups 
Illight favour the exhibition of one Ovef Ihe olher type. After 
se\eclÎ\'e protection of the putalive CtIA-adrenoceptor popula-
tion from inactÎvation by phenoxybenzamine (sec Methods), 
the affinity of RS-17053 against A61603 was assessed in a 
paired cun'e design. Hili slope parameters of the first A61603 
EI[A] curve weTe: nll=2.3±0.5. Ct=69.3±4.5% of the 
calihration contraction, pEC~n=6.37±0.1O. RS-17053 (10-
100 nM) caused a rightward shift of the A61603 Ej[A] curve. 
Notwithslanding a significant steepening oflhe A6!603 E/[A] 
curve (nn=3.21±O.26: P<0.05) with RS-17053 (100 nM). 
Schild analysis was perfornled (Figure 4). The Schild slope 
parameter was not significantly ditTerent from unit)' 
(b= 1.0~±O.l6l and the estimated pA2 (8.25±0.06) was 
praclÎcally identÎcal la the potency in untreated tissues 
(pK B =8.40±O.09: Figure 2). 
COlllbilll/tioll of RS-/7053 alld tall1511l0sill 
The previously demonstrated susceplibility of Ihe afflnity 
estimate of RS-17053 bul not of tamsulosin to expcrimental 
conditions (Wil!iams et al .• 1996) Illight indicate that RS-17053 
and lamsulosin act at differenl sites of CtIA-adrenoceptofs. A 
combincd concentration-ratio analysis experiment was de-
signed 10 test whelher RS-17053 and tamsulosin act 
synlopicaHy in rat SMA. As shown in Figure 5. both RS-
17053 and lamsulosin produced a parallel rightward shift of 




Figure'" Schild plot for the intewction of RS-17053 \\ith A61603 
arter selectiw pratection of (ll,,-adrenoceptors with RS-17053 (2 n!'>l, 
60 min) from inuctivalion by pheno;<;yh<'nZilmine (I n~l, 15 min); 
1/=4 (for detuils, sec l\lethods). The solid line superimposed on mean 
data points wus simuluted using the pardmeters obtained from the 
constr.Iined model fit. Please note thaI the E/[Aj curws have been 
omitted from lhe figure because they showed considerable \-ariability 
due to unpredictable c_,tent of receptor inactÎmtion by phenoxy-
henzamine in indhidual segments. 
Table 2 Effect of experimenta! protocol on the Hili equation parameters of noradrenaline and affinity e;;timates for RS-17053 in Tat 
SMA 
E.\"perime/l/alpr%eol 
(see Me//wi/.I for de/uil5) 
Standard* 
Low bath fluid temperature (27'C) (11""4) 
Protocol according to ehen el al. (1996) (n=3) 
Depolarization \\ith KT after RS-17053 (1/=5) 
Depolarizulion \\ith K+ before RS-17053 (/1=7) 
Pre-conlraction \\ith U46619 (10-25 11.\1) (11=5) 
Data are mean±s.e.mean. *Data from Figure 2. 
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Figun.' 5 Comhined concentration-fatio i.lIlal},!s: concentralion-
... [f1X1 CUf\'ö 10 nOf.:Jdrenaline ohlained on Tdl SMA in tbe ;,Jh,ence 
or pr<,sence of 100 mi RS-1705J, I n\! tamsulosin or hOlh 100 mI 
RS-17053 L!nd JO n\\ lamsu!o,in (1/=3 eJch). The jine, ,I1Own 
superlmposed on tbe me.1I1 data points Ilere simubted ming thc Hili 
equalion. Thc d.lshed [jne ,hows Ihe Joc.uion of the conc"fllration-
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Figure 6 Rebtion helweefl pA2 <,slimates in hurnan 100\er urin~ry 
tmet (Ford <'I lil., 1996) and pKa1pA: .:';Iimate;; in rat SMA, 
delermined against noradrenaline (tbis study and V<ln der GW'lr el 
uf., 1996) rOf (I) BM\' 7378, (2) HV 723, (3) prazosin, (4) RS-17053. 
(5) tamsulosin. (6) 5-metbylunlpidil. (7J WB4101. Tbe solid IIne 
repreó;cnts tbe line or identity. 
and 20.8±3A, respectively; pA~=8.29±O.22 and 1O.06±0.20. 
respectivcly). The potenc}' of lamsulosin was in accordance 
with a prcvious reported value in rM SMA (9.8; Van der Graaf 
('( al., 1996) and wilh ils reported alTmity for .;t[L and :"lIK 
adrenoceptors (10-10.5: Van der Graaf ('I al .. 1996). 
Combinen concenlralion-ralio anal}'sis indicaled Ihat RS-
17053 (100 nM) and tamsuJosin (I nM) compeled for binding 
10 Ihe same sile, since the lest slatistic SA for Ihe additÎ\"e model 
(SA = ~O.J6±O.09) was not significant!)' dineren! from 0 
(P>O.05). whereas the lesl statistic SM for Ihe llIulliplicalÎve 
model was significantly smaller Ihan 0 (SM= -1.07 ±O.24: 
P<0.05). 
Discussioll 
The official nomenclalure of :"l[-adrenoceptors recognizes :"ll,\-. 
·êtw- and êtw-adrenoceptors. which have all heen c!oned and 
which uH display high, subnanomolar uffinily for pra:7.0sin 
(Hieble ('I al.. 1995). Based on funclional studies. an allerrwli\"e 
c!ussificalion scheme e.\ists. which n:cogrlizes ·:tU!- ,md ·:tIC 
adrenoceplors displaying high (êt l.\-. ·êtw- .md êtllradrenocep-
lors) and low afijnily for pmzosin, respectively (Fla\"ahun & 
Vanhoulte, 1986: McGr,lIh & \VilsOlI, 1988: Muramalsu c/ til .. 
1990; Ford cf (11., 1994). lJ('('ause oflhe reporled high (>9.2) or 
low ( <8.5) llffinity of pmzosin, the im'olvemenl of eilher êtl,\-
or ·êtwadrènoceplors in ral isolalèd SMA, which is helie\'èd 10 
represent rt'sislance vösel5 (Mulvany & Aalkjaer. 1990: 
Christensen & }"Iul\"llll)'. 1993: Fenger-Gron Cl al .. 1995). is 
controversiul (Högest::ill & Andersson. 1984; Niels('!1 & 
Muh'any. 1990: Chen ct tl/ .. 1996; Van der Gmuf e/ al .. 
1996). The prö('nl slud)' has further C.\umined this conlroversy 
using pmzosin und seveml recenlly discovered. sdecti\'e :"ll-
adrenoceplor antagonisls under differ('nl experimental condi-
!ions. 
Illm/l'ell/ml of 'l-ICtlt!I"t'IIOCCplOr ÎII thl' colltractÎolI (!f rat 
SMA 
The low allinil)' of prazosin (pA~=8.29-S.80) in rat SMA 
pro\"ed 10 bè ugonist ind('jlendent (TabIc I) and indicated êtlL-
adrenoceptor involvemenl (MuramalSu Cl til .. 1990). 1I may 
bc noled that Ihc aftinily or prazosin in our experiments \l"ith 
intact endolheliulll did nol diner from thai found in rut SMA 
denuded of endothelium (pA~=8.5: Van der Graaf el al.. 
1996). The poLcncy rank order of Ihc agonisls SKFS9748-A 
> dralOiine > noradrenaline > ST-587 > melhoxamine 
(TabIe I) mIs similar 10 thai ohser\"ed ror Ihe c10ned ((1.,-
subtypc (Minneman Cl al .. 1994), excepl for SKF8974S-A 
which was less potent Lhan bath drazolinc and noradrenaline 
al Ihe ((I.-adrenoceptor. A lack of eneel or chloroethylc1oni-
di ne (10 jlXI), which in Ihi5 conccnlralion inactivales Tilt :"l!!l"' 
adrenoceptors (Michel t'/ al.. 199.1: Sugden ('( u/., 1996). and 
the low potency of the potenl and selectivc é1n.,-adrenoceptor 
anlagonist BMY 7378 (pK i ror ral c10ned .êthl-adrenocep-
tors=8.2: Goelz cl (/f .• 1995) exc1uded the involvemenl of 
é1Ul' and :"lm-adrenoceplors, respcctive!y, in the noradrena-
line-induced conlraction of ral SMA (Figure I). Moreover. 
the aflinily or another pulati\"e Cl:JB-adrenoceplor antagonist 
(+)-cyclazosin (Giardina Cl al., 1996) in rat SMA 
(pK Il =7.78) did not indicate êt[lj-adrenoceptor involvcmenL 
either (Slam el al., 1998). 
The aflinity of Ihe seketive Cl:1A-adrenoceptor antagonist 
RS-17053 (Ford Cl al.. 1996) against noradrenaline 
(pK Il =8.J5) and ugainst the selecli\'c :"lIA-adrenoceptor agonist 
A6160J (pK ll =8.40) was 100 low (sec Figure 2) 10 account for 
C(IA-adrenoccplor invol\"cmenl (pK i for é11A-adrenoccptors in 
ral submaxi!1ary gland=9.1 and pA~ in Ihe perfused 
mesenlery=9.9; Ford el til .. 1996). Inlerestingly. JTH-601 
caused a complex shirt of Ihe noradrenaline Ej[AJ cur\"e 
(Figure 3) in ral SMA. Howe\'cr, funclional data for JTH-601 
on é11.\-adrcnoceptors arc required in order 10 assess Ihe nature 
of Ihis complex behaviour. 
Is t!te Cl.11.-adrenoceplor a coI1/Î.mllaaOlla{ slatc of 
Cl.1.radrenoceplor? 
Thc uffinity of RS-!7053 in rat SMA was 35 rold lower in 
the present experiments than Ihal reported by Ford and 
co!1eagues for antagonizing pressor responses 10 noradrena-
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lint' in the perfused mcscnlèry (pK[I=9.9: Ford (" uI., 1996): 
the lalter being in ugrcemcnl with fUllctiollal uffiniLy 
esLimales for ,xl,\-adrenoceptors in ral ~rfused kidney 
(pA2 =9.8: Ford cl al .. 1996) and ral vas deferens (pA2 =9.5: 
Marsha!l Cl al.. [996). Then::fore. il appears thaI '11.\-
udn.'lIoceptors mediale the pressor response in rat p-erfused 
mesenll'fy. wher,;-ils I1oradrellaline-induc('d çonlraclÎon in ral 
isolaled SMA is mediated by a different type of ·:11-
adrenoceplor. J1ossib!y 'lIL_ One e\:)llallulion [or Ihis 
discrepancy is thaI the prösor response in the perfused 
mesentery Lo noradrenaline reReels resistunce changes in 
dis lal arLerÎoks. which wen~ showII 10 co-determine vasen]ar 
resistunce (Fengcr-Gron el al .• 1997). 
Allernatiwly. thc :..'IL-adrenoceptor in the SMA assay might 
he a pharm3cologic.:t1 phenotype of the :;(l,\-adrl:nOCepIOr 
subtype (Ford Cl af .. 1997). Functional studies in rat vas 
defercns (Ohmura cl 11/ •• 1992: Prins ä a/.. 1992: Burt 1'1 aJ.. 
1995: Guh I't af .• 1995: Chess-Williams et al .. 1996: Muramatsu 
('I al .. 1996). port:tl win (Digg('s & Summers. 1983: Chess-
Willial11s ct al., 1996: Green et al.. 1996) and human lower 
minary tracl (se-e Hiehle & Ruffol0, 1996). where Ihe presenee 
of bolh :tIK and Q;lL-adrenocl:plor has been claimed on Ihe 
basis of prazosin allinity. ha\·c now produced a range of 
affinities for RS-17053. The high affinity for RS-17053 in ral 
\'as defcrens (pK[j=9.5: Marshall Cl a/ .. 1996) and perfmed 
mesentery (pA~=9.9: Ford Cl ol .• 1996) indicate-d ZIA-
adrl:noceplOr in\'olvement. However. an :;(IL-adrenoceptor 
displaying a 250 fold lower potenc)' for RS-17053 was found 
in ral porlal vein (pK u=7.\: Marshall el al .. 1996), hUJllan 
!ower minar)' lract (pA~=7.3: ford I't al.. 1996) and proslalc 
(pA~ '--' 7.2: Marshall ct al .• 1996). Interestingly, aparl from R$-
17053. Ihe affinity eslimates of dinerent anlagonists in Ihc 
SMA are in good agrt'<'menl wilh lhose delermined in human 
lower urinary traet (Figure 6). Thl: affinily of RS-17053 in ral 
SMA (pK B = 8.35) is marl: in accordllnee wilh an intennediate 
affinily \'alue demonsIraled in the prostalic portion of rat vas 
defercns by Burl and colleagues (pA~=8.3: 1998). Furlher-
more. accumulalion of ['H]-inosilol phosphales hy eells 
expressing the human z!,-adrenoceplor was anlagonized hy 
RS-17053 wilh simi!ar Întemledlale affinity (pA~= 8.3: Ford Cl 
al.. 1997). Consequently, lhe aulhors postulaled thaI Ihis Q;w 
ndrenoceplor was an nffinity state oftlle Q;IA-ndrenoceplor gene 
product. Taken together. these ohservations indicate thai Ihe 
SlrtleluraJ[y denned Q;IA-adrenoceptor cilher presents ilself 
functional!y as, or consisls of. al leasl Ihrt'<' dHferent subtypes 
whieh can he discriminated by RS-!7053. Indeed. in 
mdio!igand binding studies a complete switch from an (llL-
adrenoceplor pharmaco!ogical profile into an Q;lA-adrenocl:p-
lor profile could be indueed by changing e-xperimental 
conditÎons, whieh inc\uded (i) a decrease in tempemlure from 
3710 20··C, (i i) the use ofTRISjEDTA buffer Înstead of Ham's 
buffer and (iii) the disrupiion of cells inlo membmnes 
(Williams el al .. 1996). 
Thereforl:, we found il of interest 10 study whether a 
switch in the state of afilnity of RS-17053 can he eslablished 
in funetional studies wilh rat SMA (see Table 2). For 
ob\'iou5 reasons, in sueh studies one cannot employ TRISI 
EDTA bufter or cell mcmbranes as used in the radioligand 
binding assay (Williams et "I.. 1996). However, we 
determined the afilnily of RS-17053 at a lower bath 
lemperature. The pK Il eslimate of RS-17053 in Ihe Sl\.IA 
was unaffected hy decreasing the lemperatnre from 37 10 
2TC. Experiments carried out aecording 10 the protocol of 
Chen and co·workers (1996) demonstrated simple compeli-
live antagonism and also yielded an affinity eSlimate for RS-
17053 similar to that ohlained under standard condilions 
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and Ihu5 incompnlihle wilh Ihe suggested Q;l,\-adrenocl:ptor 
involvemenl (Chen ct al .. 1996). Intereslingly, high affinilies 
for RS-17053 have bt'<'1l estimaled in Jk'rfused assays, like 
ral kidney (pA2 =9,8 Ford cl al.. 1996). mesenler)' 
(pA~=9.9, Ford Cl al .• (996) or hind limb (pA~=9.47: Zhu 
et al .. 1997). The sponlaneous de\dopmenl of myogenie 
lonc in perfused vessels mighl he a major experimenlal 
differenee with Ihe SMA prepawtion (Dunn ct al.. 1994). 
We indueed myogenic tone in rat SMA hy either parlinl 
depo[arizalion \\'Ith KC! (20 n1.\1) or by a Ihreshold 
eontraclion with Ihe thromboxane A2-mimetic. U46619. 
U46619 was selecled. sinee thromboxane Al is produced by 
Ihe endolhelium. a tissue which runetion varics IIpon 
perfusion (Furehgolt & Vanhoulle. 1989). Intereslingly. Ihe-
induction of myogenic lone modified Ihe shape and location 
or Ihe noradrenaline EI[A] curves similar lolhal obsen·ed in 
the ral and rabbil pressurized perfused SMA (Buus el al .. 
1994: Dunn et lil .. 1994), hut did nol afl'ecl Ihe- anlagonizillg 
polency for RS-17053 (Tahle 2). 
Do !Oll' affinil)' ('J./c) (//ullll:r:h a.ffil/ity 
('l.l.I-adrenoceplors) si/es co-exisl iJl ral Sj\fA 
By selective inactivation of the Q;IL-adrenoceplors with 
pheno:\ybenzamine while protecling h\-adrenoceptors, we 
atlempted 10 unmask a putalive "'I.\-adrcnoceptor population 
in rat SMA. However, Schild analysis demonstrated a single 
receptor ngain displaying lol\' afflnit)' for RS-17053 
(pA~=8.25). Thererore, it is unlike1y Ihal ''''lA- and ':;(1l-
adrenoeeplors co-exist as distincl subtypes in ral SMA. 
Observations from previous reports led to the idea th at thl: 
Q;l ... -adrenoceptor antagonisls, lamsulosin and RS-17053, 
mighl acl al din'erenl si les at thc >'l.l-adrenoeeptor. which 
display differentiaJ sU5eeptibiJily for :tll1nity changes. For 
e:...ampk. e:-.perimenta[ conditions innuenced Ihe binding 
allinities of. among olhers, RS-17053 and prazosin, whercas 
Ihat of lamsulosin and indoramin renlHined unalTecled 
(Williams cl al.. 1996). Aceordingly, tamsulosin displayed 
similar affinitics for funclional "'l,,-adrenoeeptors and Q;ll-
adrenoceplors (Ford t'I til .. 1996). Combim'd coneentralion-
ralio analysÎs. however, indicaled Ihat RS-17053 and 
tamsulosin compete for binding 10 the Q;l-adrenoceplor site in 
ral SMA. which indicatcs Ihal bOlh Q;l-adrenoceplor antago-
nisls ael syntopically. 
In summary, data oblained in our experiments in rat SMA 
indicale Ihat (i) Ihe ctl-adrenoeeptor me-diating noradrenaline-
induced contraction displays a distinct (lll-adrenoceplor 
phamllleology, whcre both prazosin and RS-17053 have a low 
afflnit)'; (H) the afHnity of ctlL-adrelloceplor for RS-17053 is nol 
affected by changes in öperimental conditions: (iii) il is 
unlikely thalthere is a co-existing ctlA-adrenoceplor populalion 
and (iv) lamslllosin, whieh does nol diseriminale between CllA-
and Q;wadrenoceplors, acls al the same site as RS-17053. 
Overall. Ihis stud)' does nol provide evidence for Ihe 
hypothesis thai Q;ll.-adrenoceptors represenl an affinit)' stale 
oflhe Q;IA-adrenoceplor in funetional assHys (Ford Cl al., (997). 
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Abstract 
The alm of (his stud)' was 10 evaluate whether the operational model of ngonism can yield independent estimates of agonist affinity 
(pKA ) and eflîcacy (log .. ) when furchgoU's method ofirreversible receptor inactivation isemploycd. FOT !his purpose, the interaction be-
tween noradrenaline and phenoxybenzamine was studied in rat sma[[ mescnteric arter)' using a paired-curvc design. Phenoxybcnzamine 
pretrelllment produced a significant rightward shift and depression ofthe upIXr asymptote of the noradrenaline concentration·dfect (Er 
[AJ)cUTve. Although the operational model of agonism apIXared to pro\'ilk an adequate fit oflhe individual EliA) curves, a highly signif-
icant correlation was found between the eslimates of pKA ;:Ind log 7 (r = -0,80, p < 0.0001), inconsistent with the assumption that a(finity 
and efficacy are independent parameters (bestline fit: pKA = -0.96 x log 7 + 6.75). The pKA and log 7 estimates were not canelated \\ilh 
eilher the pEC,..,s ofthe control curves or upper asymptotes oftile phenoxybenzamine·treated curves. Sinlllialions showed thatthe cone-
lalion between affinity and efficac)' can be explained by the effect on the outcome of Ihe analysis of random errors in the response meao 
5urements. Therdore, although in theor)' Ihe operational model of agonism should provide independent estimates of agonist affinit)' and 
efficacy, tllis is unlikely to be the case with experimental data. © 1999 Elsc\ier Science Inc. AI! rights reserved. 
Ke}lwrd;: IlrAdrenu~.:pl{)rs; ACfinily; Effk3Ç)~ Furçhgott m.:!hnJ; Nomdrenaline; ()j1<.'raliun3t mllJd of agoni,m; i'hcnl>x}'b~nzamine: 
Sm311 m~s~nh:rîc arh'ry (ral) 
1. Introduction 
The idea that agonisl affinîty and efficac)' are indepen-
dent properties has been a central concept of classical phar-
macological receptor theory. In recent years, numerous 
groups have suggested that when Furchgott's (1966) irre-
versible receptor inactivation method is employed, agonist 
concentralÏon-effect (EI[A]) curves from control and trenled 
tissues cnn be fitted directi)' 10 Black nnd Leffs (1983) op-
erational model of agonism 10 obtain eSlimates of affinity 
nnd relntive eft1cacy for a varicty of receptor syslems in iso-
laled tissue bioassays (see, for example, Black t't al., 
1985n,b; Leff, 1988; Leff et al., 1990; Christie et al., 1992; 
Palea ('t al., 1995; SaIlés et al., 1996; Tabernero et al., 1996; 
Kramer et al., 1997; 1."lncLcnnan et al., 1997a; l'\'lartin ct al., 
1997; Pineda et al., 1997; Vivas et al., 1997; Watt et al., 
1997; Deymp et al., 1998), recombinant expression systems 
(Giles et lil., 1996; ~'laeLennan et al., 1997b) and;1/ 1';1"0 an-
• Prc,cnl ~dJrc,s: Pfl/cr Centr,l! Re,~,m:h. Disç\lwry Bjnj,,!",)'. S:md\\i,·h. 
K.:nt, CTIJ <,INl, UK. F.Lx· ++-+-I-jJn .. I-651-:.1.f.J; c-nuil: pkl_l'an_Jcc 
grJaf0' >anJ\\ kh.pfi/cr.çoijl 
imal models (Zernig et lil., 1996). A similar model-fitting 
approach has recent!y also been used to estimate ngonisl af~ 
finity and efficacy from EJ[A] curves obtained in cell !ines 
wilh different receptor expression levels (WHson et al., 
1996; Corli et al., 1997). Two kinds of experimenlal design 
are commonly used in irreversible receptor inaclivalion ex-
periments whieh aim to estimate agonist afl1nity and effi-
cnc)': a single- nnd multiple-curve design (Leff et (/1., 1990; 
Dougnll, 1998). With the single-curve approach, individual 
FifA] eurves from contra! nnd irreversibie anlagonist~ 
Ir~ated tissues are fitted simultaneously 10 Ihc operational 




E = --""--:-'--:'----, 
(KA + [A])" + ,". [A]" 
ti) 
10 obtain single eslimates of the maximum response achic\'~ 
able in the syslem (Em), Ihe sJope index of the occupancy-
effect functioll (n), and the agonist dissociation equilibrium 
conslant (KA) and imlividua! eS!Îmates of Ihe eftïcacy pa-
rameter (7) for each curve. Recently, we hnve demonslrnled 
thaI Ihe practical utility of this sÎmuitaneous fitting proce-
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dure is limited, bccuuse the outcomes are highl)' dependent 
on bctween-lissue variability of Ihc upper as)'mptotes of the 
conlrol curves and ma)' he unrelinble even undcr well-con-
trolled cxperimental conditions (Vun der Graaf nnd Danhof, 
[997). Thcrefore, it has been suggestd that whenever pos-
sib!e a multiple-curve design should be adopted in which 
prc- and posttreatment EI[A] curves are obtained in the 
same tissue to cslimate parameters that are not biased by be-
tween-tissue \'uriability (Leff et al., 1990; Van der Graaf 
und Oanhof, 1997; Dougull, 1998). Ta date, however, Ihe 
reliabilit)' of thc multiple-curve design has not been evulu-
aled in detail yet. Interestingly, however, Henry et al. 
(1992) have reportcd in a meeting abstract that the opera-
tionai model of ngonism in cOlllbination with the multiple-
curve design yielded aftïnity and eftïcacy values that were 
highi)' correlated across different expcriments, inconsistent 
with the basie assulllption that these parameters can be est!-
mated independently. Therefore, in Ihe present study, we 
have sludied the interaction between noradrenaline (NA) 
and phenoxybenzamine (PSZ) in rat isoJated smal! mesen-
teric artery (S~ofA) using a paired-cUfw design. We applied 
the operational model of agonism to analyze these data and 
found that the model yielded highly variabie and correlated 
estimates of affinit)' and efficac)', confirming the prelimi-
nar)' report by Henry eta!. (1992). On the basis of simula-
tions it is shown Ihat Ihis, at first sight unexpccled, vuriabil-
ity of and correlation between aft1nity und eft1caey can be 
explained by the eftÎ.'ct on the outcome of the analysis of 
random errors in the response measurements. This indicales 
Ihat the multiple-curve design does not necessarily provide 
areliabic alternative for the single-curve method. 
Prelilllinary accounts of these data were presenlcd to the 
British Phamlucological Society (Vun der Graaf, 1996a,b). 
2. i\Icthods 
2. J. Rat i.wlated sliU/llm!.'st!lIfnic art!.'l)' preplIratitm 
l\'lale Wistar rats (225-300 g) were killed by cervic,ll dis-
location, and the mesenlery was reJlloved nnd placed in iee-
cold modified Krebs-llenseleit solution (KHS) of the fol-
lowing composition (mr..'I): NaCII19.0, NaHC03 25.0, KCI 
4.7, KH1P0.t 1.2, MgSO~ 1.2, glucose 5.5, CaCI2 2.5, and 
ethylenediaminetetru-acetic acid (EDTA) 0.026. Six arterial 
trees were dissected from each Illesenteric vascular bed and 
cleared from smrounding adiposc tissue. From each arterial 
tree, a rv2-mm ring segment was lIlounled in a small-vessel 
myograph (l.P. Trading, Aarhus, Denmark) with separated 
6-mL organ baths (thermostutically controlled at 37 :::!::. 
OSC, containing the KHS und continuously gassed with 
95% O2 and 5% COl) as described before (Van der Graaf et 
al., 1996). The endothelium was removed by gentie rubbing 
of tbe inti mal smface with u thin, scoured, Illetal wirc. Tis-
sue responses were continuollsly measmed as changes in 
isometrie tension and displayed on pOlentiometric chart re-
corders. 
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2.2. E.\l'erilllt!/Ital protocol 
Following a 30-min stabilization period, the intemal di-
nmeter of each vessel WilS set la a tension equivalent to 0.9 
times the estimuted diameter at 100 mmHg effcctive trans-
mura! pressure (lwo = 245 ± 7 1J.1ll, 11 = 30) according 10 
the slandurd procedure of ~·tulvany und Halpern (1977). Af-
ter a further I."i-min stabiliwtion period, tissues were ex-
poscd to tïve concentrations of NA (I 0 f.1M), separated by 
5-min washout periods. Thc absence of functional endothe-
Hum was confirmed by the lack of a relaxation response la 
10 f.1M of the acetylcholine !\'I-receptor agoni.st 5-methyl-
furmethide, added to the organ bath after the fifth exposure 
la NA had produced a plateau response. Effects wen;! ex-
pressed as percentage of the response (7.8 ± 0.5 mN) pro-
duced by the fifth exposure to NA. After a IS-min washout 
period. tissues were incubaled for 90 min with 30 f.lM co-
caine and 6 f.1M timolol to block neuron al uplake and 
~-adrenoceptors, respectively, and a fiTSt NA E/(A] curve 
was obtained by cumulalÏve dosing at third- or half-log unit 
concentration increments. Following a 15-min washout pe-
riod, tissues were exposed to 0.1 nM (30 or 45 min) or I oM 
(lO or 15 min) PBZ and were subsequently washed for 30 
min. Cocaine and limolol were Ihen incubatcd as described 
above and a seeond NA E1[A] curve was oblained in each 
tissue. 
2.3. Data 1II1l1lysis 
2.3.1. Hili cfJuatioll 
Individual agonist curve data were fitted to the following 
form of the Hili equation, using an iterative, least-squares 
methad {Eg. (2)]: 
a'[At" E ~ ----'~'-'--;;: 
EC50 OH + [At' 
(2) 
to provide estimates of midpoint slope (nH)' midpoint loca-
tion (ECso, estimated a<; a logarithm) and uppcr asymptote 
(a). The effect of drug treatment on these parameters was 
assessed by Student's paired Hes!. Yalues of p < 0.05 were 
considered 10 be significant. 
2.3.2. Estim(/titm of NA (/ffll/it)' mul efficlicy 
Agonist affinity and efficacy estirnates were obtained by 
fitting each pair of control and PBZ-treated curves directly 
la the operational model of agonism [Eg. Cl n, providing a 
common estimate of F'"1II' KA und 11 for cach pair and two 'I 
values, 'T""ntwh .md 'TU,.H',j, for the control and PBZ-treated 
curves, respectively. KA' 'Twl1ln ,!, ;md 'T!f<"dlc~ were estimated as 
logarithms, because these parameters arc assUllled 10 be log-
normally distribuled (Lcff t't al., 1990; Christopoulos, 
1998). The cSlimales of~" pKA (that is -log KA)' 11 and 
log 'T"onln,l frolll each pair of curves were then used la ca\cu-
late means :::!::. S.E. mean. The fitting procedures were car-
ried out on a YAX 6000-310 computer employing the AR 
module (derivative-frcc, nonlinear rcgression) ofthe BMDP 
statistical software package (Dixon et al., (990). Por the 
simtt!atiOIl studies (sec ChriSlopoulos, 1998), 100 pairs of 
theoretical E/[A] cur\'eS \Vere generated with the opcra-
tional m(}(lel of agonism and mndom error was added to 
each simulated data point wilh the statistical software pack-
age S-PLUS ("ersion 4.5, tvlathSoft U.K.). Ench pair of sim-
ulnted Ef(A] curves was subsequclltly fitted 10 the opera-
tionalmodcl of agonism as described above. 
2.3.3. Graphical test /(/ lIS.W:.H Ilte goot!lIcss-of-fit 
Blad: and Shankley (1990) have de\'cloped n graphical 
method 10 visualize systcmntic devintions of curve fits ob-
tained with the operational model of agonism from experi-
mentnl E/(A] data. Briefly, it was shown that a plot of 
- loge l-aJE.n) against log EC;.o data [rom rectangular hy-
perbolie agonist EI[A] curves obtained in Ihe presence and 
absence of pretreatment with irreversible antagonist should 
yield a !inear plot with unity slope. This tesl, howcyer, only 
applics for rectangular hyperbolie E/[A] curves Ilnd could 
not bc used for the NA EI[A] curves in Ihe SMA, since the 
slopes of these curves were fOllnd 10 be significantly greater 
than unity. Therefore, an equivalent has been derived for 
nonrcctangular hyperbolie curves from the operational 
model of agonism. Thc Hill-equation parameters, 0: and 
EC5Q, are related to the operational model parameters Eru' T, 




I + t n 
(31 
KA 
ECSO = n IIn (4) (2 + 1") ~ I 
From Eq. (3) and (4), for an)' experimental curve, Eq. (5), 
," ;;;; __ a_ = (KA + EC50 )" _ 2 
Em~a ECso 
(SI 
whieh can be rcarranged as fo11ows: 
10g((Em~a + 2 yin -I) ;;;; ~ log EC50 + 10gKA (6) 
Therefore, a plot of log {Ca/En, -0:)+2)J/L J} against 
-log (EC5c1KA) should yield a straight line wilh slope of 
unity and abscissa intercept of zero. Nole that when 11 = I, 
corresponding to a rcctangular hyperbolie E/[A] curve, Eq. 
(6) simplifies 10 Eq. (7): 
-log(l- ~);;;; -logECso+logK A Em (71 
whieh is the cqualion derived by Black and Shankley 
(19901. 
2.4. CompOl/llds 
Compollnds wen: obluîned from Ihe following sources; 
cocaïne hydrochlorïde, I-noradrenaline hydrochloride (NA), 
phenoxybenzamine hydrochloride (PBZ) and prazosill hy-
droehloride: Sigma, U.K.; chloroethylclonidine dihydro-
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chloride (CEC): Research Biochemicals Incorpornted, U.S.A.; 
limolo! maleate: Merck, Sharp & Dohme, U.K.; 5-methylfur-
mcthide iodide: Jnmes Black Foundation, V.K. 
NA was dissolved and diluted in stoichiometrie, uqueous 
ascorbie acid solution. PBZ was dissoh'ed in absolute etha-
nol. Prazosin was dissolved initiully in 50% ethanol 10 give 
a 2-mM stock sol ut ion and subsequently diluted in distilled 
waler. All olher drugs were dissoh'ed in distilled waler. NA 
solutions were made up each da)'. All other drug stock solu-
tions were slored below - 20"'C and diluted on the day of 
the experiment. The maximum volume of drug salut ion ad-
ministered la Ihe 6-mL organ baths did not execed 100 f-lL. 
Neither the vehicles nor the antagonists were found 10 pro-
duce significant effects on basal tone. 
3. Resull'i 
3.1. I!.jfec/sofPBZ 011 NA E/[AJ C/In'es 
NA (10 nM-30 flM) produccd concentration-dependent 
contraction of the SMA and the con trol EI[A] data (11 = 19) 
were fiUed 10 the Hili equation to provide eslimates (mean .:!:: 
S.E. mean) of midpoint localion (pEC50 = 6.69 .:!:: 0.07), up-
per <lSymptote (0: = 101.6 ± 0.9%), and midpoint slope (nH = 
1.45 .:!:: 0.08). PBZ pretreutment produced a significant 
rightward shift and deprcssion ofthe upper as)'mptote ofthe 
NA EI{A] curves (Fig. land Table 1). The Hili slopes ofthe 
NA EI[A] curves obtained after PBZ treatmenl were always 
slightly lower than the slopès of Ihe corresponding control 
curves, but Ihis effect was not significant tar an)' of the 
trealment groups as judged by Studenl's paired t test (TabIe 
1). 
The differences between the first and seeond NA curves 
were due 10 an effect of PBZ, sincc incubation with vehiele 
(10 f-lL ethanol) for 45 min (whieh was the longest incuba-
tion time used for PBZ) hud no significant cffects on the 
Hili slope parameters (pEC5Q = 6.63 .:!:: 0.10 and 6.64 .:!:: 
0.07; 0: = 102.0 .:!:: 1.9% and 102.6 .:!:: 2.0%; nll = 1.34 .:!:: 
0.12 and 1.32 .:!:: 0.06 for the first and second curve, respec-
liveI)', II = 5). FurlhemlOfè. the ruuagonistic effecls of PBZ 
were shown to he solely due to irreversible blockade of 0:1-
Tu\llc I 
HiJ! cqualinn par.l!nctcr c51irn~tcs (m('aIl :':: S.E. m('.lO) fnf nllrJtlr('nilinc 
c(lnc"c"ntruti(ln-.:ftê~·tl·urY,'S n\ltuineJ Iln rut ,mJlI me<;coterie artenes 
\ldorc .md uftcr treutmcnt with phcnu"yl>cnzumin(' 
rBZ treJtment pEC~) ,,' (~1) 
'" 
," 
Cnntr'll ó.ó') :':: 0.07 IOl.ó:,:: UH t.45 ± (l.OS ,y 
0.1 nM: 30 min 6.2[ :':: O.OÓ 'XL\ :'::05 UI} ± U.J4 3 
0.1 n;<.l; 45 min 6.32:':: U.U Jn.}: :'::4.2 IA3 :':: 0.12 4 
I n;<'!: 10 min 6.1') ± 0.14 5ó.J ± 5.3 1.25:':: 0.11 8 
I nM: [5 min 6.12:':: 0.00 12.0 ± 1.4 1.27 :':: 0.21) 4 





~fL:LCLt IQ IQ 100 10 5 5 50 5 O~ -6 -4 - -6 -4 - -5 -4 - -6 -4 
U:iL:tc:~ 10 100 IQ 10 5 5 5 5 
- -6 -4 - -6 -4 - -6 -4 -8 -6 -4 
12:, ik· 11: ~ IQ 10 IQ IQ '_ -6 _,'0 -6 _,'_ -6 _,'_ -6-' 
kê hé: ti: 1L.:, 10 10 10 10 5 5 5 5 -8 -6 -4- -6 -4- -(; -4- -6-4 
Fig. I. Indi\"idual (lJ.irs or cünccnlrati\\!l--Cffcct ':Uf',es tn nn"lurcnalinc nht:lln~d nn rdl smal! nlCsemaÎC arterie> bef"r.: (e) :md aCter (O) prc/r('"atm.:nl with 
ph,'[]o.\yh~[]I~!11inc (aHe) <ti 0:-'1 fnf 3D min; (dHg) 0.1 oM fnr45 min; (hHn) I nM fllr 10 min J.mJ (pHs) 1 oM [or 15 min. Th.: Jin.:s shlJwn wp.:-rim. 
po>cd on thc e.'p.:rimenlal lbla points \wr.: silllulatcd wilh thc nperJtiona\ m(Jdel of ag,lnism uling lhc jndiyidual parJmNCr cstimatcs gh"cn in Tahl" 2. 
Ahsdssac: 1nglo [no[,ldrcnaline! (M). Oro.linalç's: ~n:Cnlagc ofthe respnnsc 10 Ihc finh nllfadrcmlin.: (10 p.M) calîhratinn (nntracIÎon. 
adrenoceplors in the Sr-.1A, since co-incubation with the se-
lectÎ"c C'lrndrenoceptor antagonist, prazosin (20 nM, '"'-'6.5 
times the apparent affinit)' for o:(-adrenoceptors in rat Sr-.'IA, 
Van der Graaf et al., (996), produced complete protection 
against the effects of 20-min pretreatment with I nl',,1 PBZ 
(pEC.5ü = 6.16:!:: 0.08 and 6.22:!:: 0.05; 0: = \05.8 :!:: 4.59'0 
and 104.0:± 0.4%; nH = 1.88 ± 0.24 and 1.52 :!:: 0.05 in the 
absence and presence of PBZ pretreatment, respectively, 11 = 
3). In contrast, incubation 00 min) with another im.wersible 
O:I-adrenoccptor antagonist, chloroelhylelonidine (CEC, 10 
I-lM), had no significant effect on the NA W[A] response 
(pEC;.o = 6.31 ± 0.15 and 6.27 ± 0.09; ('( = 108.0:± J.4% and 
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102.2 ± 4.3%; IlH = 2.11 ± 0.12 and 1.93 ::!:: 0.11 in the ab-
sence and presence ofCEC pretreatment, respcclively, 11 = 3). 
3.2. Opuatiolltllll/odd of llgollismjiuÎng 
Each pair of NA control and PBZ~treated E/[A] curves 
was fitted to the operational model of agonism 10 provide 19 
individual seis of estimate-s of E"" 1/, pKA• log 'Tç,,,,!,,,l and log 
'TWat,-J (TabIc 2), from whieh mean alld S.E. mean valm's 
wen:: calculated (TabIc 2). Eslimated F411 values wem always 
greater than the upper asymplotes of the NA EJ[A] control 
curves, indicaling thai according 10 the model NA behaves 
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T~ble 2 
Op.:rJûnnal ml~cl "r agnnism p;lfJlllclcr C,!iIIll[C, nhlaincJ [rom fitting individu;!} pJir;; nf n"fJdrcnJline ~nn(cntralilln-çffcct <:l1r\"<'S uhtJin.:,] nn rJl smJll 
rTlCSCnlCnc arteries h..::fnre ,md aftcr trcalmCn[ wiLh phcnnx}'b.:nzarninc (Fig. I) 
Expçrimcnt' Eo' log '".",,1 log !".",.'J pK, 
" 
120.9 054 a.JO} 1.41\ 6.03 
h ')9.5 J.l8 U.1W' 1.22 5.43 
115.9 OJ!': O.22Y 255 6.10 
d 106.3 0."' 0.226 [.93 (dJ 
[125 Oj(i 0.3[6 U;1 5.'JO 
120.4 0.26 D.l5') 3.19 6.76 
, 12JJ! 0.25 0.128 2.11 6.71 
h 1105 0.91 -0.275 0.97 6.43 
101.0 0,88 0.172 2.00 5.!.:3 
j 105.7 0.112 0.0376 1.66 5.'" , 127.8 0.20 -O.Q.I,) .l60 6.38 
179.8 O.[] -0.379 Jjl 6.61 
m 1135 0.75 0.0816 l.W 6.4lJ 
" 
105.0 1.05 0.0109 1.03 5.56 
" 
J 10.[ 0.98 0502 1.23 5.46 
P 99.5 1.14 -0557 1.25 5.'}) 
4 158.5 0.21 -0.M5 UI 6A7 
156.7 0.20 -0597 1.81 6.57 
117.0 0...10 -0.486 2.24 (i52 
Mtan + S.E. me;).n 120.2 ± 5.0 0.60 ± 0.03 L88 ± 0.17 6.18 ± 0.10 
'Lellers çorrespnnd \0 the labels in Fig. 2. 
tE)\pre~s~J as perçentagc ofthe fjflh nllradf~naline (10 IlM) cJlibrJtÎnn respom~. 
as a partial agonist in the Si\·tA gencnlling 86.3 ± 2.5% of 
the maximum possiblc response. Thc individual cstimntes 
were uscd 10 simulate the curves shown superimposcd on 
the individual e;-;perimental data points in Fig. J. The goodness-
of-fit was assessed b)' tIle graphical test outlint'd in the i\kthods 
section. Jndividual value.s of log{(o:JE.n -a)+2)11n -I) and 

















Fig. 2. Rda!Înn h.:!lween Îmlivit.!ual ~$!imates oflng{("IE", -a)+2)1', - [I 
and -·[ng (ECÓ'JK.,) nb!aÎn~d frnm mrnld fitting of pairi of çontml and 
ph"n(l)\yhcn7aminc-tr~a!td llIwdt.!rCnJlÎne l'nncentratÎnn--cfftt\ çur\'~s 
nhlain.:d Iln cdl sm:JlJ m.:s.:nleri~ art~ric;;. 
0.99, p < 0.0001), and linear regression )'iclded a slope 
whieh was not significanti)' different from unit)' (1.04 ± 
0.03) and an absdssa intereept whieh was not significantly 
different from zero (-0.03 ± 0.02), indicating that the 
model provided an adequate description of the experilllental 
data (Fig. 2). 
Howè"er, a highly significant, negative correlation was 
6.5 • • 
• 6 
• 
5.5 •• • 
o 0.5 1 
log T con trol 
Fig. 3. Rd~linn I>.:!w~.:n indiviuuJl C5tÎm~t~s nf (pK,,) ;mt.! Cft1l'JC)' (log 
<.""r,'I) nhtain~J from lÏuing pairs of clIntrnJ and ph~n(l.,,)'l>.:n7.amin.:­
tr~ateJ n"rJd!~nJline c()nl'~nlrJlinn--cff~ct .:urws nhlaineJ on rat ~maJJ 
mesent~rk arlcrin In th~ np.:wlinnaJ mnucl (Jf agonism. 
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fouod between the individual estimales of pKA and log 1"(,<1[1\'1 
(r = -0.80, p < 0.0(01), inconsistent witb Ihe assumplion 
that aftinity aod eft1cacy are independent model parameters 
(best line fït: pKA = -0.96 X log T",ntf,.! + 6.75; fig. 3). 
Thc pKA <tod log 1",,-.mw! estimates \Vere not correlated with 
the pEC50 values of thc NA eontrol curve (I' = 0.31 aod 
0.30. respcctively, p > 0.01. Fig. 4), Furthennore, the oul~ 
comes of thc model iïtting were independent of the degree 
of receptor inactivation, sinee pKA aod log ",''''lwl weTe not 
significant I)' correJated with Ihc upper asymptotcs of the 
PBZ-Ireated curves (I' = -0.33 aod 0.14, respectively,p > 
0.1, Fig. 5). 
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Fig. 4. Rcblinll bNwC~[] indiviJuJl çstirnJICS of p{lICn~y (pEC.,.,) ~ml (a) 
aftlnily (pK.,1 am! {hl dfiL"aG (log T.~",~,!) obl~incJ from fitting p~ir;; or 
~ontrol anti phenl,:o;}·ocntanlinc·tr<.'ateJ nnradren~linc con~enlrJli()n--.:ffcçt 
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fig. 5. Relalion hctw""n indi\"idual cSlimJ.les nf Ihe upp.:r <lsymplo!e aCta 
phcn"xyocn7aminc lrealmenl (o~,.<.-Jl and (a) affinily (pKA) and {hl effi-
~a~}' (log T,w.,,"",) \'alucs ohtaincJ frnm filling pairs of ~ontrnl aIld phenoxy. 
ocnzaminc-lrcatcd noradrenaline l:onccntratÎon-·dfe..:t CUTves ublaincJ IOn 
ral small mcscnleric arteries In Ihc 0l'eratinml model of agnni,nl. 
3.3. SilllllfatÎlms 
In an altempt to investigate whether the correlation be-
tween affinity and eftkacy was due to a statistical rather 
than a pharmacological phenomenon, a simulation study WIL" 
perfomled. First. "perfect" control and PBZ-treated E/[A] 
curves were simulated with the opcrational model of ago-
nÎsm using the average parameters estimaled for NA (Em = 
120.2. log T,~,"tn>l = 0.60, log Ttr.\'I.oJ = 0.00. n = 1.88 and 
pKA = 6.18; Table 2) and the same dosing scheme as em-
ployed in the experiments. The second step was 10 add ran-
dom ooise 10 the data points 10 simulnte the influence of ex-
perimental error in the response measurements. For the 
nineteen experimeolal NA control cun'cs, Ihe coefftcieol of 
variation (CV) for each data point was found 10 be rcluted 10 
the eflèct level (E) as follows: log CV = -0.02 X E + 
2.34; r = 1.00). Although Ihis empirical reJationship coo-
tains bath inter- and intratissue varinbility, for the sake of 
simplicity il was assumed that intertissue variability was in-
significant sinee all responses were nOfmulizcd to a calibra-
lion response. Thus, the linear relationship between log CV 
and E was used 10 add random noise 10 thc data points as if 
Ihey onginated from a nonnal distribution and 100 pairs of 
curves were simulated and subsequently fitted to the opera-
tÎonal model of ugonism. Although the meun affinity and ef-
ficacy estimates were praclically identical to the "truc" 
mean \'ulues used for the simulation (pKA = 6.29 ± 0.0-1-
alld log 'T,-<<lln'l = 0.56 ± 0.03; 11 = 100), individual pKA and 
log 'Tn>ntml estimated varied over ",,2 log-unit between tissues 
(Fig. 6). The correlation be!ween indi\'idual pKA and log 
'T"<,ln.'1 estimates was highly significant (r = 0.94, p < 
0.0001), and the best !ine fit was practically identical 10 the 
one obtuined from the experimental data (pKA = -1.16 X 
log 'T,-"n!n'1 + 6.94; Fig. 6). 
4. Discussion 
The operational model of agonism has beeorne a stan-
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Fig. 6. Re]aûon ~Iwe\:n individual cstimalcs of affinity (pK.\) and cffkacy 
(log T"",,"".~) ohtainè'J [rmll /luing 100 pairs of simulatcJ c(\ncè'nlratilln· 
eff<"Ct curves /t) the op.:ralinnal model of agonism. In all simubtiOrl5, pKA 
amllog T".,~,! w<:re fixcd al 6.1& and 0.60. rC;;p.:clively, and thc dcvblion; 
from th<:se '·(ruc·· valucs are thc rc,ult uf nlIldom norse add<i.l 10 Ihc data 
pornis (se\: lexl for dctails). 
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10 estimate agonist affinit)' and effîcacy from receptor inac-
ti vat ion experiments (see Introduction for references). Re-
centl)', we have demonstrated that the simultaneotls fitting 
melhod, based on a single-cur\'c design, onl)' )'ields reliable 
aftïnity and eftïcac)' estÎmJtes when therc is practical I)' no 
between-lissue varialion of the upper as)'mptotes of the con-
trol curves, which limits to a great cxtent the utility of this 
approach for the analysis of expcrimental data (Van der 
Graaf and Danhof, 1997). In the presenl stud)', the alterna-
tive approach of a multiple-curve design was cvaluated us-
ing both experimental anti simulated data. The main finding 
was that thc operational model of agonisrn yielded highly 
variabie and correlated estimates of aftïnity and eftïcacy of 
NA at O'I-adrenoceptors in the ral SJ\-IA assay, inconsistent 
with the basic assurnption that these are independent param-
eters. Remarkably, thc individual pKA estimates \'nried over 
1.3 log units between different tissues (Tabie 2; Fig. 3). Pre-
viousl)', Bevan et al. (1988) have shown that the apparent 
aflïnit)' of NA for the O'I-adrenoceptor, determined by 
Furchgou's melhod, varied by over Ihree orders of magni-
tude between 12 rabbil arteries and aortae of five species. 
Furthermore, it was found that NA's pKA and potenc)' 
(pEC5il ) in these tissues were positivel)' correlated, In con-
trast, Ihere was !iltJe variation in the affinity of the 0'1-
adrenoceptor antagonist, prazosin, between these tissues. 
On the basis of these observations, the so-called mriahle re-
ceplor ({(jillity hypofhesis was proposed which suggests thaI 
variation in NA 's aflïnity for the O':l-adrenoreptor is brought 
about b)' "Iocal cellular influences" and does nol retlect dif-
ferences in Ihe O':l-adrenoceptor subtypes between tissues. It 
was suggested Ihat this mechaniSIll can also rause large pKA 
vuriations for NA in the same tissue (Bevan et al" 1989), 
when il was found that during a 3-monlh period the pKA for 
NA in rabbil thorade aorta vnried between 5.4 and 7.3 (11 = 
21) and was positively corrclated with pOlency. The comer-
stone on which Bevan and coworkers have built their hy-
pothesis is the correlalion between NA's aftïnity and po-
lene)'. In the present case, however, there was no significant 
correlation between pEC5(l values for the control curves and 
pKA estimates [Fig. 4(a)J, and our data are therefore not 
consistent with expectations of the variabIe receptor afflnit)' 
hypothesis (Bevan el al" 1988, 1989). 
It is also unlikely that the complexity in the present study 
was due to faHure to satisfy basic experimental criteria for 
the application of the operational lIlodeI of agonism. First, 
following "ehiele treatment, the second NA E/[AJ curve 
was practically superimposed on the first one, confirming 
the validit)' of the paired-cun'e design. Second, the revers-
ible O':cadrenoceptor a'ntagonist, prazosin, could proteet 
completely against the inhibitor)' effect of PBZ, confirming 
that this was due onl)' to inactivation of O':I-adrenoeeplors. 
Another possibility could be the involvclllent ofmuJtiple re-
ceplors, since at lenst three ui-adrenoceptor subtypes (O':IAIL' 
O':IB, Md 0':10) operate in vaseulnr tissues (sec Stam et al., 
(999). However, a 30-min pretreatment of the SI\1A with 10 
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Fig. 7. Rdatiorl octw,:en prc\inusly publi,h('"u individua! ",Iima!c> of 
affinity (('KA) aml efl1CJcy (log T".,~,l) nbtained from npaatiollal model 
fiuing of (lJirs of coolr,,1 aml phenoxyben/al\1ine-tr~.ltcd çOll<:.:ntra!iorl· 
effect curn:, [n (a) 5·h}'drnxytryptaminc nbtained on rJbbil ;:\\1fI3 (Lef( t'I 
Cl/" \')90; original dat;) frum Black el u/., 1985b) and (b) 5·mcth)'lfurmc-
thid" nbW.Încd on guine-a-pig trachea (Leff tI (1/" 1985). 
while ie is known 10 innclivale, at least parlially, IXIB- nnd 
(Xw-adrenoccptors under these conditions (r.,·lichel et al., 
1995; Stam el af., 1999). Finally, the endothelium was al-
ways remoycd, cocaine nnd timolol were pre_sent in aH ex· 
periments 10 block Uptake, nnd (3,-adrenoceptors, respec-
tivei)', und Uptakel does not play a significant role in the 
SMA assny (Van der Graaf et al., 1996). 
Overall thcrefore, the simulations perfofilled in this 
study (Fig. 6) strongly suggest that the large variabilîty in 
pKA and log 'T estimntes and the associated correlation are 
due to a statistical ralher Ihan a pharmacological phenome-
46 
non and call inlo question the vaUdit)' of the widely used 
curve-fitting procedure for the estimation of agonist aftïnit)' 
and efficac)'. ft was shown thai when random noise (at ex-
perimentalI)' encountered levels) was added to "perfect" 
curves generated b)' the operalional Illodel of agonism, af-
fiuit)' cstimates varied over IWO log units between indepen-
dent experiments (Fig. 6). This implies that the failure ofthe 
operational model of agonism to estimate robust and inde-
pendent values of affinity atld efficaey is not limiled 10 the 
present experiment but is an inherent weakness of the 
mcthod. Although detailed studies in other assays are re-
quired la substantiatc Ihis eonclllsion furthcr, some previ-
ousi}' published results ma)' he related directi)' to Ihe phe-
nomenon described in the present arlkle. First, Henr)' et af. 
(1992) have rcporled thai in guinea-pig ilellm earbacho\ and 
pilocarpine aftinity estimatcs obtained by the operational 
model of agonism varied by two and one orders of magni-
tude, respeclÎvely, and high correlations werc observed be-
tween pKA and log, cstimates. Second, Ullalysis of prevÎollsl)' 
published pK,\ and log, estimatcs for 5-hydroxytryptamine in 
rabbit aorta (Black et al., 1985a; lcff et al., 1990) and for 
5-melhylfurmethidc in guinea-pig trachea (leff et al., 1985) 
also re\'ealed notabIe corrclatio'rls between affinity and effi-
cae}' (I' = -0.77 and -0.S3, respectivel)', Fig. 7), althollgh 
it should be noted that the range and number of values arc 
ralher limited in these studies. Final!)', Tabemero et (lf. (1996) 
have reported a correlation belween pKA nnd log, for thc 
Cil-adrenoceptor agonist, phenylephrine, in the lail arter)' of 
spontaneousi)' hypertensive ruts with intact or damaged en-
dotllelium . 
in conclusion, Ihis study extends our previous (Van der 
Graaf and Danhof, 1997) assessment of the reliability of agonist 
arnnit)' and efticaey estimation using the operutional model of 
agonism and demonstrates that the lllultiple-ÇUIye design does 
not neccssarily provide areliabie altemative for the single-cuf\'e 
methOO. Altbough in theory tbe operational model of agonism 
should provide indepèndent estimates of agOilist amnity and ef-
ficaey, dlÎs is ulllikel)' to he the case with experimental data. 
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Short cOlllmunication 
Functional characterisation of the pharmacological profile of the putative 
Ct IB-adrenoceptor antagonist, (+ l-cyclazosin 
\Viro B. Stam a,., Pieter H. Van der Graaf h, Pramod R. Saxen a a 
, Departmlll/ 11 Phllmw<,o!o,I?Y, Fumfty "I Mt'dicillf WIlI Hftl!th Scit'IIC"J, ErWmllJ Unil'eoity RolfcnfilllJ, P,O. Bm /738, 
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Ahstract 
We sludied the functÎonal pharmacological profile of (+ )-cyclazosin, which has bçen characterised as a selectivc, high-affmity 
(pK, = 9,68) Cl]8-adrenoceptor jigand in binding e,,.perimenls wilh mI liver membmnes. Thc pK a/pA2 \'nlues for llnlagonism of 
contr.tctions mediated via Cl. IAIL -adrenoceptors of rat sn1nll mesenteric mtery. a JI)-adrenoceptors of rat aorta ,lIJd o.1B-adrenoceptors of 
rat spleen were 7.78 ± O.o.t, 6.86 ± 0.07 nnd 7.96 ± 0.08, respectively. FurthemlOre, in mouse spleen, which is also rcgarded as an 
a l!I-ildrenoceptor preparation, (+ )-cyclazosin displaycd Jow potency ilnd did not act as a competilivc antagonist. Thus, in contrast with 
results obtained in radioligand binding experiments. (+ )-cyclnzosin does not behave as a sclective Cl. Is-adrcnoceptOf antagonist in 
functionill tissues. \Vhether Ihis discrepancy has consequences for the dassification of ClI-adrclloccptors n:quires further investigation. 
·B 1998 Elsevier Science B.V. All righls reservcd. 
K.·.nro"b: Cl I·Adl~nll<.·ep!nr. Aorta, r~l: (+ )-Cydlln;;in: SrnJ!l me,,;:nlcric ~rtcr)", r~l: Splcen, mHll,e: Sp1<'cn, r..tl: T~llI,ulo>in 
1. Inlroduction 
RarJioligand binding studies and molecular biology e.-..:-
periments have demonstrated the e.-..:istence of at least tllfee 
0: I-adrcnoceptor subtypes, now referred to as 0: IA' U IB 
and U ID (Hieble et al., 1995). Functional studies sugge.st 
Ihe existence of an additional a Il.-udrenoceptor subtype 
displaying low affinity for prazosin (Hieble cl al., 1995). 
Recently, it was postuluted thai the a JL ~adrenoceptor Illight 
represent a low amnity state of the a IA -adrenoceptor 
(Ford et al., 1997). Selective competitive antagonists for 
0: IA - and aw-adrenoceptors, have been described in detail 
(see Hieble et al., 1995; Slam el al., 1996; Ford et al., 
1997). A1though the preferential susceptibililY 10 irre-
versible inactivation by chloroethylclonidine has been uscd 
10 subclassify O:1B-adrenoceptors (Hieble el aL, 1995), the 
lack of a selective compelilive antagonist has impeded a 
precise quantitalive characterisation of a lB-adrenoceptors. 
• Com:sponding :iulhor. Tel.: +3[-10-403-7543; Fa~: +31-1Q..436-
6S39 
Initially, some data obtained in radioligand binding e.-..:peri-
ments suggesled Ihat spiperone and risperidone were COIll-
petitive, selcclÏve a JB-adrenoceptor nntagonists, but func~ 
tional studies were not ablc 10 confirm this (Burl el aL, 
1995; Eltze, 1996b). Recently, however, Giardina el aL 
(1996) have described a potenl compcliti"e alB-adrenoc-
eptor antagonist, (+ )-cycluzosin, which displays a 90- 10 
130-fold selcctivity for binding 10 rat aJB-udrenoceplors 
compared to a IA and a!D subtypes (p Kj = 9.68, 7.73 and 
7.57 for rat Iiver a JB' hippocampus 0: JA and doned 
a IJ-adrenoceptors, respeçtively). The selectivity of ( + )-
cyclazosin on functional responses medialed by thc a 1-
adrenoceplor subtypes has however not yel been studied. 
Thereforc, in the present Slud)' we exalllined the effect of 
(+ )-cycla7.0sin on the contractile responses 10 noradrena-
line and phenylephrine in rat smul! mesenteric arlery, rat 
aorla and ral and mouse spleen, responses which are 
belic\'ed la be medialed mainly by a IAIL - (Stam el aL, 
1996), alD- (Hieble et al., 1995) and alB-adrenoceptors 




2. l\latcrial8 and mcthods 
2.1. Tissut' pn:paratilJl/ 
The mesentery. aorta and spleen were isolated from 
male Wistar rals {250-350 g} und spleen from while llliee 
(25-30 g) which had been kil!ed by cervicu! dislocution. 
Rats recCÎvcd prior anaesthesia (sodium pentobarbitone, 60 
mg kg-I, Lp.), Tissues wen! placed in ice~cold modifïed 
Krebs-Hense1eit solution (KHS) of the following composi-
lion (mr-.-t>: NaCI 119.0, NaHCO.1 25.0, KCI 4.7, KH .... P0-l 
1.2, i'vlgS0-l 1.2, glucose 5.5, CuC1 2 2.5 aflll ethylenedi-
uminetetraacetic acid 0.026. The Ca2+ concentration 
(Cuel .... = 0.25 mM) uscd for rat aorta was anI.' Icnth of that 
of standard KHS (sec Van der Graaf et al., 1996,,). Tissues 
were mounted in thermostatica!!y controlled (37~C) orgnn 
baths 10 measure isometric contractions. The b<lth medium 
was continllously gassed with 95S1· O~ and 5% CO2. 
Rat smal! mesenteric arteries were isolaled from the 
arlerial tret~ and lllounted as ring segments (,... 2 mm in 
Icngth) in a rnyograph (l.P. Trading, Aarhus, Denmark), as 
described by us prè"iously (Van der Gra<lf et al., 1996b). 
Afler a 30 min stabilization period, the prepamtiolls were 
ch<lllcnged five times with noradremlinè (JO 1l1'.-t) wilh 
washouts after e<lch challenge. The endothelium was lèfl 
intact, sincc its removal !Urned out to bc technically dift1-
cult and was found to be associatcd with a substantial 
decreasc in thc functional reaclivity (unpublished obscrva-
tion). Thc integrity of the endothelium was confinned af ter 
the first challenge with noradrenaline b)' using acetyl-
choline (10 IlM), which produced at ka"t 60% rèlaxation 
in all tissues. 
After remO\'al of the endothelium by gentlè rubbing 
with a pol)'ethylene tube, ral aortie ring sègments (3 mIJl) 
were mounted in IS-mi organ baths and equilibrated <lt 20 
mN for 90 min. Subsequently, a calibration contraction 
was obtained to 30 IlM 5-h)'droxytr)'ptmuine (5-HT) and 
the absence of the endothelium wa~ then confirmed by thc 
lack of relaxation in response 10 acetylcholine (10 Ill\ü. 
Rat and mouse splenie strips, obtained af ter longitlldinal 
bisection, were mounted in 15 mi organ baths and equili-
brated at a tension of 15 rnN for 90 min and at 8 mN for 
60 min, respectively. 
2.2. Experimellwll'rol/Jco{ 
Tissues \Vere incubated with desipraminc (10 p.M), 
timolol (6 p.M) aud corticosterone (JO p.M) to block 
neuronal uptake, p-adrenoceptors and non-neuronal up-
take, respective1y. Sixly minutes later and in the presenee 
of these substances, agonist (noradrenaline in rat small 
mesentene arleT)' and mousc spleen; phenylephrine in rat 
aorta and spleen) concentration-effect (EI[A]) curves were 
recordcd. In the ase of rat smallmesenterie artery, cocaine 
(30 p.M) replaced desipramine, cortÎCosterone was omitted 
and SCH~23390 (10 nM) was added to block dopamine Dl 
receptors (Van der Gra<lf et al., 1996b). 
S2 
A multiple-curve design was used in experimenls with 
rat small mesenteric arter)' and fat and mouse spleen. After 
the first (ral small llleSènterÎC artery and spleen) or third 
(mouse spleen) agonist EI[A] curve was reeorded, each 
tissue segment was washed (HIt slllall mesenteric arter)': 30 
min, rat spleen: 120 min, mouse spleen: 60 min) aml 
equilibrated (60 min) with vehidè or antagonist at diftèr-
ent concentralÎons. Subsequently, another agonisl H/[A] 
curve was obtained and the responses werè expressed as a 
percentage of those of the preceding agonist curve. 
A single curYè design was used for rat aorta. Thus, aftèr 
the calibration contraction in response 10 5-HT, separate 
segments from eaeh vessel were incub<lted with either 
"ehiele or different antagonist concenlrations. Subse-
quently, a single Hl [A] curve was obtained for phen)'l-
ephrine. Data arc expressed as percentages of the calibra-
lion contraction. 
2.3. Amtly.,·is 
Individual agonisl curve data WeTe fitted to the Hili 
equ<ltion by using an iterative, least-squares method to 
calculo.te the midpoint localion (pEC54:)' Hili slope (n H ) 
anti upper asymptote (a). The effect of drug Ireatment on 
these parameters was assessed by one-way analysis of 
varianee (ANOVA) or Student's I-Iesl, as appropriate. 
Vallles of P < 0.05 were considered 10 be significant. 
When minimum criteria for competitive antagonism 
were satisfied, that is the ant<lgonist prodllced a p<lrallel 
rightward shift of the agonist H/[A] curve with no change 
in the upper asymptotè, antagonist aftïnity was estimated 
by fitting the individual pEC5(I values obtained in the 
absence and presenCe of antagonist 10 the Schild equation 
as described previously (Van der Graaf et al., 1 996a). 
When Ihe Schild plol SIOPè parameter (IJ) was not signifi-
canti)' different from unity, thc data were re-fitted with h 
constrained to unit)' so that the antagonist dissociation 
equilibrium constant, KB' could be estimaled (Jenkinson et 
al., 1995). When thc criteria of competitive antagonism 
were not completely satistled, an empirical pA2 vuluc was 
estimated b)' using the Schild equation, with b constrained 
10 unity. All data are presented as llleans ± S.E.M. 
2.4. Cmll!,ol/ll/ü 
Compounds were obtained from the following sou rees: 
eocaine h)'drochloride, 5-hydroxytryptamine creatine sul-
phate (5-HT), (- )-noradrenaline hydrochloride, acetyl-
choline chloride, (- )-phenylephrinc hydrochloride, de-
sipramine, corticosterone were from Sigma, The Nether-
lands; SCH-23390 (R-( + )-7-chloro-S-hydroxy-3-methyl-
l-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepine h)'drochlo-
ride) was from Research Biochemicais, USA; timolol 
mrlleate was from ICN Biomedicals, Thc Netherlands; 
tamsulosin h)'drochloride was a gift from Yamanouchi 
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Phaonnceutical, Japan; (+ )-cyclazosin (+[4-(4-amino-6,7-
dimelhoxyquinazolin-2-yO - cis-octahydroquinoxalin-I-yl}-
furan-2-ylmethanone) was a gin from Or. A. Leonardi, 
Recordati, IIal)'. (+ )-Cyclazosin was dissolved in dimt'-
thylsulfoxide 10 give a 0.1 M stock solution oud furthcr 
diluled in distilled water. Corlicoslerone was dissolyed in 
ethanol 10 give a stock solution of 30 1llf\'1. All olher dmgs 
were dissolved in distilled water. 
3. Results 
3.1. Effect of (+ )'l)'clawsill (lil l/oradrenalillc-jl/{llIced 
cOII/mClioll (lf rat JI/wllmcsellferic aIkI)' 
Noradrenaline produced concentration-dependent con-
IructiollS of rat smul! mesenteric arter)' (Fig. IA), Hili 
parameters of Ihe control noradrenaline E/[A) curvc-s 
(11 = 7) were: midpoint location (pECso ) = 6.40 ± 0.17, 
Hili slope (IIH) = 3.34 ± 0.45 and upper asymplote «(d = 
95 ± 2% of that of thc first noradrenaline E/[A] curve 
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(20.6 ± 2.1 mN). (+ )·Cyclazosin (0.1-1 ~M) produced a 
parallel, rightward shift of thc noradrenaline E/[A] curvc. 
Schild analysis (Fig. IB) yielded a stope parameter not 
different from unity (1.15 ± 0.11, df= 18) and a pKs of 
7.78 ± O.O-l was estimated. 
3.2. Effect of ( + )-tyclawsi/l 011 plw//ylephrille-imlllccd 
colllractÎml of rat aorta 
Phcnylephrine produced concentration-dcpendent con-
traclÎons of ral aortic rings: pEC so = 6.76 ± 0.05, IJ" = 
0.62 ± O.O-l and a = 108 ± 7% of Ihat of the 5-HT calibra-
lion contraction (9.3 ± 0.1 mN, 11 = 5). (+ )-Cyclazosin 
(0.1-3 ~~.f) concentration dependcntly shifted the phenyl-
ephrinc E/[A] curve 10 the right (Fig. IC). However, the 
criteria for compctitiye antagonism were nol completely 
satisfied, since ( + )-cyclazosin produccd a conccntration-
dependent steepening of thc E/[A] curves (/I" = 0.75 ± 
0.02, 0.82 ± 0.06, 0.89 ± 0.02 and 0.96 ± 0.06 for 0.1, 
0.3, 1 and 3 ~~'I (+ )-cyclazosin, respectively (P < O.OOI). 
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formed (Fig. 10). Tbc Schild slope parameter was not 
different [rom unit)' (1.07 ± 0.09. df=21) and a pA~ 
vulue of 6.86 ± 0.07 was estimaled. 
3.3. l!.ffect of ( + )'L)'c!aW.I'ÎII 011 pht'llylephrint'-iml/lced 
colltrac/ÎfIIl of ral spleen 
Hili parameters for the phenylephrinc-induced contrac-
Iion of vehicle-Ireuted rat spleen (11 = 6) \Vere pEC 5C1 = 
5.22 ± 0.04-, Il H = 0.75 ± 0.05 und a = 127 ± 9% of that 
of the first phenylephrine EI[A] curve (35 ± 0.1 mN). 
(+ }-Cydazosin at concentrations of 0.03-0.3 p.M pro-
duced a parallel, rightward displacement of the phcnyl-
ephrine E/[A1 curve (Fig. 2A). In the presence of a higher 
concentration of (+ )-cyclazosin (I p.M), the maximum of 
the agonist EI[A1 curve could not he attained with the 
highest concenlration of phenylephrine (10 m1·f), and the 
phenylephrine E/[A] curve flattened (/lH = 0.45 ± 0.01, 
P < 0.05). Schild analysis was performed only fOr the 
concentrations of (+ }-cyclazosin (0.03-0.3 JlM) tbat met 
tbc criteria of competitive antagonism: b = 1.02 ± 0.20 
(df~ 11) .nd pK, ~ 7.96 ± 0.08 (F;g. 2B). 
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FOT comparison, the amnity of the reference al-aJren-
oceptor antagonist, tamsulasin, was estimated. Tamsulosin 
(10 nM) produced a parallel rightward displacement of the 
phenylephrine E/[A] eurve and yielded a p A, of 9. [6 ± 
0.14 (11 = 3), similar to that reported by NOble ct al. 
(pA 2 = 8.9; Noble et aL, 1997). 
3.4. Effect of (+ )-eyclalOsill 011 lIoradrenalille-indueed 
rOIl/me/ion of //JOIISt! spleelI 
As shown in Fig. 2C, noradrenaline produced concen-
tration-dependent contractions of mouse spleen and the 
Hili parameters in the con trol (11 = 8) tissue were pEC50 = 
6.44±0.07, 11 !I =0.74 ± O.O-t, a= 107.3±0.4% of thai 
of the third ElIA] curve (2.7 ± 0.02 mN). (+ )-Cyclazosin 
(0.1 I1M) produced a parallel, rightward shift of thc nor-
adrenaline E/[A] curve, with an associated pA, value of 
7.38 ± 0.08. Higher conccntrations of (+ )-cycla-zosin (0.3 
nod 1 111\.1), however. did not produce any further shift 
(Fig. 2C). A slight decrease in Ihe ma.-dmal response 
(a = 89.4 ± 0.6%, P < 0.05) was produced by (+)-












Fig. 2. Ej[A] curyes nf ph~!l)"krhrine in '.J.I spleen (p~nd Al and nll(,ldrenaline in mome spken (pJJld cl in the ahsence (el or prc;;ence nfO.OJ (0), 0.1 
(0).0.3 (.) and I (0) flM (+ )~rç]awsin. Thc cMTc;;ponding Schild plot in thc ,.11 spleen is shown in pJJld B. Thc lino.' sUJ'l.'rimrns~'d on the dj!.] 
points was uClerrnincu hy using par.J.mclcrs ohtaineu frllm Ihc consl,J..ined rnn.Jel fit. 
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the rightwllrd shift produced by 10 ni"t tamsulosin (pA 2 = 
8.44 ± 0.14, 1/ = 3) was in good agreement with Ihat of a 
prevÎous report (pKa = 8.62; Eltze, 1996a). 
4. Discussion 
In Ihis stud)', wc characterised the potency of the 
putative 0: [B-selectivc antagonist ( + )-cycJazosin in tissues 
expressing different subtypes of functional o:,-adrenocep-
tors. Thc aftïnity estimute of ( + )-cyclazosin in Iut smal! 
mesenteric mIer)' (pKB = 7.78 ± 0,04) was in agreement 
with the reported binding affiuit)' for 0: IA -adrenoccptors in 
rat hippocampus. human cloned Ct:1a-adrenoceptors and 
0: IL -adrcnoceptors (pK,/pK B = 7.1-7.7; Giardina et al., 
1996; Kava et al., 1998), 
In rat aorta, which is considered 10 be a functional 
0: lD-adrenoceptor correlate (Hieble et al., 1995), the right-
ward displacement of the phenylephrine E/[A] curves by 
(+ )-eyclazosin was aecompanied b)' a concentration-de-
pendent steepcning of the phenylephrine E/[A] curye. 
This phenomenon has also been reported for otller antago-
nists and is suggested to be due la Ihe expression of IWO 
closely related farms of the 0: lD-adrenoceplor in rat aorta 
(Van der Graaf et al., 1996a). The futlClionnl potene)' in rat 
aorta of( + )-eyclazosin (pA 2 = 6.86), however, was within 
the range of its affluity for rat cloned 0: IJ-adrenoceptors 
(pK; = 7.57~ Giardina et al., 1996). 
On the basis of the high sensitivity to inactivalion by 
chloroethylclonidine, the receptors mediating contraction 
of rat spleen in response 10 phenylephrine have been 
classified as O:lB-adrenoceptors (Han et al., 1987; Burl el 
al., 1995). However, the pA 2 value of 7.96 cstimated from 
the competitive antagonislll displaycd by (+ )-cyclazosin 
(0_03-0.3 v.l\Ü is incompatible with its amnit)' for rat 
Jiver 0: )B-adrenoceplors (pK; = 9.68; Giardina et al., 1996). 
This discrepancy with radioligand binding data led us to 
stud)' the antagonism of (+ )-cyclazosin in mouse spleen, a 
tissue where an even beUer corre!ation of antagonist affini~ 
tics with cloned 0': Jt,-adrenoceptors has been observed (Burt 
ct al., 1995; Eltze. 1996al Surprisingly. the rightward 
displacemcnt of the noradrenaline E/[A] curve by (+)-
e)'clazosin was onl)' sm all and was not concentration 
dependent (Fig. 2C). It should be noted that in our hands 
tamsulosin. the reference O':)-adrenoceptor antagonist, 
yielded amnity estimates in rat and moust' spleen that 
were in accordancc with those of previous studies (Ehze, 
1996a; Noble et al., 1997). Thus, in contrast with the 
resulls of radioligand binding experilllents (Giardina el al., 
1996), (+ )-c)'clazosin appears not 10 behavc as a selectivc 
a ls-adrenoceptor antagonist in functional studies_ Whether 
this discrepanc)' has conscquences for the classification of 
0: )-adrenoceptors requircs further investigation. 
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Characterization of receptors mediating contractioll of the rat 
isolated small mesenteric artery and aorta to arginine vasopressin 
and oxytocin 
'~1'Viro B. Stam, lPieter H. Van der Graaf & IPramod R. Saxen a 
JDepartmenl ofPhanllaco!ogy, Faculty ofMedicine and Health Sciences, Erasmus University Rotterdam, P.O. Box 1738,3000 DR 
Rotterdam. Thc Netherlands and ~Leiden/Amsterdam Center for Drug Research, Division ofPharmuco!ogy, Sylvius Laboralories. 
P.O. Box 9503. 2300 RA Leiden. Thc Netherlands 
J Thc exact nature of Ihe r~'Ceptor subt)1)c(s) involved in Ihe aclion of arg-vusopressin (AVP) on the 
rat aorta and smal! mesenteric aflery (SMA) is controvcrsial. Therefore. we have studied Ihe effecls of 
the selecth'c VIA receptor anlagonists. apc 21268 and SR 49059, and Ihe oxytocin (OT) receptor 
antagonist. alosiban, on the A VP- and OT-induced contraetbns of the two wssels. 
2 AVP and OT displayed similar intrinsic activities in the rat aorta and SMA. but AVP was - 130 fold 
and -500 fold more potent than OT. respectively. In the rat aorta, Hili slopes (n ll ) were similar for OT 
and AVP. However, in rat SMA, the OT concentration-effe<:t (EjIA]) curve was significantly steeper Ihan 
the AVP EJfA) curve (nll,=3.3±0.20. 2.3±O.l5; P<O.OOI). 
3 In Ihe aorta OPC 21268, SR 49059 and atosiban competitively antagonÎzed the AVP and OT EJIA] 
curves. Except for atosiban and SR 49059 against AVP, cOnlpetiti\'e antagonism was also observed in 
the SMA. Atosiban caused concentration-dependent steepening of the AVP Ej[A] CUf\'e, whercas 
SR 49059 decrcased Ihe upper asymptote. 
4 Schild analysis yielded affinilies indicative of VIA receptor invol\'ement in both wssels: pK,,1 
pA~ =9.20-9.48. 7.56- 7.71 and 6.19-6.48 for SR 49059. OPC 21268 and atosiban. respectively. 
5 Neither AVP nor OT relaxed U46619 prc-contracled aorta or SMA in the pr.:sence of SR 49059. 
suggesting no interference of a vasodiJatory component. 
6 Despite predominant invol\'emenl of VIA r('ceptors in both wssels, the different Hili slopes of AVP 
and OT Ef[A] curves as weU as Ihe sleepening of Ihe AVP E/[AJ curves by atosiban arc indicative of 
receptor heterogeneity in the rat SMA. 
Kcynords: Aorta: atosiban: arc 21268: oxytocin: rat; smllll nlesenterÎe artery; SR 49059; vasopressin receptors 
Introduction 
Arg-vasopressin (AVP) is believed (0 exerl ils action through 
binding 10 two major classes of receptors: VI (suhdivided in 
VIA and VI" subtypes) and V1 receptors (Manning & Sawyer. 
1989). In man)' isolated arteries. including those from hunllln 
(L1uch et al .. 1984: Martin De Aguilera et al., 1990; Uu el al .. 
1994: Martinez el al., 1994a,b; Bax el al., 1995: Jovanovic el 
al.. 1995: Medina et al., 1996; Calo el al., 1997). rabbit 
(Garcia-Villalon el al., 1996), dog (Katusic el (/1., 1984: Myers 
et al .. 1989) and Ihe rat (Angus et al., 1994). wlsotonstriction is 
mediated by the V IA receptor. However, an early sludy 
dernonstrated thai the potenc)' order of vasopressin analogues 
on the rat mesenteric arterioles differed from that on the rat 
aorla. sugge5ting the in\'ol\'ement of distinct receptors (Altura. 
1975). This notion seeOlS to be suhstantiated by the finding 
thai the seIcclÏve peptide VI receptor antagonist, Id(CH~hTyr 
(Mef'JAVP, was ten times more potent on the mi aorta 
(pA!= 10.84: AnoulJr et al.. 1996) than on the rat small 
mcsenteric ,Irlery (SMA; pK,,=9.76); the latter affinity value 
indicated Ihe invol\'emenl or V1.\ receptor in the rat SMA 
(Angus t't al., 1994). Allhough Burren and colkagues (1994) 
reported that the AVP-induced contractions of the rat SMA 
were alm potently antagonized b)' the non-peptide VI receptor 
antagonist OPC 21268 (Yamamura el al., 1991). the disp1ayed 
antagonism was non·competitive as weJ[ as too potent 10 
accounl for V [ receptor involvement. These ineonsistenCÎcs 
concerning Lhe action of AVP in the rat SMA and aorla might 
JAmhor for corre-spondence-. 
suggcst interfer.::nce hy a vusodilator component in the rat 
SMA (Walker et al.. [989; Matinez et al.. 1994a) and/or the 
involvement of multiple rec.::ptors (Altura. 1975; Angus el al., 
1994) in the Iwo vessels. In this connection, oxytocin (OT) 
receptors mayalso be important. sinc.:: OT receptors are 
operati\'e in cardio\'ascular tissues (Yazawa el (11 .. 1996; 
Gutkowska el af .. 1997) and AVP and OT cun activa!e each 
other's primary receptors (Manning & Sawyer, 1984: 
Jovanovic el al., 1995, 1997). 
In the present study we ,limed to eliminate the incon-
sistencies conceming the receptor subtype(s) involved in the 
response to AVP in the rat SMA and aorW. For Ihis purpose. 
we analyscd the mechanisms invo1\'ed in the contractile act ion 
of AVP and OT in these vessels. using the non-peptide V [ 
receptor untagonisls, orc 21268 (Yamamura et al .. 1991) and 
SR 49059 (Smadeil-Le Ga[ et al .. 1993). ~lI1d the peptide OT 
receptor antagonist, atosiban (also kno\\'n as ORF22164, 
RWJ 22[64, or l-deatllino-[D-Tyr(OEt)!Thr~Orn);]OT 
(dETYT)) (Pettibone cl al .. 1992). A pre1iminary account of 
pilrl of these data was presellted to the Brilish Phamwcological 
Society (Stam et al., 1996). 
Methods 
The ral smalll11esw(eric arter)' preparalioll 
Male Wislar rats (250 - 350 g) were ;lIlaesthetized (sodiulll 
pentobarbitone, 60 mg kg-I. Lp.) and killed by een'ical 
59 
Chapter 5 
dislocatioll and the mescnlery was remo\'Cd nnd placcd in kc-
cold modified Krehs-HenseJheil solution (KHS) of thc 
following composition (nUIt): NaCl 119.0, NaHC03 25.0, KCI 
4.7, KH2PO~ 1.2. MgS04 1.2, glucose 5.5. CaCl~ 2.5. Arlerial 
(r~s were dissected and cleared from surrounding adipose 
tissue. From each arterial tree. a ring segment (,,- 2 mm in 
length) was ll10lmted in a myograph (J.P. Trading. Aarhus, 
Denmark) wilh separated 6 mi organ baths (thermostatically 
control!ed at 37 'e containing modified KHS aod continuously 
gassed with 95% O2 aod 5% COl) as described previously 
(Mulvany & Halpern. 1977). Tissue responses were measured 
continuously as changes in isometrie force. Following a 30 min 
stabilizalion period. Ihe internal diameter of each w:ssel was 
set 10 a lension equivalent 10 0.9 times the estimated diameter 
at 100 nunHg cffeclive Iransmural pressure (lw·,=200-
300 Jlm) according 10 the standard procedure of Mulvany & 
Halpern (1977). Aner a fllfther 30 min stabilization period, a 
calibration contract ion (12.5±0.5 mN, 1/=61) was obtained 10 
100 JIM phenylephrine and the presence of the endothelium 
confirmed. This procedure was followed by 30 min washing. 
The rat iso/met! aortie ring prepamtioJl 
The ral aorta was removed and pJaced in Îce..çoJd modified 
KHS of the same composition as for the SMA, except for, the 
Ca~· concentratioll, which was one tenth of Ihat of slandard 
KHS in order to eJiminate the spontaneOlls phasic contractions 
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as 3 IllIl1 ring segments in 15 mi organ baths containing KHS 
(CaCb=0.25 mM) aerated with 95% O2 and 5% CO2 and 
mainlailled at 37"C. The ring segments were a!lowed la 
equilibrate al a tensioJl of 20 mN for (jO min and were washed 
ever)' 15 min. Af ter cquilibration, a calibration contraetioll 
(0.90±0.02 g, 1/=58) was obtained 10 30 J1M 5-hydroxytrypla-
mine (5-HT) and Ihe absence of the cndotheJium was 
confim1ed. This procedure was followed hy (jO min washing. 
Tissue responses were measured continuously as changes in 
isometrie force with a Harvard isometrie transduecr. 
Tabi .. I E,tim;Hes (me.\l1s±s.e.mean) of the upper <ls)mp-
wte hl, midpoinl I(lÇJtion (pEe" .. ) <lnd Hili slope (nu) 
obtuined ufter fitting the indil'iduals AVP and OT E.'[A] 
cmw, in the rut SMA and (Jorta to the HiH equation 
SMA , pEC .. " 1111 
AVP 1l8±3% 9.4S±O.04 1.3±O.15 1/=16 
OT 116±3% 6.76±O.I).t* 3.3±O.20· 1/=21 
P> 0.05 P<O.OOI P<O.OOI 
Aorfa pEC.", 11/1 
AVP 73±S% 9.19±0.1J.t 1.9±0.10 1/=13 
OT 53±5% 7.07±0.0-4* I.S±O.iO 11=9 
P> 0.05 P<O.OOI P>O.5 















Icpe 212681 !rog ,oM} 
0(0); 0.03 (0); 0.1 (.); 0.3 (0); 1 (A) j.lM OPC 21268 
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Figure I (Left pJnel,) Conc"ntration·effect curws 10 AVP ;.md OT obwinffi on the [,11 SMA in Ihe abs"nce or presence of 
OPC 21268. The lines superimposed on the me,]l\ data poinls were simulated ming the Hili equ;Hion. (Right panels) Schild plOl~ for 
the interaction of orc 21268 wîth AVP (upper p,lnel) and OT (Jower panel). The solid line~ sUpo;'rimposed on mean data points 
were simulated using the pJr<lmeters obtained from the constwined model fits. 
Rell/oral ol/!I1dotlte/illll/ 
ft is weil known Ihal conlraclile responses to a number of 
ugonisis Can he intluenced by endolhelium-derived factors 
(Furchgott & VanhouHe, (989). Indeed, the conlraClile 
responses 10 AVP show tachyphylaxis in Ihe rat aortu wilh 
inlncl endolheJiurn (i\:lillelte & Lamontagne, (996). Therefon." 
the endolhdium of Ihe uorla was denllded by gent!y rubbing 
with a poly-ethylene tube. In contras!. the endothelium of Ihe 
rul SMA was lef! inlucl, since ils removal turned out la he 
Iffhnically difficull and was found 10 he associated with a 
substantial decrease of the fllnctional renctivilY (unpublishcd 
obsen'.\lion). Fortunately, Ihe necessity 10 remove the 
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Vasopressin receptors 
repelitivc AVP [i(A] curl/es could be produced wÎthout 
lachyphylaxis (Angus et al., 1994). 
The integrily of endotheliutll was checked ",ilh acetylcho-
line (lOli:>'!). which fai/ed 10 relllx ral aorta segments, but 
produced at least 60% rc1axation in all segments of Ihe ral 
SMA. 
Experil11clltal protocol 
Tissues wen~ incubalcd for 60 min with antagonist or vehide 
and single ngonist concenlralion-elYecl (E/[AJ) curves were 
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IOPC 212681 (lo9roM) 
o (e); 0.1 (B); 0.3 (0); 1 ( .. ); 3 (A) pM OPC 21268 
Figure 2 (Lefl pands) Concenlration-elfecl curye, to AVP <lnd OT ohtained on the ral aorta in the absence or presente of 
OPC 21268. The Iines superimposed on Ihe mean dala points were simulated u,ing Ibe Hili equation. (Rigbt panels) Schild plots for 
tbe interaclion of OI'C 21268 wilb AVP (upper panel) and OT (Iower pand). The solid line, superimposed on meJ.n data points 
weu simulated ming the parameters ohtained from Ibe constrained mode! fits. 
Tablc 2 pK B lpA1 values (means±s.e.me.Jn) for SR 49059, arc 21268 and Atosiban on the mi SMA and aorta against AVP and OT 
and reported pK, values for rat lira VIA roxeptors 
SMA AOr/u pKi for lIl(' nu 
Anlugmli.lt AVP OT AVP OT Iher Vu H'CCplOr 
SR 49059 9.20±O.IY 9.38±O.O6 9,4S±O.09 9.29±O.12' 9.l h 
OPC 21268 7.56±O.1I 7,49±O.O8 7.6~J±O.07 7.71±O,08' 6.5_7.6c 
Atosiban 6,48±O.W 6.34±O.16 6.19±0.O6 6.30±O.04 6.7.1 
·pA2. bSerradeil_Le Gal el of" 1993. cYamamura cl /.11., 1991; peUibone cl ul., 1992; Buml! el ol., 1993a,b; Serradeil-le Gal el o/., 1993, 




Individual agonisl curve data were fitled 10 the Hili equation 
using an iterative. [('ast-squares method: 
10 provide eslÎmates ofmidlJOÎnt slope (l1u). midpointlocution 
«(Ah .. estimaled as a loganthm) aod upper asymplote (<:tl. The 
effect of drug tr('almen! on these parameters was assessed hy 
one-wa}' analysis of variancç (ANOVA) or Sludent's I-test. as 
appropriate. Yalues of P<O.05 were consideH~d 10 be 
significant. 
When the minimum criteria for compelilive antagonism 
were satisfied. thai is the antagonist produced parallel 
rightwurd shift of the agonisl E/[AJ curves with na change in 
upper asymplote. antagonist affinity estimales wefe obtailled 
by fitting the individual midpoint location valu('s obtained in 
the absencc (log[Ah) and presellCe (log[Ahll) of antagonist 
(B) to the following derivatioll of the Schild cquatÎoll as 
described previously (Black et al .. 1985a)_ 
log [AhoB = log[AJ~,) + log(l + [Bt IIO'",~J.:k) 
Whcn the Schild plot slope parameter (b) was not significantly 
din'erenl from unity. thcn the data were re-fitled with b 
conslwilled to unity so that the antagonist dissodation 
equilibrium constant. KB. could he cstimated as log Ku±s,e. 
(Jenkinson et tri.. 1995). When one concentration of 
antagonist was tested or the criteria of competitive 
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o (e), 3 (0), 10 (11), 30 (0) nM SR 49059 
value was estÎmated using \he ahove equution. with b 
çonslmined 10 unity. 
Compolillds 
Compoullds were oblained from tlle following sources: 5-
hydrox}'tryptamine creatine sulphate, acetylcholine chloride, 
(- )-phenylephrine hydrochloride, oxylocin. [ArgS]vasopressin 
acelate, U466l9 (9.II-dideoxy-1 h.9)'-epoxy-methanoprosl-
glandin F~,); Sigma Chemical Company LId .. The Nether-
lands: SR 49059 H2S) 1-[(2R 3.S1-5-chloro-3-(2-chlorophenyl)-
1-(3.4- dimethoxybcnzene - sul phon yl)-3-hydroxy-2,3- dih yd ro-
I H-indole-2-carhonyl]-pyrrolidine-2·carboxamide) and apc 
21268 (I-I 1-[4-(3-acclylaminopropoxy)benzoyIH-piperidyl)-
J.4-dihydro-2(l H-benzazepinej): a gift from Or D. Nisato. 
Sanofi Recherche, MontpeJlier Cedex, Fmnce: Atosiban: a gift 
from Dr p, Mclin, Ferring Phamlacwtica!s, Malmö, Swedcn. 
U46619 was dissolved initiaHy in 20% ethanol 10 give a I 111:"1 
stock solution and fUriherdiluted in distilled waler. arc 21268 
and SR 49059 were dissolwd in dimelhy!sulphoxide 10 givc a 
I nnI stock solution and further diluted in dislilled water. All 
other drugs wcre dissol\'ed in distilled water. 
RestIlts 
Coll1rac/iOJls fo AVP {/lui OT 
AVP and OT produced concentration-dependcnt contractions 
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ISR 49059) 1i09,oM) 
Figurc 3 (Left p~nels) Concentration·efflXt curves to A yP and OT obtained on the rat SMA in the absence or presence of 
SR 49059, Thc Hnes superimposed on the meao data points were simulated using the Hili equatioo. (Right panels) SchUd plots for 
the interactioo of SR 49059 with AVP (upper panel) and OT (\ower panel). Thc solid lines superimposed on mean data points wae 
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o (e); 3 (0); 10 (.); 30 (0) nM SR 49059 
Figur .. <I (LeCt r.ln~[S) Concentration·df.x( curws 10 AVP 3nd OT oblained on thc rat aorta in the absen<:e or presence of 
SR 49059. The [Înes sup.-rinlposed on the mean data points II.:re simulate.:i using the Hili equution. (Right panel) Schild plol for the 
iotu.JClion of SR 49059 \\Îlh AVP. The solid Jine, supuimpo,<'tl on me.in dala points was simulated using the parameter, obtained 
from (he conslrained mode! nis. 
the Hili equalion 10 provide cslÎmales arthe midpoint loealion 
(pEC~), slope (nu) :tod uppcr asymptole (-:c) (Table I). The 
inlrinsic acli\'Îties of AVP and OT were nol significantl)' 
diOèrènt, bul AVP was'"" 500 aod '" 130 fold more potent than 
OT in the S!\fA and aorta, resf>eclively. Interestingly. in the 
S1\IA, but not in the aorta, the OT E/[Al curve was 
significantly sleeper Ihan the AVP E/[A] curve. 
Effect of OPC 21268011 the respollse to AVP oud OT 
The seleclh'e VI receptor antagonist OPC 21268 (O.I-3 tiM. 
1/=4-11) behaved as a competÎtive antagonist of AVP- and 
OT-induced conlractions of the rat SMA {Figure I} as weil as 
aorta (Figure 2). The Schild slope pilramelers tb} for the 
antagonism ofOPC 21268 agilinst AVP and OT in Ihe SMA 
(b= 1.27±0.15 and 0.84±O.l4. respectively) and aorta 
(b=0.82±0.1O and 1.~±0.48, respecti\'e1y) were nol sig-
nificantly diftèrent front unit)', allowing for the estimation of 
pKfI \'alues (TabIe 2). 
Effeet of SR 49059 011 file respol1se 10 AVP alld OT 
In the rat SMA (Figure 3), the other selecth'e VI receptor 
antagonist SR 49059 (3 and 10 nM, 1J=5) behaved as a 
compelitive antagonist of OT (b=0.86±0.15; pKB = 
9.38 ± 0.06; Table 2). In contrast, however, SR 49059 
produeed a smal! non-concentralion rdated depression of the 
maximum response 10 AVP. Notwilhstanding Ihis complex 
behaviour of SR 49059, the data were fitted la Ihe Schild 
equalion. The Schild slope rammeIer was nol significantly 
different from unity (b=0.97±0.17) and the estünated pA~ 
value was 9.20±0.13 (Tabie 2). 
In the rat aorta (Figure 4), SR 49059 (3-30 m.1, 1/=3-5) 
produced parallel rightward shifts of the AVP and OT E/[A] 
curves. Schild lInalysis yielded a slope parameter not 
significantly different from unity (b= 1.15±0.J) for Ihe 
antagonism of the AVP response (pKfj=9.48±0.09; Tab!e 
2). pA~ value for SR 49059 against OT, obtained after fitting 
the data 10 Ihe Schild equalion with b eonslrained to unity, 
was 9.29±0.J2 (TabIe 2). 
Eljèe! af atosibGII Oll t!te response 10 AVP alld OT 
In Ihe rat SMA (Figure 5; Table 2), atosiban (0.3-3 JIM, 
1/=4-5) behu\'ed as a competitive antagonist of the OT Elf A] 
curves. Again, however, the AVP Elf A} curve În the ral SJ\'IA 
was nol displaced in a parallel manner, sinee alosiban (I-
lO jl:"l, J/=4) produced a significant concenlralioll+dependent 
steepening (Hili slopes: 1.96±0.OI, 2.14±0.1O, 2.40±O.l6 and 
2.70±0.11 for 0, I, 3 and JO J1M atosiban, respectively, 
P<0.05). NOlwithstanding Ihis complex behaviour, the data 
were fitted 10 the Schild equation 10 obtain "alues of b 
(1.06±0.15) and pA~ (6.48±O.II; Table 2). 
In the rat aorta (Figure 6), atosiban (0.3-10 tlM, 1/= 5-7) 
produced parallel righlward shifts of the AVP and OT E/[AJ 
curves. Schild analysis yielded slope parameters not signifi· 











































Figure 5 (Left panels) Concentf,ltion-effext cup;e, 10 AVP (JnLi OT obtained on thc rat SMA in tbe ah;enc<, or presenee of 
alosîb.m. The !ines superimpo,ed on l11<"\IO d.lt.l poinls \Iwe simubted using Ibe Hl\[ equation. (Right panels) Schild plots for Ihe 
intcwction of ato,lhJn \\ith AVP (upper panel) aod OT (lower panel). Thc solid [ine, superÎmpose-d on mC.In d.Ha poiots lI"ere 
simulated u,ing the par.lInetns obtained from lhe constr.üned model fits. 
pKIl values or6.19 ±O.06 and 6.30±O.Q..l against AVP nod OT, 
respectivdy (Tab!e 2). 
Relaxallt resj/ol/Ses 10 AVP (lJld OT 
In order to stud}' whether AVP and OT disp!ayed ti nonN I'" 
receptor-mediated vasodilator response, the rat SMAs nnd 
aorlae were pre..çontracted with 100-200 n~! and 10-30 nM 
U46619, resp«:tivc1y, arter selective VIA receptor blockade by 
30 min pre-incubalion with the SR 49059 (10 nM). Mter the 
contractiIe response had stabilized (78± 11% and 73± 11 % of 
the calibration contraction, for the rat S~'IA and aorta, 
respective1y) AVP or OT E/(A] curves were obtuined. No 
relaxation to AVP and OT was obserwd in either tissue 
(11=4- 5, data nol shown). In fact, a slighl furlheT contraction 
was seen. 
Discussion 
Ta date the receptor subtype Învolved in the A VP-induced 
contraction of the rat SMA has been controversÎal. The 
peptide VI receptor antagonist {d(eH~)~Tyr(Me)lAVP defined 
the receptor invoIved as V I (Angus et al .• 1994). However, Ihe 
data obtained with are 21268 in the rat SMA were 
inconsistent with the Învolvemenl of a V I receptor (Hurrell et 
al., 1994). FurthemlOre, the potencÎes of AVP receptor agonist 
as weU as antagonist peptides differed for the rat aorta and 
64 
mesenteric resistance arteries (Altura, 1975: Angus et al., 1994: 
Anouar et al .. 1996). This suggests rcgional difièrcllCl!s in the 
receptor subtype(s) involved in Ihe response 10 AVP. 
In the present study, AVP and OT produced concentralion-
dependent contructions of Ihe ral SMA and aorta, with AVP 
heing about 500 and 130 times, respectively, more pOlenllhan 
OT. The estimated antagonist affinities ofOpe 21268 (7.49-
7.71), SR 49059 (9.2-9.5) and alosiban (6.19-6.48) were 
similar with respect to the agonists (AVP and OT) and \'cssds 
(SM A and aorta) studied. Sinc~ these affinity \'.1lues are in 
accordance with the reportcd binding affinities for V I ... 
receptors on the mt Jiver membranes (Tab!e 2) and SR 49059 
displays only a 10- 7 M aflinit)' fOf the OT receptor (Serradeil-
Le Gal et (11., 1993), it is tempting to conc\ude that the 
funclionat responses to both AVP and OT inlhe mt SMA and 
aorta are mediated ria a single receptor thai eau he c\assified as 
VI .... However, the ana!ysis of the action of AVP suggests a 
more complex situation in the rat SMA. The Hili slopes of the 
AVP and OT EJiA] curves (nll=2.3, 3.3, respectively) diftèred' 
significantI)'. In case of a homogeneous receptor population> 
different Hili stopes wou!d he expected onl)' if the intrinsic ' 
activities of the agonists were different (Black et al., 1985b). 
This was not the case as Ihe uppcr asymptotes of the AVP and 
OT EJ(A] curves in the rat SMA were similar (see Table 1). 
Studying Cll-adrenoceplor responses in Ihe rat aorla, Van 
der Graaf and colleagues have modelled thallhe differcnces in 
Hili slope values of agonists "ith similar intrinsic activity are 






u ~ < 0 50 .~ 







-10 -, -, 
-7 -7 -, -, 








50 0 0 u 








-7 -, -, 
-7 -, -, 
{OXYTOCJNJ U0910MI (Atoslban) (log,oMJ 
0(0); 0.3 (0); 1 (R); 3 (0); 10 ( .... ) J.tl\l atosihan 
Figure 6 (Lef! p,mels) Cül1ct'nlr.J!ion·elTect cun"ö to AVP and OT ohtuined on thc rat aorta in the absence of prt'sencc of 
atosib;m. The rines supuîmposed on the meJIl data point~ wer .. simulatcd Ilsing lhe Hili eqLl~lion. (Right p.mels) Schild rlol~ for the 
inlcf;\ction of a\(l~iban lI'ilh A \'P (uppçr panel) uIJd OT (lcwer r.mel). The snlid lines sUj1Çrimposed on the 111<',111 data points \\ere 
simu[alcd using thc p.tr<InWers oh!;lined from lhe cOl1ltrained modelllIS. 
Graaf ct al., 1995). Tilc concclltrillion·depelldenl steepening 
of the AVP EJ[AJ curve by atosiban in rhe fal SMA 
substantiates the significance of the difference in Hili slope 
plIrameter bclween OT and AVP Ef[A] curves. Interestingly, 
alosiban caused Ihe Hili slope parameter of Ihe AVP Ef[A] 
curve 10 shift lowards Ihal of the OT Elf A] curve (sec Table 
I). In olher cases also, the antllgonist-induced chang('s of the 
HiU slope parameter prowd 10 be a more sensitive indicator 
of r('ceptor helerogeneity than the Schild plOI slope pammeter 
(Van der Grmlf et al., 1996; Prentice & Houmni, 1997). Thus, 
in the present study, the contraction of the SMA by AVP is 
1ike1y 10 involve a heterogeneous (VIA and non-VI,,) receptor 
population_ Receptor heterogencily does not readily explain 
Ihe failure of SR 49059 10 satisf}' the criteria l'or competitive 
antagonism of the A VP-induced contraction in Ihe SMA. The 
compound exhibits slow dissodalion kinetics due 10 its high 
Hffinity (0_ Nisato, personal communication). Indeffi, 
inc.ubatlon of the ral S~'IAs with SR 49059 decreased the 
E,:,,'~ of the AVP EliA] curve (Figure 3). Howe\'er, the 
d't;fr~ase in Es" was smal! und independent of Ihe 
concentration used_ A simiJar small decrease in AVP Em., in 
the rat SMA has also becn obsen'ed wilh peptide antagonists 
(Angus et al., 1994). 
Interestingly, in contrast 10 the non-competitive nature of 
SR 49059 and atosiban in the rat SMA with intact 
endotheliulll, both compounds behaved as compctilÏ\'e 
antagonists in the ral aorta, where endothe1ium had been 
removed (sec Methods). Thus, il is possible that vasodilator 
responses elicited by AVP due 10 a release of endotheliulll-
derived factors (Katusic et al .. 1984: Myers et a/.. 1989; Russ & 
Walker. [992: Martinez et al .. 1994b: Suzuki et al., 1994) ma)' 
interfere with its contraclile responses in the rat SMA. Since. in 
addition. AVP can also c!icit endothe1iulll-independenl 
vasodilatalion (Marlinez et al .. 1994a.b), we sludied the etTecls 
of AVP as we1l as OT on bolh vessds after pre-conlraction 
with the IhrOlllboxane-mimelic agent, U46619 in Ihe presence 
of SR 49059. Both agonisls, howe\"Cf, failed to relax dlher the 
mt S;"·IA or the rat aorta. The Iack of vasodilalor responses 
with AVP and OT slrengthens the notion that the AVP-
induccd contraclion of the rat Si\fA seems 10 În\'ol\"e 
helerogeneous receplors. 
We would like 10 point out tlwl our results wilh respect 10 
Ihe cOlllpetiti\"e anlagonism displayed b)' üPC 2[268 in the rat 
SMA (jlA~= 7.56) differ from those reporled in an earlier study 
(Burrell et a/., 1994). Rurre!! and col!eagues (1994) delllon-
straled thaI apc 21268, al a concenlralÏon of onl)' 10 nM, 
almost completely blocked the A VP-induced contraction oflhe 
ral SMA. A1though the atllhors did nol discuss Ihis 
observalion, Ihe antagonism of OPC 21268 suggested either 
a non'compcIÏIÎ\'e actÎon or the co-exislence of an underlying 
re!axanl response (nOl obser\'ed in Ihe present study). We 
cannol explain the discrepanc}'. However, the pAl values 
oblained by us are in agreement with the reporled pK; \'Ulues 
in the rat liver (see Tab!e 2). Moreover, a parallel rightward 
shift of Ihe AVP-induced prcssor response in Ihe ral by 
ürc 21268 (Yamamura et al., 1991) is al50 in acçordance wilh 
our findings in the rat SMA, whieh is generally belie\'cd 10 
repTesenl a resistance vessci (Fenger-Gron et al., 1997). 
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Chapter 5 
In sUDllllury.lhe results ofthe present study show that AVP 
and OT contract the rat aorta and SMA ulld. according 10 
most criteria. lhe data are consislo::nt with Ihe response being 
predominantly mediated by a VIA receptor. However. the non-
competitive anLagonism afthe A VP~induced conlraclion afthe 
rat SMA by atosiban and SR 49059 as weil as Ihc Hili slope 
dinerence bel ween AVP und OT E/[Aj curves indicutc receptor 
hetcrogeneit)' in the rat SMA. In Ihis respect, it is ofinter('si 10 
flote thai lIeinemanll el 111. (1998) have suggested Ihe 
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Summary 
Thc Înteraction between arg-vasopressin (A VP) and noradrenaline in rat smal! mesenteric m1cry 
(SMA) was invcstigatcd and the data analysed according to a theoretica I two-rcccptor:one-transduccr 
model. 
Noradrenaline produced concentration-depcndent contractions of SMAs (pECso=6.50±O.08, 
llH=2.62±O.23). In the presence of A VP-induccd threshold contractiolls (5.3±O.2%, 12.4±O.7% and 
28.3± 1.5% ofthe calibration contraction), noradrenaline concentration-cffect (E/( A]) curves were flattened 
(n,,~1.05±0.08, p<O.OI; 0.86±0.03, P<O.OOI and 0.78±0.03, P<O.OOI, respeetivcly) and potentiated 
(pEC50~ 6.89±0.14; 7.19±0.09, P<O.OOOI; 7.17±0.12, P<O.OOOI, respeetivcly). The maximum response 
to noradrenaline, howcvcr, was not affected by the prcscnce of AVP, 
The potentiation and flattening ofthe noradrenaline Ef[A] curves by AVP was abolished by SR 49059 
(2 nM), indicating involvement ofthe VIA receptor. 
AVP produced concentration-dependent contractions (pECso=9.7 I±O. 16, nll=2.3I±0.57). In the presence 
ofnoradrenaline-induced threshold contractÎons (5.8±O.9%, I O.9±O.7% and 23.8± 1.5% ofthe calibration 
contraction) AVP Ef[A] curves were flattened (n,,~1.08±O.07; 0.86±0.09 and O.86±0.03, respeetively) 
and potentiated (pEC50~9.95±0.09; 1O.21±0.11; 9.86±0.12, respeetivcly), but the l11aximnl11 response 
remained unaffected. 
After treatment with phenoxybenzamine, noradrenaline behaved as a weak partial agonist 
(pEC50~4.87±0.04, nH~1.80±O.12 and a,~ I 0.5±3.8% of the ealibration contract ion). Under these 
conditions, AVP (O.38±O.! 0 nM) not only produced a significant potentiation (pECso=5.59±O.1 I) and 
flattening (I1H= 1.ll±O.17) ofthe noradrenaline E/[A] curve but aIso significantly incrcased the maximum 
response more than 4-fold (a=43.4±6.2% ofthe calibration contraction). 
A two-receptor:one-transducer model could satisfactory fit all experimcntal data and the slope of the 
common transducer pathway was found to be steep (n3=5.4). In conclusion, wc have demonstrated that 
the Înteractiol1 between AVP and noradrenaline on rat SMA follows the theoretical 
two-receptor:one-tnmsducer model, with the slope-dcpcndence residing in the comlllon transducer 
pathway. 
Introduction 
Agonist-agonist interactions have been studied for 
many years which has resultcd in a wealth of 
theoretical as weil as expcrimcntal reports (see 
Scaramellini ct. al., 1997). Synergistic interactions 
between agonists are particularly intriguing 
because ofthcir clinical implications. For example, 
a synergistic interaction betwccn 
5-hydroxytryptamine (5-fTl', serotonin) and 
noradrenaline has been suggested to play a role in 
the actiology of hypertension [1 J. Moreover, the 
antihypertensive cffccts ofketanselin and captopril 
was suggcsted to be at least partially based upon 
reversal of synergistic interaction of 5-HT and 
angiotensin 11, respectively, with noradrenaline [I J 
[2]. Additionally, MaasscnVanDenBrink and 
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colleagucs [3] suggestcd that a thromboxanc 
Az-induccd enhancemcnt of the cOlltractilc 
response of human coronary arteries to the 
anti-migraine drug, sumatriptan, may be involved 
in the chcst symptoms observed with the drug. 
Scveral studies have repOlted amplification 
(the response ta the combillation of two agonists 
cxcceding the sum oftheir individual cffects) andl 
or potentiation (inereasc in pECso) of responses 
clicitcd by agonists acting at t\va different 
receptors, including 5-HT and noradrenaline [4-
6], angiotcnsin IJ and noradrenaline [7, 8], 
melatonin and noradrenaline [9], thromboxanc Al 
and 5-HT [3, 10, 11] as weil as arg-vasopressin 
(A VP) and noradrenaline [12, 13]. Although most 
studies on the interaction between two agonists are 
merely of a descriptive nature, for one type of 
agonist-agonist interaction, namely two receptors 
conneeted with Qne transducer pathway, a 
theoretieal model has been developed [14]. 
Accordillg to the geometry of the agonist E/[A] 
curve, this two-receptor:one-transducer model 
accounted for phenomena like threshold 
amplification and potentiation, and predicted the 
conditions under which they will occur [15] [10] 
[5]. Rccently, this model was extended to allow 
for the interacting agonists to have E/[ A] curves 
with different slop es [16]. Interestingly, this model 
provides a framework by which agonist-agonist 
interactions can be interpreted and predicted. 
Aecordingly, in the present investigation in rat 
small mesenteric micries (SMA), we studied the 
interaction between AVP and noradrenaline, which 
eau se eontractions via predominantly V IA [17] and 
all. adrenergic receptors, respectively [18] [19]. 
Melhods 
The ral smalllllesenleric arlel)' preparation 
Male \Vistal' rats (250-350 g) were anacsthetised 
(sodium pentobarbitone, 60 mg kg-I, Lp.) and ki lied 
by cervical disloeation. The mesentcry was 
remaved and plaecd in iee-eoId madified 
Krebs-Henseleit solution (KHS) ofthe following 
eomposition (mM): NaCI 119.0, NaHCO, 25.0, 
KCI 4.7, KH,PO, 1.2, MgSO, 1.2, glucose 5.5, 
CaCIl 2.5 and EDTA 0.026. Alierial trees were 
dissected and c1eared from sUlTounding adipose 
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tissue. Prom each micrial tree, a ring segment (~2 
mm in length) was mountcd in a myograph (lP. 
Trading, Aarhus, Denmark) with separated 6 mi 
organ baths (thennostatically controlled at 37'C) 
containing modified KHS and continuously gassed 
with 95% 01 and 5% Cal)' as described previously 
[20]. Tissue responses were measured 
continuously as changes in isometrie force. 
Following a 30 min stabilisation pedod, the intemal 
diameter of each vessel was set ta atension 
equivalent to 0.9 times the estimated diameter at 
100 mm Hg effeetive transmural pressure 
(I\Oo~200 - 300 flm) according to the standard 
procedure ofMulvany & Halpem (1977). After a 
further 30-min stabilisatioll pedod, the preparatians 
\Vere challenged fi ve times with noradrenaline 
(10 flM) with washouts after each challenge. The 
integrity of the endothelium was confinned after 
the first challenge with 10 flM of methacholine, 
which produccd at least 60% relaxation in all vessel 
segments. A fter a first noradrenaline E/[ A] curve, 
each vessel segment was washed for 30 min and 
equilibrated for 45 min. Subsequently, we aimed 
to in duce a threshold contraction by either A YP or 
noradrenaline that amounted about 5%, 10% or 
25% of the maxima I contraction of the first 
noradrenaline E/[A] curve. After the threshold 
contraction to AVP or noradrenaline had stabiliscd, 
a second noradrcnaline or AVP EI [A ] curve, 
respectively, was produced. Responses were 
expresscd as percentage of fifth noradrenaline 
challenge, which served as calibration contraction 
(13.4 ± 0.4 mN, IF31). 
In one set of experiments, it was 
investigated whether the potentiation of the 
noradrenaline E/[A] curve was mediated via the 
V IA receptor. Therefore, after the A VP-induced 
thrcshold contraction rcaehed its maximum, 
SR 49059 (2 nM), a selective VlA receptor 
antagonist [21], was added followed by a secOlld 
noradrenaline E/[ A] curve. 
In another set of experiments, the 
interaction between AVP and noradrenaline on the 
contraction of rat SMA was assessed after pmiial 
inactivation of a-adrenoceptars by 
phenoxybenzamine. After the 5 challenges with 
noradrenaline (1 0 ~tM), phenoxybenzamine (3 nM) 
Inleraction of vasopressin and noradrenaline 
was added to vessel scgmcnts for 5 min, 
Subsequently, the segments were washcd 8 times 
during a 30-min pcriod and equilibrated for 45 min. 
A contral noradrenaline E/[A] curve was obtained 
ancl, after washing aud equilibration, a threshold 
contraction ta A VP (~l 0 %) was induced. UpaB 
stabilisation of the thrcshold contract ion to AVP, 
a sec011d noradrenaline E/[ A] curve was produced. 
In one set of experimcnts BHT-933 was used as 
agonist ta observe possiblc Învolvement of 
u 2-adrenoceptors. After washing and cquilibration, 
a third noradrenaline E/[ A J curve was produccd. 
In all expcrimcllts, a mixture of cocaine 
(30 f!M), timolo! (6 f!M) and SCH-23390 (R(+)-
7 -eh loro-8-h ydroxy-3 -methyl-I-phen yl-
2,3,4,5 - t et rah y dro- ! H - 3 - benzaz cp i n e 
hydrochloride; 10 nM) was added during the 
cquilibration period ta block neuronal uptake, B/ 
B2-adrcnoceptors and DJ receptors, rcspectively 
[22]. 
Analysis 
Individual agonist curve data were fitted to the Hili 
equation using all iterath'e, least-squares mcthod 
a * [AJ"" E = (1) 
[Al~~ + [AJ"" 
to provide estimates of midpoint slope (n H), 
midpoint location ([A ]50 estimated as a logarithm) 
and upper asyrnptote (a). The effect of drug 
treatment on these parameters was assessed by 
one-way analysis of varianee (ANOV A) or 
Studcnt's t-test, as appropriate. Va lues ofP<O.05 
were considercd to be significant. 
Applicatioll of Ihe Iwo-receploJ':ol1e-trallsducel' 
model 
Experimental data were fitted to the 
two-receptor:one-transducer model derived by 
Scararnellini and colleagues (1997). 
: AI + RI"-" AIR! nl ~M 
n2 
A2 + R2"-" A2R2 
The model describes the interaction between two 
interacting agonists, A I anel A2, which occupy 
diffcrent receptors (Rl and R2), ta produce a 
common intracellular mediatar, M, leading to a 
pharmacolagical effect, E. The separate and 
common elements of the transduction pathway 
have the algebraic fonn of the HiI1 equation with 
nl and n2 as slope factors for the separate parts 
and n3 for the common part. The production ofM 
by A! and A2 is described by the following 
equations: 
11/ *[A ]'" [M] - , , (2) 




[M],,, = (Ml Ai +[MlA2 (4) 
In which mi and m2 are the maxima! 
concentrations ofM th at A land A2 can produce, 
respectivcly" and Kl and K2 are the midpoint 
location parameters of the functions. The tata I 
concentration ofM is given by 
and the pharmacological effect is relatcd ta [M]!O! 
as follows: 
E *[M] ,,3 E = 111 !Ol (5) 
K,,3 +[M] ,,3 
'" 
where EM is the maxÎmum effect in the system and 
Kis the value of [M]!O! for halfE:-,. 
TIle AR module (derivative-frcc, non-Iinear 
regression) of the BMDP statistical software 
package [23] was used for the fitting procedures. 
At first instance we applicd a graphical method (see 
Rcsuits section) to deduce the slopc parameter, 113, 
cOlTesponding to the common part ofthe transdllccr 
pathway. SlIbscquently, the noradrenaline control 
E/[ A] curves (n= 19) alld the phenoxybcllzamine 
treated E/[ A 1 curves (!F7), both produced in the 
absence of AVP, were simultaneously fitted to 
equation 5 to obtain cstimates ofEm, pKI (that is 
-log Kl) and nl and individual estimates ofml. 
Subsequently, the noradrenaline E/[A] curves 
obtained in the prcsence of an AVP threshold 
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Figure 1. Lelt panel: E/{A] curves of noradrenaline in rat SMA in the absence or presence of 
threshofd contraclions of AVP (EAVP)' Tlle lines superimposed on Ihe mean data points were simufaled 
using the Hili equalion. Righl panel: The refalionship between Ihe Hili sfope parameter and tllreshofd 
contraclion of A VP (EAVP)' 
inactivation by phcnoxybenzamine, and AVP EI 
[A] curves (n= 17) in the absence or presence of a 
noradrcnaline-induccd threshold contraction, were 
simultaneously fitted to equation 5, ta obtain 
estimates of 111 I, m2, n2 and pK2. For the sake of 
simplicity, the midpoint location (K) ofthc E/[M]", 
relation was constrained ta unity in the present 
analysis. 
Compolmds 
[Arg 8]vasopressin, methacholine bromide, 
I-noradrenaline hydrochloride, phenoxybenzamine 
hydrochloride and timolol malcate (purchased from 
Sigma, Thc Netherlands); I3HT-933 (azcpexolc,2-
amino-6-cth yl-4 ,5 ,6,7 -tctrah ydro-6 H -ox ozal 0-
(5,4-d)-azepindihydrochloride), SCH-23390 and 
(purchased from Research Biochemicals 
Incorporatcd, U.S.A); SR 49059 «2S) 1-[(2R 
3 S) -5 -ch I 0 1'0- 3 -(2-ch I orop h cn y 1)- I -( 3 ,4-
cl i 111 et h ox ybenzen e -5 II I fon y I) -3 -hy dra x y-
2,3-dihydro-1 H-indolc-2-carbonyl]-PYIT0Iidine-
2-carboxamide; a gift from Or. D. Nisato, Sanofi 
Recherche, Montpellier Cedcx, Francc). 
Noradrenaline was dissolved in stoichiometrie 
ascorbic acid solution. Mcthacholinc and 
phenoxybenzaminc \Vere dissol\'ed in ethanol. 
74 
SR 49059 was dissolved in dimethylsulfoxidc to 
give a I mM stock solutioll and filrther dilutcd in 
distillcd water. All other drugs \Vere dissolvcd in 
distilled water. 
Resul!s 
Effect of AVP thl'eshold conlractÎons all 
l/oradrellalille-Îlldtlced COl/tractioll of rat SAIA 
Noradrenaline produccd concentration-dependent 
contractions of SMAs (Fig. I) and the individllUl 
E/[A] curves (IFS) were fitted to the Hili equation 
ta provide estimates of midpoint Iocation 
(pEC50~6.50±0.OS), Hill slope (nH~2.62±0.23) alld 
lIppcr asymptotc (a~IIO±I% of the fifth 
noradrenaline calîbration contraction). Threshold 
contractions that amounted 5.3±O.2%, 12.4±O.7% 
ulld 28.3± 1.5% ofthe calibration contractioll were 
indllccd by 0.13±0.05, 0.16±0.09 alld 
O.17±0.OS IIM A YP (IF4-S), respectivcly. The 
three thrcshold contractions ta AVP cuuscd a 
tlattenillg of the noradrenaline E/[A] curves 
(nll~1.05±O.OS, p<O.O I; 0.S6±O.03, P<O.OOI and 
0.78±0.03, P<O.OOI, rcspcctively; see Fig. I) 
togcther with a leftward shift which became 
significant at a threshold of 12.4% (pECso= 
6.S9±0.14; 7.19±0.09, P<O.OOOI; 7.17±O.12, 
P<O.OOO 1) respcctivc1y). The maximum response 
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Figure 2. Lef! panel: EI[A] curves of A VP in rat SMA in the absence or presence of Ihreshold 
conlractions of noradrenaline. The lines superimposed on the mean data poinls were simulated 
using Ihe Hili equation. Right panel: The relationship between the Hili slope parameier and threshold 
contraction of noradrenaline (ENoradrena,l(nJ. 
obtained with noradrenaline was not affect ed. 
Effect afnoradrenaline tlires//Old cOllfractiol1s 011 
A VP-induced con/rac/ioll of rat SAIA 
Subsequcntly. we invcstigated the rcciprocal 
interaction between a fixcd concentration of 
noradrenaline and variabie COllcentrations of A vr. 
AVP produced concentration-dcpelldellt 
contractions ofrat SMA (Fig. 2). HilI parameters 
of the control AVP E/[A] curves (n~4) wcre: 
pEC,,~9.71±O.16, nH 2.31±0.57 and cF94±5% of 
the fifth noradrenaline (10 ~tM) calibration 
contractioll. Threshold contractions amounting 
5.8±0.9%, 10.9±0.7% and 23.8±1.5% of the 
noradrenaline calibration contraction were induced 
by 0.08±0.02, 0.08±0.02 and 0.21 ±0.03 ~IM 
noradrenaline (n=4-5), respcctively. The threc 
threshold contractions to noradrenaline caused a 
nattclling ofthe AVP E/[A] curves (IlH~I.08±0.07; 
0.86±0.09 and 0.86±0.03, P<O.OO I, respectively; 
see Fig. 2 insert). There was also a Ieftward shift 
(])EC50~9.95±0.09; 10.21±0.11; 9.86±0.12, 
respectivcly), which was significant at a threshold 
of -10.9% (p<0.05). The maximum response 
obtaincd with AVP was not affected. 
Effec/ of SR 49059 on polen/ia/ion of 
noradrenaline response by A VP 
Since the A VP-induced potentiatiol1 of 
u]-adrenergic pressor responses in the perfused 
nlcsentery was rep0l1ed not to he mediated via a 
vasopressin V] receptor [24], we investigatcd 
whether this was also the case in the SMA. Aftcr a 
control noradrenaline E/[A] curve 
(pEC50~6.31±0.08, nll~2.38±0.36 and a~III±2% 
of the calibration contraction, 11=4), a thrcshold 
contraction was induccd by AVP (0.02-0.06 nM) 
th at resultcd in 41±7% of the calibration 
contraction. Addition of a V!A-se1ective 
concentration (2 nM) of SR 49059 produced a 
complete reversal of the AVP contraction within 
seconds. Furthermorc, the subsequent 
noradrenaline B/[ A] curve was identical to the first 
control noradrenaline E/[A] curve 
(pEC50~6.45±0.1 0, nH~2.04±0.32 and a~ 107±1 % 
ofthe calibration contraction), indicating th at VIA 
receptors mediated the potentiatioll of the 
noradrenaline E/[ A] curve. 
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Chapfer6 
Ejjèct of parlial inactivation of a-adrelloceptors 
wifh phenoxybenzamine 011 potellliation of the 
noradrenaline response by A VP 
After pre-treatment with phenoxybenzamine (3 
IltvI) for 5 min, noradrenaline bchaved as a weak 
partial agonist (pEC50~4.87±0.04, nH~1.80±O.l2 
and a=IO.5±3.8% ofthe ealibration contraction). 
Under these conditîons, a threshold contraction 
(10.6±0.5%) with A YP (0.38±0.1 0 nM) not only 
produced a significant potentiation 
(pEC50~5.59±0.11) and flattening (nH~ 1.l1±O.l7) 
of the noradrenaline E/[A] curve but also 
significant!y incrcased the maximum response 
more than 4-fold (a~43.4±6.2% ofthe calibration 
contraction). 
This increasc in a proved to be highly significant 
afler subtraction ofthe AVP threshold contraction 
(P<0.002). Following was hout, a third 
noradrenaline Ef[A] curve did not differ trom the 
first (pEC50~4. 75±0.06, n,,~ 1.62±0.14 and 
a=13.1±5.4% of thc noradrenaline calibration 
contraction). 















to AVP the selectÏ\'e u 2-adrenoceptor agonist 
BHT-933 (0.01-100 ~tM) did not induce any 
contraction (data not shown). 
Applicatioll of file two-receptor:one-trmzsduccl' 
model 
Ta fmiheT analyse thc data in a quantitative matUlCr 
we applied the two-receptor:one-transduccr model 
as developcd by Scaramellini et al. (! 997). As 
descrihcd in detail by these authors the slope ratias 
(the quotient of the Ef[A 1] curve obtained in the 
prcscnce and absence of AZ) dep end purelyon the 
slope of thc common transclueer pathway, 113. 
Interestingly, the slope ratias of AVP and 
noradrenaline (assigned ta represent A 1 and A2 in 
the model des cri bed in thc Mcthods section, 
respcctively) Ef[A] curvcs plotted against the 
contractiIe effect of the corresponding agonist 
overlap (Figure 4), consistent with expectations for 
a reciprocal interaction via a common transclueer 
pathway [16]. Since an algebraic relationship 
between slope ratio and 113 was found to he 
intraetabie [16], a set of standard curves was 
produced by Searamellini et al. (1997) that 
displayed the relationship between sloperatios <1 
and n3 (Figure 5, left panel). We employed this 
data set (kindly provided by Clare Scaramellini, 
AstraZeneca, Loughborough) to estimatc n3 for 
noradrenaline and AVP in rat SMA via a graphical 
method. \Ve found that Iincar regression of the 
semi-Iogarithmically plotted data yieldcd lines that 
displayed a streng (r>0.98) and highly significant 
(P<O.OOI) conelation (Figure 5, middle panel). 
Interestingly, a subscquently perfornled linear 
o 
00 
o ~ regression ofthc intercepts of these lines (Figure 5, right panel) yielded another line (intercept ~ ~~---'-"""'''''-'''~~=-r-~-.--~ -0.112808*n3 + 1.1579) that showed an almost 
-8 -7 -6 -5 -, 
[Noradrenaline] (l09IoMI 
Figure 3. EI[A] curves of noradrenaline in rat 
SMA af ter receptor alkylation with 
phenoxybenzamine (3 nM for 5 min) in the 
absence or presence of a threshold contraction 
of AVP. The lines superimposed on the mean 
data points were simulated using the Hili 
equation. 
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perfect COlTelation (r=O.99) with the corrcsponding 
slope parameter, 113. Additionally, thc line obtained 
by Iinear regression ofthe noradrenaline and AVP 
slope ratias from our experimental data (Figure 5, 
middle panel; Slope ratio ~ -0.1560705 Log [A2] 
+ 0.546693) also displayed a significant corre1ation 
(r=0.49, p~0.0036). Accordingly, the intercept of 
this line corrcspondcd with an estimatc for 113 of 
5.4 (Figllfe 5, right panel). 
In order to obtain the model parameters for 
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Figllre 4. Plot of fhe slope ratios oJ noradrenaline 
mul A VP EI[AJ curves (see Figllres I alld 2, 
respectivel)~ versus fhe tlIres/101d cOIl/melton of 
fhe interacting agollist (E,). 
noradrenaline in the SlvlA, the contral 
noradrenaline E/[A] curves (11=19) and the 
noradrenaline E/[A] curves produced after 
phenoxybcnzamine treatment (n=7), bath obtaincd 
in the abscnccof[A VP]. were simultaneously fitted 
to the two-receptor:onc-transducermodel (cquation 
2-5 with [M]!(lt=[~'I]Al) to estimate the parameters 
of the noradrenaline E/[A] curve: EM (108.48), 
pKI (5.58), nl (0.59). The individual estimates 
ofml were averaged to obtain MI (5.06 ± 0.30). 
It should be noted that in thîs fit the converge 
criteria were not met (standard errors are lacking). 
However, since the parameters that were estimated 
with the smal1cst slim of squares appcared realistic, 
we used these for fUlihcr analysis. Subscquently, 
the noradrenaline E/[AJ curves (either with or 
without previous inactivation by 
phenoxybenzamine), obtained in the presence of 
an A VP-indueed threshold contraction (n~26) and 
AVP E/[A] curves (n~17) in the absence or 
presence of a noradrenaline-induced threshold 
contract ion, were simultaneously fitted to 
twa-receptor: one-transducer model (equation 2-5) 
to obtain estimates ofmi (5.04 ± 0.32), m2 (1.88 
± 0.14), n2 (0.48 ± 0.03) and pK2 (9.25 ± 0.08). 
Some cxamples ofthc twa-receptor:onc-transducer 
model fit are shown in Figure 6, where parameter 
cstimates were uscd ta simlilate the curves shown 
superimposed on the expcrîmental data. 
Discussion 
Recently, Scaramellini and co-workers (1997) 
prcsented a theoretica! model which considers the 
interaction between two agollists occupying two 
different receptors to produce a commOll 
intracellular mediator leading to a phammcological 
effect. This theoretica! model, wl1ich extended an 
earlier version [I4J by taking into account a 
possib!e rale ofthe separate pmis ofthe pathway, 
prediets a wide variety of possible !ocation and 
slope changes ofE/[A] curves upon interaetion of 
two agonists [16]. Briefiy, the location of the 
slope-dependence of the agonist E/[ A J curve, in 
either the separate (n I) or common pathway (n3), 
detennines the geometry and location ofthe agonist 
E/[ Al] curve interacting with a fixed conccntration 
ofthe secOild agonist [A2]. Wh en n3>1, E/[AI] 
curves are potentiated and flatten with increasing 
[A2] and, if A I is a partial agonist, the E/[A I] curve 
will also be amplified (the response to the 
combination exceeds the sum of the îndividual 
effects of A land A2). When n3<1, E/[A IJ curves 
are right shified and steepen with increasing [A2]. 
A Ithough nl contributes to the location and shape 
of the contra! E/[ A I J curve, its impact on agonist 
interaction, other than quantitative changes, is 
rather insignificant [16]. Thus, the [A2]-indnced 
relative changes in the slope of the E/[ Al] curve 
dep end totallyon n3. Although there have been 
many reports considering agonist-agonist 
Înteractions, only few studies have examined their 
observations according to this model or to its earl ier 
vers ion [14] [25] [15] [5]. As a conscquence, the 
applieability of this model to predict 
agonistwagonist interactions lacks thorough 
cxperimental backup. 
In the present study, we interpreted the 
interaction between AVP and noradrenaline in rat 
SMA using this model as a framcwork. 









'iO 0.6 2.0 
ro 
~ 

















2 3 4 5 6 
n3 
contraction clicited by thc athef (Figures land 2). 
The initial1eftward (potentiation) and subsequent 
rightward shift with higher threshold contraction 
was in accordancc with the theoretical model, 
asslIll1Îng that thc slope dependenee oflhe obscrved 
agonist E/[A] curve lies in the common transducer 
pathway (n3) [16J. TIle dependenee of curve shape 
on the common transclueer pathway was further 
strengthened by the predicted and the observed 
flattcning of thc noradrenaline and AVP E/[A] 
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Figure 5. Upper lelt panel: Dependence of slope 
ratio on the common transducer pathway. Plot 
was reproduced for n3> 1 with the theoretical 
data obtained from Scaramellini et al. /161. Upper 
right panel: Semi/ogaritmic plot of the slope 
ratios versus the threshold contraction of the 
interacting agonist (EA,); experimental data from 
the present study !*! are shown together with 
the theoretical data. Lines were produced by 
linear regression. Lower lelt panel: In order to 
estimate n3 from the experimental data, the 
intercepts of the lines obtained with the 
theoretical data (upper right panel) were plotled 
versus n3. The solid line was obtained by linear 
regression of these data. The dashed line 
displays the projection of the intercept (0.55) of 
the line fitfed through the experimental data 
(middle panel), thus the n3 for the interaction 
between AVP and noradrenaline was found to 
be 5.4. 
induced by thc intcracting agonist. Thus, thc steep 
slopes ofboth AVP and noradrenaline E/[A] curves 
(n,,~2.31 and 2.62, respectivcly) depend on a 
commonly shared transducer pathway for which 
we also estimated a steep slope (n3=5.4, Figure 5, 
light panel). Moreover, the dependenee ofthe steep 
slopes ofthe AVP and noradrenaline E/[ A] curves 
011 the shared transducer pathway was confirnled 
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Figure 6. Six individual examples af Ille Iwa-receplar:ane-Iransducer madel fit Ille 
E/{A] curves ablained in Ihe absence (salid circ/es) ar presence af a Ihrshal canlraclian 




by the interaction of noradrenaline and AVP aftel' 
partial inactivation of a-adrenoccptors by 
phenoxybenzaminc. The E/[A] curve ta 
noradrenaline, now beha ving as a less cfficacious 
partial agonist, was potcntiated, tlattened and 
amplificd (see Figure 3), again fillly consistent with 
the model predictions for 113> 1 [16]. Intercstingly, 
a si mil ar interaction as described in the present 
study was ohservcd previously in the rabbit femoral 
artery for noradrenaline and angiotensin 11, whieh 
mutually potentiated and amplificd each other's 
effect obtained after paftial receptor inactivation 
via ei th er an irrcvcrsible or a non-competitive 
antagonist (7, 8J. 
Fram the interaction cxperiments, model 
parameters could be derived that could satisfactory 
describe all data (see Figure 6). lt should be uoted 
that this good fit was obtaincd with a Kl value for 
noradrenaline (5.58#) that were vcry similar to 
previously reported functional agonist affinity 
constants in rat SMA (pKA ~ 5.64-6.18; [26] 
Fm1hcrmore, , the K2 model parameter for AVP 
(9.25) was in good agreement with the binding 
affinity reported for the c1011ed rat VIA receptor 
(pKo and pKi ~ 9.17 and 8.73; [27]). This 
substantiates the validity and physiological 
relevance of the theoretical two-receptor-one 
transducer model to describe the interaction 
between AVP and noradrenaline in rat SMA. 
Interestingly, in branches ofthe superior mesenteric 
artery, the contraction induccd by endogcl1Olls 
(nervc released) as weil as exogenous noradrenaline 
was also potentiated by low coneentrations of A VP 
[12]. Though the interaction was neitller analyscd 
1101' interpreted according to the 
two-receptor-one-transducer model, the figures in 
the original paper elearly show that, in accordance 
with our study, the A VP-induced potentiation 
accompanics a flattening of the noradrenaline EI 
[A] curve. 
Prcviously, wc have demonstrated the 
A VP-induced contraction of rat SMA is 
predominantly mediated by the VIA receptor, 
although there was some indicatiol1 for the 
co-involvement ofan atypical receptor [17]. The 
SMA is generally considered as model of a 
resistance vessel [28]. Nevertheless, the 
80 
A VP-induced potentiation of methoxamine 
responses in the perfused rat meselltery was 
reported to be mediatcd via all atypical vasopressin 
receptor, not antagonised by SR 49059 [24]. 
However, in contrast to this pcrfused assay syste111, 
the VIA receptor antagonist SR 49059, at a 
concentration (2 nM) sc1ective for the V IA receptor 
[21], blocked the A VP-induced potentiation of 
noradrenaline in the SMA. In previous studics, 
we dernonstrated that the noradrenaline-induced 
contraction of rat SMA is rnediated via 
ulL-adrenoceptors [18, 19], without involvcment 
of u 2-adrenoceptors [29]. Other studies 
demonstrated that u1-adrelloceptor-mediated 
contractions could be uncovered in the prcsence 
of a threshold contraction to U46619 [30, 31]. 
However, AVP did not uncover any contractilc 
response to the u 2-adrenoccptor agonist BHT -933 
in the Si\1A. Therefore, we feel confident that the 
interaction between AVP and noradrenaline is 
mediated by the VIA receptor and alL adrenoceptor. 
Thc theoreticalmodel used to analyse our 
data does not consider the lllolecular entities 
iuvolved in the transducer pathway. Howcver, it 
is likely th at the common transduccr pathway 
involves the activation of phospholipase C, 
followed by the production of 
inositol-I ,4,5-triphosphate (lP,) and diacylglycerol, 
release of Ca2t ,md activation of protein kinase C 
[32]. The contraction ofvascular smooHl muscIe 
via al-adrenoceptors is mediated via the second 
messengers lP, aud DAG [33, 34]. Although the 
exact nature of the adrenoceptors in rat S:MA is 
not clear [18], the ctlAII,-adrenoceptors in rat vas 
deferens as weil as the cloned alA-adrenoceptor 
expressed in cell-Iines display a similar 
pharmacological profile [18] [35,36] aud are 
coupled to lP, [35, 36]. Similarly, the V'A receptor 
has been shown to couple to this second messenger 
system [37]. Therefore, the hydrolysis ofinositol 
phospholipids might be thc physical representative 
of thc common transducer pathway. Since the 
steepness of the AVP and noradrenaline E/[ A] 
curve rcsides in the transducer pathway, a similar 
interaction profile is predicted between all agonists 
which couple to thc same transducer pathway in 
the SMA. Interestiugly, 5-HT as weil as U46619 
Inleraction of vasopressin and noradrenaline 
bath produced steep E/[ A] curves in rat SMA via 
5-HT, and TP receptors, respectively [38, 39]. 
Sin ce, bath these receptors coup Ie to thc inositol 
phosphate pathway [40, 41), a si mil ar patten! of 
interaction can be expccted for the interaction 
between these agonists and with noradrenaline and 
AVP. Although not studied intense!y enough for 
dcfinite conclusions, the potentiation and flattcning 
of thc noradrenaline E/[A) curve by U46619 
(pEC50~5.92 and 6.65; nH~3.1 and 1.4 in the 
absence or presence of U466 19) is in accordance 
with the interaction pattem between AVP and 
noradrenaline [18). 
Anothcr type of intcractiol1 in isolated 
vessels has been described for 5-HT, aeting via the 
5-HTw receptor ncgatively coupled ta adenylyl 
eyclase, and U46619, aeting via TxA2 receptor 
eoupled to inositol phospholipids [10,31,42]. A 
threshold contraction by U46619 uncovercd 5-
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Functional affinity states: a general feature 
of u,·adrenoceptors ? 
In the classica! receptor concept all antagonist is 
devoid of efficacy and its interaction with a distinct 
receptor subtype Îs govemed solely by its binding 
affinity. This binding affinity is considered ta be 
system and agollist independent. These 
characteIistics have made antagonists very valuablc 
tools for the classification of receptor subtypes. 
Throughout history novel receptor subtypes were 
initially defined by the construction of a 
'fingerprint' of antagonist affinities. Via this 
method the existence of all a!L-adrenoceptor 
subtype was proposed in functional studies. 
Initially, through the displayed low affinity valtles 
for prazosin and subsequently by its low affinity 
for the scleetive alA-adrenoeeptor antagonist, RS-
17053 (sec Chapter I). Despitc its recognised 
potential as a drug target in a cloning era, intensive 
c10ning has thus far failed to identify agene eoding 
for this 'navel' subtype. This led several 
investigators to the beliefthat the u IL-adrenoceptor 
might not exist as a separate entity. It was 
postulated that the alL -adrenoceptor might be a low 
afflnity state ofthe uIA-subtype [1]. Evidence for 
this belief bas been provided in pharmacological 
experiments with cells expressing a lA-
adrenoceptors. a lA -Adrenoceptors, displayed high 
binding affinities for prazosin, RS-17053, \VB 
4101 and 5·Mu (pKi ~ 9.9,9.3,9.8 and 9.2, 
respectivcly), yet the functional estimated affinities 
were about one log unit 10we1', whereas that of 
others (tamsulosin, indoramin and Ree 15/2739) 
remained unehanged [1]. Furthermore, in 
1'adioligaJld binding studies the expressed U la-
adrenoceptor gene product cOllld display, govemed 
by environmental factors, eitller an a lA- or 0. 11.-
adrenoceptor profile [2]. However, the estimated 
affinities for RS- J 7053 in those eelItJ!ar 
experiments could not cover the range of functionaI 
amnities that have been estimated in isolated 'U IA-
tissues' (see Chapter I). 
In the last two decades, molecular biology, in 
particlila1', has put severe pressure on the classical 
receptor concept (see paragraph inverse agonisJII 
below). Thus far, however, the classical theory 
has proven to be adequate for explaining the 
displayed pharmacology of111ost receptors in '11on-
genetically modified' systems. \Ve ellvisagcd the 
ulA1L-adrenoceptor controversy as a possible 
challenge to the classical receptor concept (see 
Chapter I). It is particularly interesting this 
challengc o1'iginates in native tissue. Because of 
its possible impact, it was our ambition to gain a 
better insight in this controversy. As a model we 
used rat SMA. 
In Chapter 2 we demonstrated that the a lL-
adrenoceptor subtype was involved in 
noradreualine-induced contraction of rat SMA, 
without any co-involvement ofan Cf.IA-adrenoceptor 
subtype. TIle displayed u'L-profile provcd to be 
relativcly stabie. since we were unable to idcntify 
environmental factors that could induce an affluity 
switch for RS-17053 (Chapter 2). Fm1hcmlOre, 
the u'l.-adrenoceptor did not display any variabie 
affinity for an agonist (noradrenaline, Chapter 3). 
Apparently, in a tissue system (SMA) the 
ulL-conformation is more stable than in acellular 
assay [2]. As a consequence we \Vere unable to 
prove the hypothesis that the ulA-adrenoceptor 
could present itselffunctionally as different afflnity 
states. However, the possibility of affinity states 
is still a valid hypothesis. Moreover, from the data 
in this thesis and those repOlied clsewhere we belief 
that affinity states 111ight be a general feature among 
the class of u,-adrenoceptor instead ofunique for 
aIA-adrenoceptors. I believe that for all tluee 
al-adrenoccptor subtypes the existence of 
'receptor afflnity states' should be considered as a 
serious possibility. Fo1' Cf. IH- aud al!J-adrenoceptors 
the reasonÎng for this stand can be sUll1mariscd as 
follows. 
a/B-adrelloceptors: A discordance between 
radioligand binding and fuuctional studies was 
noted for the interaction of (+)-cyclazosin with 
alB-adrenoceptors, similar to that of 
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u'A-adrenoceptors (Chapter 4). The high binding 
a[finit)' in rat Iiver (pK;~9.68) initialI)' designated 
(+)-cyclazosin as a selective a!B-adrcnoceptor 
antagonist [3]. However, the functional pA2 value 
(7.96) for (+)-cyc1azosin estimated in rat spleen 
was c1early incompatible with this binding affluity 
(Chapter 4). F1Il1henTIorc, in thc matlse spleen, 
another 'am-tissue' [4, 5], (+)-cyclazosin did not 
behave as a compctitive antagonist. Thus, apart 
from the discordance betwcen binding and 
functional assays (+)-cyclazosin does not behave 
homogeneo\lsly in different functional aIB-assays. 
This substantiates earlier reports with spipcrone and 
rispcridonc. Initially, radioligand binding studies 
identified spiperone and risperidone as selectivc 
am-adrenoceptor antagonists that display a 13- and 
120-fold higher affinity, respectively, for binding 
to rat ClIB-adrcnoceptors than for a'Aadrenoceptors 
[6],[7], [8, 9]. However, the functional selectivity 
of spiperone was only 2-5 fald and even more 
remarkable risperidonc functionally behaved as 
moderate selective (I O-fold) antagonist of 
u'A-adrenoceptors [5, 10]. 
Thcreforc, as proposed for the Cl!A-adrcnoceptors 
[I] it is tempting to spcctliate that the 
CljB-adrcnoceptor can present itself as different 
affinity stat es. 
alD-adrenoceptors: In the rat aorta, which is 
considered ta be a functional alD-adrenoceptor 
corrc1ate [11], the rightward dis placement of the 
phenylephrinc Ef[A] curves b)' (+)-c)'c1azosin was 
accompanied by a conccntration-dependellt 
steepening of the phen)'lephrine Ef[A] curve 
(Chapter 5). 111is phcnomellon was a150 reported 
For other antagonists, and has been suggested ta 
be duc ta the expression of two closely-rclated 
farms of the um-adrcnoceptor in rat aorta [12]. 
Analysis of agonism provided more evidence that 
a1-adrenoceptors in rat aorta do not operate as a 
homogenous one~receptor~one-transducer system 
[ 13]. 
In the absence of molecular evidence in support of 
additional cxl-adrenoceptor subtypes, I believe that 
multiple receptor states should be considered for 
all u]-adrenoceptor subtypes as all explanation for 
these observations. Jt should be noted that evidence 
86 
provided from molecular phalmacology in recent 
years (as discussed below) supports sueh a stand. 
Functional receptor affinity states: wh at is the 
mechanism? 
Splice variants 
Spike variatlts of the UIA -adrenoceptor have been 
considered as a possible explanation for affinity 
states of uIA-adrenoceptors. However, although 
four functionally active splice variants of UIA -
adrenoceptors were defined, their pharmacological 
profiles werc similar [14] [15]. Interestingl)', a 
recent study identified additional spliee variants 
that led to trulleated receptors lacking a 
transmembrane domain [16]. Though these 
truncated isoforms were illcapable of ligatld 
binding and signal transduction co-expres sion with 
functional isoforms diminished the number of 
prazosin binding sites. Prazosin affinity was not 
affectcd by the interaetion with trulleated isofonns, 
but the eeH surface trafficking ofthe co-expressed 
original seven transmembrane ulA-adrcnoceptor 
was Înhibited. At present splice variants do not 
offer a direct explanation for low affinity subtypes, 
but should be considered as a regulatory pathway 
for UIA -adrenoceptors. 
Localisatioll 
It was demonstrated that UIA -adrenoceptors localise 
predominantly intracellular, whereas most of the 
um-adrenoceptors localise on thc cell surface. This 
subtype-specific ccllular distribution rather than the 
receptor structure detennined the sensitivity for 
CEC inactivation of ul-adrenoceptors [17, 18]. 
Recent studies reported th at all a]-adrenoceptor 
subtypes display a degrce of cellular distribution 
alld are localised at the plasma membrane as weil 
as illtracellularly [19, 20]. Illterestillgl)', 
uIA~adrenoceptors display a different, more 
uIL-adrenoceptor-like, pharmacological profile 
wh en treated as whole cells in contrast to an 
UIA -adrenoceptor profile in membrane preparations 
[I]. Possibly, differel1ces in subcellular localisation 
ofcxl-adrenoceptors among tissucs may explain the 
different afftnity states th at arc observed. Indced, 
MacKellzie and colleagues speculated on the basis 
of their observations that the ability to pcnetrate 
ccIIs might influence ligand affinity for 
a1-adrenoceptors [20]. Howevcr, this hypothesis 
is onl)' conccivable on the condition that these 
intracellular rcceptors do acttlally tt'3nsduce signais. 
Signa! transduction by intracellular receptors has 
not been demollstrated yet. Lipophilicity ofligancls 
wDuld be the most likely physicochemical propcrty 
th at cnables or disables celllilar penetration. 
Interestingly, RS-l7053 is a highly lipophilie 
Iigand. In contrast, however, Ree 15/2739 which 
is another example a highly Iipophilic ligatld did 
not display a discriminatory potenc)' for a 1A- or 
alL -adrenoceptors similar to th at ofRS-17053 [l]. 
Apparent!y, lipophilicity is not the crucial factor 
that cxplains the alL-profile. Furthennore, it should 
be Iloted that the two subtypes could not be 
discriminated by their agonist profiles [1 J. Same 
variation between agonist profiles would have heen 
cxpected in case physiochemical properties of 
ligands would he of crucial impoliance. 
Another intcresting feature th at should be 
considered is the ligand-induced redistribution of 
u1-adrelloceptofs. Mc Cune et al. [t9] 
demonstrated that prazosin caused a rcdistribution 
of ulD"adrenoceptors from an intracelltilar 
localisation to the cell membrane. Consistent with 
other reports (sec [21)), the authors suggest th at 
this receptor redistribution is associated with 
Iigands that dispJayed negative intrinsic activity at 
um"adrenoceptors. Howevef, redistribution of 
receptors is normally studied, and likely requires, 
a presence of the inverse agonists over a langer 
time period (>24h) than in our experiments [19, 
21]. Nevetihcless, the concept of inverse agonism 
offers other directions fOf explaining affinity states. 
rf/verse agonism 
In the classical concept the only relevant parameter 
which accounts for an antagonist's capability to 
recognise a receptor and fonn a complex with it is 
lts binding affinity. This affinity is agonist and 
system independent. Consequent!y, affluity values 
for antagonists are not expected to differ between 
fUllctional assays and binding studies and this 
makes antagonists suitable tools for receptor 
characterisation. However, in recent years a 
concept developed whieh redefines agonism and 
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antagouism and introduced tellns like cOllstitutive 
activity, neutra I antagonism and inverse agonism 
(see [22, 23]). The concept postulates that receptors 
exist in a variety of conformational stat es, some of 
which are spontaneously active. These 
spontaneously actÎ\'e cOl1formations can interact 
with the effector mcchal1isms in the absence of a 
Iigand and exp!ain constitutive activity. In the 
simplest model, the two~state model (see Figure), 
receptors are proposed to exist in equilibrium 
between two confonnations, all actÎ\'e fonn (R') 
and an inactive form CR). Agonists act by 
prcferentially binding to and enriching the active 
confonnation, thcreby increasing effector activity, 
whereas inverse agonists bind preferentially to thc 
inactive (R) conformational state, leading to a 
reduction of constitutive activity. Neutral 
antagonists bind equally weil to Rand R'J and 
therefore do not alter the equilibrium and 
constitutive receptor activity. Thus antagonists do 
not simply block the act ion of an agonist but can 
also posses efficacy, ranging from negative 




R ) R' 
AR AR' 
The equilibrium betweell the two states is 
controlled by the equilibrium constant L in the 
absence of a ligand. The interaction of all agonist 
CA) with the receptor alters the equilibrium between 
the two states aecording to its dissociation 
equilibrium constants at the two receptor states, 
namely KA and K'N In this concept the action of 
an antagonist in a givcn tissue depends first on its 
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negative or neutral efficacy but also on the basal 
R:R' ratio which is dctennincd by the constant L. 
It is not unlikely that Land consequently the bas al 
R:R' ratio might vary among tissues and thereby 
introducing a systcm dependency whieh will 
inf1uencc the affinities ofnon-neutral antagonists 
estimated in fUl1ctional studies. Thus for negative 
antagonists the affinity values estimated in 
functional assays may not be comparable with those 
obtaincd in binding expcriments. Furthennore, the 
functional affinities of negative antagonists may 
differ amongst tissucs, according to the allosteric 
parameter L. 
In Chapter 3 we have demonstrated a highly 
significant correlation between the affinity and 
efficacy for noradrenaline in the SMA, which 
traditional phannacology views as independent 
parameters. \Ve offcred thc plausible explanation 
that this correlation is a statistical phenomenon. 
l-Iowever, altematively this correlatioll could be 
interpretcd to support thc existence of multiple 
receptor states in rat SMA. In the multiple state 
receptor model efficacy is the consequence of 
affinity [14, 23, 24]. Sinee the rclative affinity for 
either R or R' detemlines the efficacyofthe system. 
This concept of inverse agonism alld system 
dependent equilibria betweell R:R' offers a 
framework for specldation about the observed 
discrepancies in antagonist affinities among 
functional assays and between radioligmld binding 
studies and functional assays. Recently it became 
clear that prazosin, 5-Mu, \V8- 4101, indoramin, 
but not Rec 15/2739 displaycd negativc intrinsic 
activity at wild type a1A-adrcnoceptors [25]. 
Furthennorc, all ofthe aforementioned antagonists 
were inverse agonists at wild type (,(m-
adrcnoceptors. Additionally, RS-17053, 
tamsulosin as weil as (+)-cyclazosin behavcd as 
inverse agonists at constitutively active mutant (,(]A-
and a]B-adrenoccptors. Similarly, for cxJ[)-
adrenoceptors; BMY 7378, phentolamine, 5-Mu 
and prazosin have been identified as inverse 
agollists [19, 26]. Moreover, soon a rcp0l1 wiII be 
published which suggcsts the presence of a 
constitutively active alD-adrenoceptor population 
in rat aorta (Gisbel'l R. el al. J.Pharmacol. Exp. 
Ther. 295(2) (2000)). Clearly the ingredients for 
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multiple affinity statcs are present within the class 
of a]-adrenoceptors. However, a straightforward 
quantitative and qualitative account for our 
observations catmot be provided yet. Particularly, 
since antagonists Iike (+)-cyclazosin and illdoramin 
were characterîsed as inverse agonists at 
a1A-adrenoceptors [25] but their functional 
a1L-adrenoceptor profile is similar to the binding 
affinities at a1A-adrenoceptors. Furthcrmore, many 
antagonists display negativc efficacy at 
a]B-adrenoccptors though functionally onIy for 
(+)-cyclazosin a discrepancy with binding amnities 
was reported (Chapter 4). One ofthe problems is 
that a two state model is clearly too simple to 
explain the experimental data. In a two-state model 
differences amongst tissues between the R:R' ratio 
should have been exprcssed as levels of constitutive 
activity. However, constitutive tissue activity or 
loss ofit by RS-17053 or (+ )-cyc1azosin was neither 
observed in our experiments, nor has it been 
reported elsewhere. Obviously, a two-state model 
is a too simplistic model to offer a complctely 
satisfactory explanation for 'antagonist affinity 
statcs' . Intercstingly, a threestate model containing 
two active receptor states has been proposed in 
order to explain the phenomenon that the same 
receptor, when cOllpled to different G protein 
cflèctor pathways. can display different affinity/ 
efficacy patterns also designated as 'agonist 
trafficking'[23). In fact it was suggested that this 
feature might partially account for the 
incompatibility of a]-adrcnoceptors in rat aorta 
with a one-receptor-one-transducer system [13]. 
Though the validity of the above-describcd 
mechanisms is well established in genetically 
engineered systems, they do not offer clear-cut 
explanations for our observations in native tissue. 
Ncvertheless, molecular pharmacology has 
idcntified conccpts that offer lIseful directions for 
further thinking and studying the inconsistencies 
of a]-adrenoceptors with traditional receptor 
theory. 
Does the rat small mesenteric artery 
represent.a resistance vessel? 
Isolated SMA assays have been used widely as 
models of re si stance vesscls [27]. Sînce small 
mesenteric arteries (SMAs; internal diameter 
1 00-300 ~nn) contribute substantially ta vascular 
resistance in rat [27-29], these vessels are bclieved 
to passes regulatory potcntiaI and consequently 
have predictive vallIe for the blood-pressurc 
response [30]. Howcvcr, this belicfwas chaIlcnged 
by the lack of effect of idazoxan in SMA, a partial 
uj-adrenoccptor agonist that incrcases blood 
pressure in pithed rat [31]. 
Our data questioll the predictive value afthe SMA 
for pressor responses within the mesenteric 
circulation. In the perfused mesentcry the selcctive 
a lA-adrenoccptor antagonist, RS-17053. 
antagonised the noradrenaline induced pressor 
response displa)'ing high affinit)' (pA, ~ 9.9; [32]). 
This pharmacological profile confirmed the 
resistance in the perfused mescntery is detcrmined 
by o:.lA-adrcnoceptors [32]. However, the affinity 
of RS-17053 in the rat SMA was 35-fold lower 
(pKB~ 8.3-8.4; Chapter 2). Therefore, it appears 
th at o:.'A-adrenoceptors mediate the pressor 
response in rat perfused mesentery, whereas the 
contract ion in rat SMA is mediated by a 
alL -adrenoceptor. 
Also comparison of our AVP experimental data in 
the SMA (Chapter 5) with reported data in the 
pcrfused mesentery argues against the SMA bcing 
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Summary and conclusions 
Summary and conclusions 
In Chapter 1 wc provided all overview of the 
historica! aspects of the classification of 
a]-adrenoccptors. The official nomencJature now 
rccognises CX 1A-, (.(18- and alD-adrenoceptor 
subtypes which all display high affinity for 
prazosin. However, functional experiments have 
suggestcd the existcnce of another 
alL-aclrenoccptor subtype that displays a Iow 
affinity for prazosin. The controversy over the 
existence of all alL-adrenoceptor subtype appears 
to focus on tissues that were înitially charactcrised 
as functîonal CX1A-tissues like, for example, rat 
mesenteric rcsistance vasculature. Thc range of 
estimatcd affinities of thc selectivc 
cx[A-adrenoceptor antagonist, RS-17053, in 
functional "aIA-tissues" substantiates the 
discordance with the official al-adrenoceptor 
nomenclature. Also in Chapter I, the nomenclature 
of vasopressin and oxytocin receptors was 
reviewed more briefly. Subsequently, the aims and 
Outlil1C ofthe thesis are described. In the absence 
of a molccular correlate, wc envisaged that the 
alL -adrcnoceptor could bcar achallenge to the 
traditional receptor concept. Givcn the possible 
impact ofthis subject it was our primary ambition 
to clarify the nature of the alL -adrenoceptor 
subtype. 
In Chapter 2 we characterised the al-adrenoceptor 
subtype involved in noradrenaline-induced 
contractions of rat SMA. This adrcnoceptor 
subtype was designated all,' bccause it displays a 
Jow affinity for prazosin and RS-17053. Since, it 
has been suggested th at the alL-adrenoceptor 
represents a conformational affinity state of the 
cxlA-adrenoceptor we elaborated on the nature of 
the alL -adrenoceptor phannacology. In brÎef, the 
pharmacological alL-adrenoceptor profile was 
agonist independent and wc were unable to define 
environmental factors that influenced this profile. 
Therefore we did 110t obtain evidence for thc 
hypothesis that the alL -adrenoceptor represcnts an 
amnity state ofthe a lA -adrcnoceptor. Furthenllore, 
a co-existing a1A-adrenoccptor in rat SMA is 
uulikely. 
Variabie receptor affinity, mthcr than different 
receptor subtypes, has been suggestcd to account 
for the variation in estimated agonist affinities in 
functional studies on a[-adrenoceptors. In case of 
a variahle affiuity for agonists, it is not 
unreasonable to assume that this phenomenon 
would also manifests itscIf for other ligands like 
antagonists and cou1d account for the 
a[L-adrenoceptor profile in rat SI\1A. In Cllapter 3 
\ve have studied the agonism of noradrenaline in 
rat SMA by analysis of receptor inactivation 
experiments using the operational model of 
agonism. 111e main finding of the study was that 
the operational model of agonism yielded highly 
variabie and correlated estimates of amnity and 
efflcacy. The correlation of afflnity and efficacy 
is inconsistent with thc basic assumption that these 
parameters are independent. Intercstingly, 
introducing random HOlse on simulated 'perfect' 
contral and PSZ treated noradrenaline E/[ A] curves 
yielded affinity and efficacy estimates th at 
displayed not only a similar degree ofvariation as 
experimentally obtained estimates, but also a high1y 
significant correlation. This suggests that a 
statistica I rather than a pharmacological 
phenomenon accounts for the large variability and 
correlation of affinity and efficacy estimates. 
TIlercfore. the alL-adrenoceptor in rat SivlA does 
not display variabie affinity for noradrenaline. 
Although the prefercntial susceptibîlity to 
ilTeversible inactivation by CEC has been used to 
subclassify aIB-adrenoceptors, all alil-adrenoceptor 
se1ective competitive antagonist has not been 
available for quantitative characterisation of 
functional alil-adrenoceptors. In Chapter 4 we 
characterised the functional pharmacological 
profile of (+)-cyclazosin, a selective competitive 
al[J-adrenoceptor antagonÎst as defined in 
radioligatld binding studies. Wc used rat Si'\'lA. 
rat aorta and rat and mousc spleen as representants 
of fUllctional a IA1L-, alO - and alil-adrenoceptors 
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respectively. The functional potency of 
(+ )-cycJazosin for u1M.-and uw-adrenoccptors was 
in accordance with radioligand binding affinity for 
these subtypes. However, the funetional 
antagonising potency of (+)-cyc1azosin in rat and 
mOtlse spleen was much lowel' than its afftnity for 
ulB-adrenoceptors in radiolîgand binding studies. 
Furthennore, (+)-eyclazosin displayed a different 
phannacology at 1110use and rat um-adrenoceptors. 
ll1US, a diseordance between radioligand binding 
and functional studies was noted for the interaction 
of (+ )-cyc1azosin with um-adrenoceptors, similar 
to that ofuIA-adrenoceptors. 
In Chapter 5 we addressed thc inCollsistencies 
betwcen variOlIs rep0l1s conccming the functional 
phannacology ofvasopressin in rat SNIA and aOl1a. 
In order to illuminate these discrepancies we 
studied the effects of the selective Y IA receptor 
antagonists, OPC 21268 and SR 49059, and the 
oxytocin receptor antagonist, atosiban, on the A VP-
and oxytocin-induced contractions of the two 
vesscls. A YP and oxytocîn contracted rat SMA 
and aorta without any vasodilatory component. 
The antagonist affinities indicated predominant 
illvolvement of Y IA receptors in both vessels. 
However, the concentration-dependent steepening 
of A VP E/[A] curves by atosiban and the Hili slope 
difference bctween oxytoein- and AVP E/[A] 
curves eould indicate receptor heterogeneity. 
Thereforc, despite predominant involvement of 
VIA reeeptors, receptor heterogeneity should be 
considered in the SMA. 
Because interactions between agonists are the in 
vivo reality, we aimed to analyse the intcraetion 
betwcen ulL-adrenoeeptors and vasopressin 
rcceptors in rat SMA (Chaptcr 6). We used the 
previously described theoretica! 
two-receptor:one-transduccr model as a framework 
for the design and analysis ofthe experiments. This 
model predicts, by tuking into account separate and 
cOI11t11on palts of the tmnsducer pathway, a wide 
variety of possible location and slape changes of 
E/[A] curves upon interaction of two agonists. 
Threshold contractiol1s by either A YP or 
noradrenaline potentiated and flattened the E/[A] 
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curves ofthe interacting agonist without affecting 
maximum responses. Also the response to 
noradrenaline, which behaved as a pattia! agonist 
after phenoxybcnzamine treatmcnt was potentiated, 
flaHened and the maximum response was itlcreased 
by all A VP-indueed threshold eOlltraetioll. All 
observed characteristics (potentiatiol1, flattening 
and the incl'eased maximum) of agonist E/[A] 
curves by threshold contractions ofthc interacting 
agonists are pl'edicted by the 
two-receptor:one-transducer model, assuming a 
steep C01111110n transducer pathway. Indeed a steep 
slope (n=5.4) was estimated for the common palt 
of the transdueer pathway and together with the 
other derived parameters the theoretical 
two-reeeptor:one-transducer mode! could 
satisfactory fit all expetimental data. In conclusion, 
we have demonstrated that interaction between 
A YP and noradrenaline, which iI1volves the 
VIA receptor and ulL-adrenoceptor, respectively, 
follows the t heoretical two-receptol':one-transducer 
model, with the slope-dependenee residing in thc 
eommon transducer pathway. 
In Chapter 7 the nature ofthe ulL-adrenoceptor is 
further discussed. From the data in this thesis and 
those reportcd elsewhere it is proposed that affinity 
statcs Illight not be unique for ulA-adrenoceptors, 
but are a common feature ofthe ul-adrenoceptor 
class. Though the nature of the affinity statcs in 
native tissue is not establishcd, moleCltlar 
phannacology has identified coneepts Iike inverse 
agonislll that offer useful directions for fmther 
thinking and studying the inconsistencies of 
ul-adrenoceptors with traditional receptor theory. 
Finally, we questioncd the validity ofthe rat SMA 
as a resistance vessel, which has a predictive value 
for pressol' responses, since aur tïndings with 
ul-adrenoceptors and vasopressin in the SMA 
differ from those in the perfused mesentery. 
Conclusions wilh reference 10 our predefined 
aims 
• The ul-adrenoceptor mcdiating noradrenaline-
induced contractions in rat SMA displays a 
distinct ulL-adrenoceptor pharmacology. 
• ll1ere is no co-existing ulA-adrenoceptor in 
the rat SMA. • 
• Environmental factors that 111ight affect thc 
phannacological profile for antagonists ofthc 
u1L-adrenoceptor could not be defilled. 
Furthcrmore, the considerabic variation of 
functionally estimatcd agonist affinities within 
the SMA was not bascd on variabie affinity • 
ofthe alL -adrenoceptor. l1lCrefore, we did not 
obtain cvidcnce for the hypothesis the 
an,-adrenoceptor reprcscnts all affinity state 
ofthe aIA-adrenoceptor. 
Summary and conclusions 
{+)-Cyc1azosin does not bch avc as a seJective 
cxlll-adrcnoceptor antagonist in functional 
tissues. This could suggcst th at the 
a1A-adrenoccptor is not the only subtype 
within the cx]-adrcnoceptor class that displays 
a heterogeneous phannacological profile. 
Thc interactÎon between noradrenaline and 
AVP follo",s the theoretical 
two-receptor:one-transducer model assuming 





Binnen de klasse van u1-adrenergc receptoren 
onderscheidt men nu officieel 3 subtypen: alA> ((tB 
en u lD - Voor deze 3 subtypen zijn moleculaire en 
fammcologische bindings- en functionele data met 
elkaar in overeenstemming. Functionele studies 
hebben echter aanwijzingen geleverd voor het 
bestaan van een vierde subtype. Deze 
alL-adrenerge receptor, kenmerkte zich in eerste 
instantie door een lage affinite!t voor prazosine. 
De affiniteit voor prazosine was gemiddeld een 
log-eenheid lager dan die voor de andere subtypen, 
welke prazosine zonder onderscheid met hoge, sub-
nanomolaire, affiniteit herkent in zowel functionele 
als bindingsstudies. Later is gerapporteerd dat RS-
17053, een selectieve a lA -receptor antagonist, een 
groter onderscheidend velmogen heeft en dat het 
uIL-subtype in verschillende weefsels een range 
van affiniteiten lijkt te hebben voor RS-17053. 
Echter, ondanks het huidige moleculair biologische 
tijdperk is een coderend gen voor dit uIL-subtype 
'nog' niet geïdentificeerd. Dit is opmerkelijk 
omdat de alL-adrenerge receptor toch als een 
potentiële "drug-target" gezien wordt. Om deze 
redcn wordt aan het bestaan van de ulL-adrellergc 
receptor als separate identiteit getwijfcld. Als 
alternatieve verklaring is de hypothese geopperd 
dat de alL -adrencrge receptor een affiniteitsvoml 
is van de alA-adrenerge receptor. De 
affiniteitsvonn waarin de UIA -adrenerge receptor 
zich presenteert wordt volgens deze hypothese 
bepaald worden door omgevingsfactoren. Dit zou 
ook verklaren waarom de affiniteiten voor 
prazosine en RS-17053 bepaald in bindingsstudies 
verschillend zijn van die in functionele studies, 
terwijl die van andere antagonisten niet 
verschilden. 
Volgens de traditionele receptor theorie is de 
bindingsaffiniteit de cnige parameter van belang 
voor de antagonist-receptor interactie. Bovendien 
is dcze bindingsaffiniteit onaflwnkelijk van 
omgevingsinvloeden. Duidelijk is dat de 
traditionele receptor theorie geen ruimte laat voor 
affiniteitsvonnell van receptoren. Ook zijn grote 
en selectieve verschillen in affiniteiten voor 
antagonisten tussen radioligatld bindingsdata en 
functioneel verkregen data niet te verwachten. 
Moleculaire biologische bevindingen hebben al 
behoorlijke druk is uitgeoefend op de traditionele 
receptor theorie en zelfs aanleiding gegeven tot de 
formulering van nieuwe concepten. Echter, 
dergelijke druk vanuit genetisch ongemodificeerde 
systemen is veel zeldzamer. Om inzicht te krijgen 
in de mogelijke implicaties was het primaire doel 
van dit onderzoek om de aard van de UIL -adrenerge 
receptor op te helderen. In hoofdstuk 2 hebben we 
de ui-adrenerge receptor in de kleine mesenteriale 
vaten gekarakteriseerd als een alL-subtype, met een 
lage affiniteit voor de antagonisten, prazosine en 
RS-17053. Er konden geen omgevingsfactoren 
worden geïdentificeerd die van invloed waren op 
de affiniteit van de receptor voor RS-17053. 
Bovendien ,vas co-aanwezigheid van een 
alA-subtype onwaarschijnlijk. In Hoofdstuk 3 
hebben we het agonisme van noradrenaline 
bestudeerd in de kleine mesenteriale vaten. 
Middels het operationele model voor agollisme 
hebben wc de parameters affiniteit en intrinsieke 
activiteit van noradrenaline geschat. De cOlTelatie 
van deze parameters, die volgens de theorie 
onafhankelijk zijn, leek geen mechanistisch, maar 
eerder een statistisch fenomeen te zijn. De 
belangrijkste uitkomst met betrekking tot onze 
doelstelling was, dat hoewel de geschatte affiniteit 
voor noradrenaline in de verschillende 
experimenten met dit preparaat sterk varieerde, 
deze variabiliteit niet berustte op een variatie vall 
de affiniteit van de receptor. Samenvattend blijkt 
uit hoofdstuk 2 en 3 dat het affiniteitsprofiel van 
de fJ.11.-adrencrge receptor stabiel is voor zowel een 
antagonist als een agonist. Hoewel beide studies 
gecn bewijs leverden voor het bestaan van 
fenotypische affiniteitsvormen van de 
alA-adrcnerge receptor is dit nog steeds een valide 
hypothese. Op basis van de resultaten voor 
u,B-adrenerge receptoren (hoofdstuk 4) en 
gegevens uit de literatuur dient men het bestaan 
van affiniteitsvonnen mijns inziens voor de gehele 
klasse van ul-adrenerge receptoren als serieuze 
97 
mogelijkheid te beschouwen (algemene discussie). 
In hoofdstuk 4, karakteriseren we het functionele 
fannacologische profiel van (+)-cycIazosine. In 
radioligand bil1dingsstudies werd (+ )-Cyclazosine 
gedefinieerd als een selectieve alB-adrenerge 
receptor antagonist. Echter, wanneer de functionele 
respons van alB-receptoren (contractie van de milt 
van een rat en muis) bestudeerd wordt komt er een 
totaal ander fannacologisch profiel naar voren. In 
de rattenmilt gedraagt (+)-cyclazosine zich 
weliswaar als een competitieve antagonist, maar 
met een bijna 100* lagere affiniteit dan in 
bindingsstudies. In de muizcnmilt gedraagt (+)-
cyclazosine zich zelfs niet als een competitieve 
antagonist. De functionele gemeten affiniteit voor 
U IAiL- en aw-adrenerge receptoren kwam wel 
overeen met die gemeten in radioligand 
bindingsstudies. Evenals voor de alA-adrenerge 
receptor lijkt er nu ook voor de alB-adrenerge 
receptor een discrepantie te bestaan voor de 
affiniteit gemeten in radioligand binding studies 
en in functionele studies. 
In aanwezigheid van (+)-Cyclazosine nam de 
helling van de phenylefrine curve in de rattenaorta 
(uw-adrenerge receptoren) op een concentratie-
afhankelijke manier toe. Deze bevinding bevestigt 
eerdere resultaten van een uitgebreidere analyse in 
ratten aorta, welke de aanwezigheid van 2 
nauwverwante receptor subtypen suggcreerde. 
Met de huidige resultaten voor de interactie van 
(+)-cyclazosine en am-en alD-adrenerge receptoren 
en eerder verschenen studies betoogt algemene 
discussie onder andere dat het bestaan van 
affîniteitsvormen voor de totale klasse van 
al-receptoren een serieus te nemen optie is. Met 
name omdat er genetisch géén aanwijzingen zijn 
voor extra subtypen. Vanuit de moleculaire 
biologie zijn er wel concepten als affiniteitsvonnen 
en invers agonismc gedefinieerd. Hoewel deze 
concepten niet direct vel1aald kunnen worden om 
onze waarnemingen te verklaren, kunnen zij wel 
richting geven aan verder filosoferen over en 
onderzoek Ilaar een verklaring. 
In hoofdstuk 2 tot en met 4 hebben we ons 
onderzoek gericht op de farmacologische analyse 
van één receptor subtype. In de in vivo situatie 
zijn er verschillende vaatverwijdende en 
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vaatvernauwende stoffen aanwezig die allen 
verschillende receptoren stimuleren. De 
uitcindelijke respons van een bloedvat vonl1t de 
resultante van alle rcceptorinteracties. 
Synergistische interacties zijn met name interessant 
vanwege de klinische implicatics. Om deze reden 
wildcn we de interactie tussen vasopressine 
receptoren en alL -adrenerge receptoren in de kleine 
mesenteriale vaten onderzoeken. Om drie redenen 
werd gekozen voor vasopressine: (1) vasopressine 
is een zeer potente vasoconstrictor en is daardoor 
waarschijnlijk al in lage concentraties betrokken 
bij interacties, (2) vasopressine is mogelijk 
belangrijk in pathologische situaties zoals hart falen 
en (3) de interactie tussen vasopressine receptoren 
en ulL-adrenerge receptoren is nog niet uitgebreid 
onderzocht. Alvorens we deze interactie 
daadwerkelijk onderzochten was het noodzakelijk 
om voorafgaand de receptor(en) betrokken bij de 
vasopressine respons te karakteriseren (hoofdstuk 
5). Met name omdat de literatuur hierover in de 
mesenteriale vaten niet eenduidig was. 
Vasopressine en oxytocine (beiden zijn agonist 
voor zowel vasopressine als oxytocine receptoren) 
gaven een contractie van de mesenteriale vaten en 
rattenaorta zonder aanwezigheid van een 
vasodilatoire component. De gerneten affiniteiten 
voor antagonisten suggereerden dat met name V IA 
reecptor de contractie medieerde. Echter, in de 
kleine mesenteriale vaten was er enige indicatie 
voor betrokkenheid van meer receptor typen. 
Vervolgens hebben we in hoofdstuk 6 de agonist-
agonist interactie van noradrenaline met 
vasopressine onderzocht. In de literatuur zijn 
diverse interacties tussen agonisten beschreven. De 
verschillende onderzoeken hebben echter niet 
gestreefd naar het classificeren van het type van 
interactie. Dam1egenover staat dat er één type van 
interactie met name als theoretisch model 
beschreven. Dit twee-receptor:één-transducer 
model beschrijft de interactie tussen twee receptor 
typen die uiteindelijk koppelen aan I transductie 
systeem en voorspelt een variëteit aan vonn en 
locatie van agonist curves bij een interactie. Lage 
contracties van vasopressine of noradrenaline 
gaven een potentiering en afvlakking van de 
concentratie respons curve van de interactercnde 
agonist (noradrenaline of vasopressine 
respectievelijk). De maximale respons van de 
agonisten wijzigde niet door de interactie. Echter, 
na inactivatic van al~adrcnerge receptoren nam de 
maximale respons van noradrenaline, welke zich 
nu gedroeg als een partiële agonist, wel toe door 
een drempelcontractie van vasopressine. AI deze 
observaties zijn verklaarbaar door het twee-
reccptor:één-transducer model mits de 
hellingsparamctcr van het gedeelde 
Samenvatting 
transductiesysteem groter is dan 1. Via een 
grafische methode werd deze hellingshoek 
inderdaad geschat op 5.4. Vervolgens bleek dat 
met deze hellingshoek en andere berekende 
parameters de totale dataset goed te simuleren was 
met het twec-fcceptor:één-transducer model. 
Concluderend, kan gesteld worden dat de interactie 
tussen a,-adrenerge en vasopressine receptoren 
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SlvIA: Smallmesenteric artery 
5-HT: 5-hydroxytryptamme 
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